Page last updated: 2024-12-04

inositol

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Occurs in Manufacturing Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Inositol: An isomer of glucose that has traditionally been considered to be a B vitamin although it has an uncertain status as a vitamin and a deficiency syndrome has not been identified in man. (From Martindale, The Extra Pharmacopoeia, 30th ed, p1379) Inositol phospholipids are important in signal transduction. [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

inositol : Any cyclohexane-1,2,3,4,5,6-hexol. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

1D-chiro-inositol : Belonging to the inositol family of compounds, D-chiro-inositol (DCI) is an isomer of glucose. It is an important secondary messenger in insulin signal transduction. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

muco-inositol : An inositol that is cyclohexane-1,2,3,4,5,6-hexol having a (1R,2R,3r,4R,5S,6r)-configuration. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID892
CHEMBL ID1222251
CHEMBL ID468154
CHEMBL ID1231671
CHEMBL ID278373
CHEMBL ID1950780
CHEMBL ID3976780
CHEBI ID17268
CHEBI ID27987
CHEBI ID27372
CHEBI ID10642
CHEBI ID27374
CHEBI ID23311
CHEBI ID22357
CHEBI ID25492
CHEBI ID23927
CHEBI ID24848
SCHEMBL ID6378921
SCHEMBL ID13058696
SCHEMBL ID5831
SCHEMBL ID5969
SCHEMBL ID5832
SCHEMBL ID187397
SCHEMBL ID187796
SCHEMBL ID188237
SCHEMBL ID188106
SCHEMBL ID187278
SCHEMBL ID1055883
SCHEMBL ID6791918
SCHEMBL ID4748543
SCHEMBL ID491333
SCHEMBL ID13580047
SCHEMBL ID12735687
SCHEMBL ID12711208
SCHEMBL ID959405
SCHEMBL ID959404
SCHEMBL ID6468882
SCHEMBL ID13207905
SCHEMBL ID12411898
SCHEMBL ID12371461
SCHEMBL ID12377889
SCHEMBL ID14542470
SCHEMBL ID13114115
SCHEMBL ID13114128
SCHEMBL ID13114116
SCHEMBL ID21388397
MeSH IDM0011374

Synonyms (495)

Synonym
LS-13189
inositol, myo
CHEMBL1222251
cyclohexanehexol
643-12-9
nsc127230
nsc-127230
inositol, d-chiro-
1,3,4,5,6-cyclohexanehexol
nsc-8101
nsc8101 ,
inositol (van8c
inosite
6917-35-7
(1r,2r,3s,4s,5r,6s)-cyclohexane-1,2,3,4,5,6-hexol
1,2,3,5/4,6-cyclohexanehexol
CHEBI:17268 ,
epi-inositol
INS ,
allo-inositol
inositol, allo-
inositol, epi-
inositol, scyllo-
MEGXP0_001817
myoinositol
mesoinosite
iso-inositol
phaseomannitol
1,3,5/4,6-cyclohexanehexol
inosital
inositol, myo-
cis-1,3,5-trans-4,6-cyclohexanehexol
inositene
mesovit
mesol
mesoinositol
inositina
scyllite
nsc-45517
myoinosite
NSC45517 ,
i-inositol
mesoinosit
nucite
phaseomannite
inositol, meso-
nsc-25142
nsc25142
NCI60_041778
CHEBI:27987 ,
CHEBI:27372 ,
CHEBI:10642 ,
(1s,2r,3r,4s,5s,6s)-cyclohexane-1,2,3,4,5,6-hexol
1d-chiro-inositol
(1r,2r,3s,4r,5s,6s)-cyclohexane-1,2,3,4,5,6-hexol
CHEBI:27374
(1r,2r,3r,4r,5s,6s)-cyclohexane-1,2,3,4,5,6-hexol
(1r,2r,3r,4r,5r,6r)-cyclohexane-1,2,3,4,5,6-hexol
1,2,4/3,5,6-cyclohexanehexol
(1r,2r,3s,4s,5s,6s)-cyclohexane-1,2,3,4,5,6-hexol
1,2,3/4,5,6-cyclohexanehexol
1,2,3,4/5,6-cyclohexanehexol
CHEBI:23311
643-10-7
1,3,5/2,4,6-cyclohexanehexol
(1r,2r,3s,4r,5r,6s)-cyclohexane-1,2,3,4,5,6-hexol
(1s,2s,3s,4s,5s,6s)-cyclohexane-1,2,3,4,5,6-hexol
cocositol
CHEBI:22357
1,2,4,5/3,6-cyclohexanehexol
cis-inositol
quercinitol
1,2,3,4,5,6/0-cyclohexanetetrol
CHEBI:25492
d-(+)-chiro-inositol
epiinositol
nsc-55551
1-l-chiro-inositol
nsc-55558
nsc-55552
inositol (d)
(-)-chiro-inositol
l-inositol
l-chiro-inositol
nsc55558
NSC55551 ,
NSC55552 ,
inositol (l)
inositol, i-
einecs 201-781-2
inositol (van)
nsc 404118
insitolum
isoinositol
nsc 8101
SPECTRUM_001595
1,2,3,4,5/6-cyclohexanehexol
1,2,3,4,5,6-cyclohexanehexol
inositols ,
CHEBI:23927 ,
CHEBI:24848
(1r,2r,3r,4s,5s,6s)-cyclohexane-1,2,3,4,5,6-hexol
BSPBIO_002606
NCGC00178580-01
CBU ,
neo-inositol
cis-1,2,3,5-trans-4,6-cyclohexanehexol
cyclohexane-1,2,3,4,5,6-hexol
NSC404118 ,
SPECTRUM5_000961
MLS001335967
MLS001332377
MLS001335966
smr000857319
smr000857320
MLS001335965
MLS001332378
MLS001335968
smr000857145
nsc103959
488-55-1
nsc-103959
d-inositol
inositol, muco-
muco-inositol
inositol, meso
nsc-404118
1,2,3,4,5,6-cyclohexanehexol, (1alpha,2alpha,3alpha,4beta,5alpha,6beta)
1,2,3,4,5,6-hexahydroxy-cyclohexane
1,2,3,5-trans-4,6-cyclohexanehexol, cis-
chiro-inositol
ccris 6745
ai3-16111
488-59-5
C06153
MYO-INOSITOL ,
87-89-8
meat sugar
scyllo-inositol
C06152
meso-inositol
d-myo-inositol
dambose
C00137
bios i
inositol
C06151
1d-myo-inositol
(-)-inositol
1l-myo-inositol
cyclohexitol
l-myo-inositol
scyllitol
551-72-4
1l-chiro-inositol
l-(-)-chiro-inositol, 95%
scyllo-inositol, >=98%
d-(+)-chiro-inositol, 95%
allo-inositol, 97%
myo-inositol, bioreagent, suitable for cell culture, suitable for insect cell culture, suitable for plant cell culture
DB03106
NCGC00159409-02
ACON1_002457
KBIO3_001826
KBIO2_002075
KBIO2_004643
KBIOSS_002075
KBIOGR_001885
KBIO2_007211
NCIOPEN2_008191
SPECTRUM3_001053
SPECTRUM4_001193
NCGC00169828-01
2OS9
I-6500
myo-inositol, >=99%
myo-inositol, bioultra, >=99.5% (hplc)
inositol, chiro-
220128F1-89BF-442D-AD6D-E6D1EA7BA625
7B0CEF84-D9CE-4A88-AA7D-EC50C89387A5
1D7A27BF-6060-4FA9-AC46-3BD18DBA406E
HMS2091N13
AC-11070
I0631
488-58-4
I0629
I0632
41546-34-3
I0633
I0630
I0628
inosital (tn)
D08079
inositol (nf)
BMSE000103
inositol, myo- (8ci)
BMSE000102
BMSE000113
d-chiro inositol
1,3,5/2,4,6-hexahydroxycyclohexane
FT-0693614
FT-0652045
FT-0693444
I0040
CHEMBL468154
elnd-005
scyllo-cyclohexanehexol
azd-103
elnd005
cyclohexane-1,2,3,4,5,6-hexaol
A834712
A836375
NCGC00159409-04
NCGC00159409-03
unii-m94176hj2f
m94176hj2f ,
38876-99-2
hexahydroxycyclohexane
1,2,4/3,5,6-cyclohexane-1,2,3,4,5,6-hexol
C19891
(+)-inositol
dtxcid2065254
NCGC00255362-01
cas-87-89-8
tox21_302035
dtxsid7023146 ,
(+)-chiro-inositol
CHEMBL1231671
tox21_111642
AKOS024318869
CHEMBL278373
AKOS006240678
nsc757076
nsc-757076
pharmakon1600-01500352
BMSE000922
BMSE000901
r1y9f3n15a ,
nsc 127230
d-chiro-inositol
unii-587a93p465
chiro-inositol, (+)-
epi-cyclohexanehexol
6r79wv4r10 ,
einecs 207-681-5
unii-r1y9f3n15a
einecs 211-394-0
einecs 209-000-7
63gqx5qw03 ,
unii-4661d3jp8d
nsc 55558
einecs 211-393-5
unii-6r79wv4r10
nsc 103959
einecs 207-682-0
nsc 55552
unii-63gqx5qw03
4661d3jp8d ,
alloinositol
587a93p465 ,
chiro-inositol, (-)-
HMS2230N03
HMS2235H05
HMS2235M23
elnd 005
unii-1vs4x81277
1vs4x81277 ,
azd 103
AKOS006332036
S4530
AKOS015960633
AKOS015994742
AKOS015960429
CCG-36096
inositol [nonspecific isomer]
einecs 230-024-9
nsc 25142
FT-0670357
FT-0670351
(+)-epi-inositol
CHEMBL1950780
unii-4l6452s749
inositol [usan:nf]
4l6452s749 ,
576-63-6
488-54-0
l-(-)-chiro-inositol
FT-0632730
FT-0632209
FT-0632208
FT-0627237
inositol [inn]
inositol [usan]
inositol [usp-rs]
myo-inositol [ep monograph]
inositol [mi]
inositol [vandf]
inositol [who-dd]
inositol [inci]
inositol [mart.]
inositol [fcc]
EPITOPE ID:144993
4IRX
AKOS015895894
AKOS015912934
AKOS015912905
S6176
rat antispectacled eye factor
mouse antialopecia factor
1,2,3,4,5,6-hexahydroxycyclohexane
gtpl4645
HMS3369F20
gtpl4648
HMS3369B06
gtpl4649
gtpl4495
HMS3373E05
SCHEMBL6378921
SCHEMBL13058696
J9.771C ,
CDAISMWEOUEBRE-GPIVLXJGSA-N
SCHEMBL5831
SCHEMBL5969
SCHEMBL5832
SCHEMBL187397
SCHEMBL187796
SCHEMBL188237
SCHEMBL188106
SCHEMBL187278
NCGC00178580-03
tox21_111642_1
KS-1284
SCHEMBL1055883
SCHEMBL6791918
CS-4782
SCHEMBL4748543
mfcd00799555
mfcd00799556
mfcd00003863
mfcd01321249
SCHEMBL491333
SCHEMBL13580047
SCHEMBL12735687
SCHEMBL12711208
SCHEMBL959405
SCHEMBL959404
SCHEMBL6468882
CDAISMWEOUEBRE-LOLGQZEGSA-N
1,2,3,4,5,6-cyclohexanehexol, (cis,cis,cis,trans,cis,trans)- #
muscle sugar
SCHEMBL13207905
W-203081
W-203168
W-202862
W-202861
W-203392
Q-201583
SCHEMBL12411898
myo-inositol-1,2,3,4,5,6-d6
2h3 ,
SCHEMBL12371461
SCHEMBL12377889
KS-1420
SCHEMBL14542470
CHEMBL3976780
SCHEMBL13114115
SCHEMBL13114128
SCHEMBL13114116
CDAISMWEOUEBRE-NIPYSYMMSA-N
CDAISMWEOUEBRE-GNIYUCBRSA-N
CDAISMWEOUEBRE-OQYPVSDDSA-N
1,2,3,4,5,6-cyclohexanehexol #
HY-B1411
chiro-inositols
AB00051982_13
dl-chiro-inositol
mfcd00077932
J101.891D ,
J101.889B ,
J101.888D ,
J101.890F ,
J101.892B ,
mfcd00065455
STL453612
1.alpha.,2.alpha.,3.beta.,4.alpha.,5.beta.,6.beta.-cyclohexanehexol
inositol, neo-
9O6Y5O4P9W ,
8LQ63P85IC ,
neoinositol
inositol, cis-
d-chiro-inositol [who-dd]
d-chiro-inositol [usp-rs]
d-(+)-chiro inositol
cyclohexane-1r,2r,3s,4s,5r,6s-hexol
cis-inositol, >=98.0% (tlc)
epi-inositol, >=98.0% (hplc)
d-chiro-inositol, >=98.0% (hplc)
M01914
AKOS027327401
(1r,2r,3s,4s,5s,6r)-cyclohexane-1,2,3,4,5,6-hexol
AKOS027320475
unii-8lq63p85ic
unii-9o6y5o4p9w
SR-05000001655-5
sr-05000001655
inositol, united states pharmacopeia (usp) reference standard
myo-inositol, purum, >=98.0% (hplc)
myo-inositol, for microbiology, >=99.0%
myo-inositol, saj special grade, >=99.0%
SR-05000001655-1
AS-68424
AS-68396
myo-inositol, european pharmacopoeia (ep) reference standard
inositol, pharmaceutical secondary standard; certified reference material
myo-inositol, vetec(tm) reagent grade, 99%
myo-inositol, p.a., 98.0%
levoinositol
SBI-0051369.P003
mfcd00272608
(1r,2r,3s,4s,5s,6s)-cyclohexane-1,2,3,4,5,6-hexaol
inositol myo-
DB13178
(1r,2r,3s,4r,5r,6s)-cyclohexane-1,2,3,4,5,6-hexaol
(1r,2r,3r,4r,5s,6s)-cyclohexane-1,2,3,4,5,6-hexaol
(1r,2r,3s,4r,5s,6s)-cyclohexane-1,2,3,4,5,6-hexaol
(1r,2s,3r,4r,5s,6s)-cyclohexane-1,2,3,4,5,6-hexol
orthorhombic myo-inositol
BCP25172
DTXSID30110000
DTXSID50905091
HY-N3021
Q407997
Q3023527
Q3011024
HY-W010041
Q3347078
Q2838375
Q2974313
Q3331426
Q3589114
Q3205874
SY060836
F19572
rel-(1r,2r,3r,4r,5r,6r)-cyclohexane-1,2,3,4,5,6-hexaol
rel-(1r,2r,3s,4r,5s,6s)-cyclohexane-1,2,3,4,5,6-hexaol
DB15350
AS-10616
Q743661
myo-inositol;meso-inositol
(1r,2r,3r,4s,5s,6s)-cyclohexane-1,2,3,4,5,6-hexaol
(1r,2r,3r,4r,5r,6r)-cyclohexane-1,2,3,4,5,6-hexaol
E78671
an inositol
D78450
cis-1,2,4-trans-3,5,6-cyclohexanehexol
CS-0023004
rac-chiro-inositol
rac-chiro-1,2,3,4,5,6-cyclohexanehexol
CS-W010757
cis-1,2,3,4,5,6-cyclohexanehexol
A866896
D91189
D91187
D91188
T72516
SCHEMBL21388397
CS-0083766
HY-121962
SB46764
SB46855
SB45039
SB44732
(1r,2s,3r,4r,5s,6r)-cyclohexane-1,2,3,4,5,6-hexol
EN300-658805
CS-0369552
DTXSID901028824
DTXSID101028820
DTXSID201028823
DTXSID601028825
DTXSID101028818
DTXSID301028826
EN300-25914216
CS-0039882
CS-0185922
EN300-7411506
(1r,2s,3s,4r,5s,6s)-cyclohexane-1,2,3,4,5,6-hexol
EN300-19631206
EN300-7361851
HY-W016509
CS-W017225
EN300-82941
EN300-19632288
HY-W127726
Z1486007281
HY-W021265

Research Excerpts

Overview

Inositol is an essential nutrient, obtained either by uptake from the environment or by de novo synthesis from glucose. Myoinositol (Myo) is an isoform of inositol, a cyclic polyol with 6 hydroxyl groups. Inositol serves as a precursor for structural and signaling molecules.

ExcerptReferenceRelevance
"Inositol is a natural substance found widely in plants. "( Study of the Potential Hepatoprotective Effect of Myo-Inositol and Its Influence on Zebrafish Development.
Antonowski, T; Osowski, A; Podlasz, P; Wiśniewski, K; Wojtkiewicz, J, 2021
)
2.31
"Myo-inositol is a precursor of the membrane phospholipid, phosphatidylinositol (PI). "( Regulated inositol synthesis is critical for balanced metabolism and development in Drosophila melanogaster.
Contreras, A; Eldon, ED; Klig, LS; Nguyen, LT; Rivera, MJ, 2021
)
1.58
"Inositol is an essential intermediate in cosmetics, food, medicine and other industries. "( Efficient production of inositol from glucose via a tri-enzymatic cascade pathway.
Cheng, H; Wang, J; Zhang, Y; Zhao, Z, 2022
)
2.47
"Inositol is an essential nutrient, obtained either by uptake from the environment or by de novo synthesis from glucose. "( The paradoxical role of inositol in cancer: a consequence of the metabolic state of a tumor.
Case, KC; Greenberg, ML; Schmidtke, MW, 2022
)
2.47
"Myo-inositol is a breakdown product of phytate produced in the gut through the action of phytase. "( Effects of supplemental myo-inositol on growth performance and apparent total tract digestibility of weanling piglets fed reduced protein high-phytate diets and intestinal epithelial cell proliferation and function.
Adeola, O; Ajuwon, KM; Bedford, MR; Ogunribido, TZ, 2022
)
1.57
"Myoinositol (Myo) is an isoform of inositol, a cyclic polyol with 6 hydroxyl groups. "( Myoinositol in Autoimmune Thyroiditis.
Antonelli, A; Balestri, E; Benvenga, S; Botrini, C; Elia, G; Fallahi, P; Ferrari, SM; Guarneri, F; Paparo, SR; Patrizio, A; Ragusa, F, 2022
)
1.96
"Inositol is an essential metabolite that serves as a precursor for structural and signaling molecules. "( Phosphatidic acid inhibits inositol synthesis by inducing nuclear translocation of kinase IP6K1 and repression of myo-inositol-3-P synthase.
Greenberg, ML; Lazcano, P; Onu, CJ; Schmidtke, MW, 2022
)
2.46
"Inositol is an effective and safe treatment in PCOS. "( Inositol is an effective and safe treatment in polycystic ovary syndrome: a systematic review and meta-analysis of randomized controlled trials.
Ács, N; Greff, D; Hegyi, P; Horváth, EM; Juhász, AE; Nyirády, P; Park, S; Sipos, Z; Szinte, J; Váncsa, S; Váradi, A; Várbíró, S, 2023
)
3.8
"Myo-inositol is a natural polyol, the most abundant among the nine possible structural isomers available in living organisms. "( Myo-Inositol and D-Chiro-Inositol as Modulators of Ovary Steroidogenesis: A Narrative Review.
Angeloni, A; Bizzarri, M; Monti, N; Piombarolo, A; Verna, R, 2023
)
2.03
"Myo-inositol is a bioactive compound having beneficial modulatory effects on metabolism in humans."( Dietary phytase and
Gonzalez-Uarquin, F; Huber, K; Kenéz, Á; Rodehutscord, M, 2020
)
1.04
"Myo-inositol (MYO) is an insulin-sensitizing compound used in PCOS patients; however, its insulin-sensitizing mechanism is unclear."( The insulin-sensitizing mechanism of myo-inositol is associated with AMPK activation and GLUT-4 expression in human endometrial cells exposed to a PCOS environment.
Cabrera-Cruz, H; Oróstica, L; Plaza-Parrochia, F; Romero, C; Torres-Pinto, I; Vega, M, 2020
)
1.3
"Myo-inositol is a major intracellular osmolyte that can be accumulated to protect cells from a variety of stresses, including fluctuations in the osmolality of the environment, and cortisol is thought to be an osmotic hormone in teleost fish. "( Myo-inositol enhances the low-salinity tolerance of turbot (Scophthalmus maximus) by modulating cortisol synthesis.
Cui, W; Huang, Z; Ma, A; Wang, X, 2020
)
1.67
"Myo-inositol is an essential vitamin for most animals, and it can modulate multiple physiological functions. "( Transcriptome analysis provides insights into the effects of myo-inositol on the turbot Scophthalmus maximus.
Cui, W; Ma, A, 2020
)
1.35
"Myo-inositol is a versatile compound and plays a vital role in plant growth and stress tolerance. "( MdINT1 enhances apple salinity tolerance by regulating the antioxidant system, homeostasis of ions, and osmosis.
Gong, X; Hu, L; Li, Y; Liu, Y; Ma, F; Yang, S; Zhang, J; Zhang, Z; Zhou, K, 2020
)
1.12
"Myo-inositol is a ubiquitous metabolite of plants. "( Role of myo-inositol during skotomorphogenesis in Arabidopsis.
Chaudhary, C; Khurana, P; Sharma, N, 2020
)
1.5
"Inositol is a carbocyclic sugar polyalcohol. "( From Myo-inositol to D-chiro-inositol molecular pathways.
Bertelli, M; Busetto, GM; Calogero, AE; Cannarella, R; De Berardinis, E; Del Giudice, F; Della Morte, C; Di Renzo, GC; Dinicola, S; Facchinetti, F; Gerli, S; Kiani, AK; Paolacci, S; Stuppia, L, 2021
)
2.48
"Myo-inositol is a nutrient that enhances cellular glucose uptake."( Nutritional Intervention Preconception and During Pregnancy to Maintain Healthy Glucose Metabolism and Offspring Health ("NiPPeR"): study protocol for a randomised controlled trial.
Baker, PN; Chan, SY; Chong, YS; Cutfield, W; Godfrey, KM, 2017
)
0.94
"The inositol is a natural compound widely used in the food industry due to its presence in carbohydrate metabolism and its sweet taste."( Thermoanalytical study of sweetener myo-inositol: α and β polymorphs.
Alarcon, RT; Bannach, G; Caires, FJ; de Castro, RAE; Gaglieri, C; Magdalena, AG, 2017
)
1.2
"Myo-inositol is a ubiquitous cyclitol, has an important regulatory role, and its intracellular depletion is associated with pathological changes. "( Lack of effects of myo-inositol on metabolism of primary rat adipocytes.
Hertig, I; Szkudelska, K; Szkudelski, T, 2018
)
1.35
"Myo-inositol is a natural molecule with important therapeutic applications and an impaired oral absorption may result in a reduced clinical effect. "( Alpha-lactalbumin Effect on Myo-inositol Intestinal Absorption: In vivo and In vitro.
Ferrari, D; Ferruzza, S; Monastra, G; Ranaldi, G; Sambuy, Y, 2018
)
1.32
"Myo-inositol is a precursor of several membrane phospholipids and sphingolipids and plays a key role in gene regulation in Saccharomyces cerevisiae (S. "( Regulation of the inositol transporter Itr1p by hydrogen peroxide in Saccharomyces cerevisiae.
Cyrne, L; Marinho, HS; Santos, T, 2019
)
1.41
"Myo-inositol is a highly abundant stereoisomer of the inositol family of sugar alcohols and forms the structural basis for a variety of polyphosphate derivatives including second messengers and membrane phospholipids. "( Myo-inositol Effects on the Developing Respiratory Neural Control System.
Di Fiore, JM; MacFarlane, PM,
)
1.25
"Inositol is an essential nutrient required by human cells in culture for growth and survival. "( Inositol in preterm infants at risk for or having respiratory distress syndrome.
Howlett, A; Ohlsson, A; Plakkal, N, 2019
)
3.4
"Myo-inositol is an abundant carbohydrate in the environment and in certain organs of the human body, especially the brain."( Myo-inositol utilization by Citrobacter koseri promotes brain infection.
Jiang, L; Wang, J; Yang, P; Yuan, C, 2019
)
1.55
"myo-inositol (MI) is a key sugar alcohol component of various metabolites, e.g. "( Novel inositol catabolic pathway in Thermotoga maritima.
Boucher, N; Burkart, MD; Leyn, SA; Noll, KM; Osterman, AL; Rodionov, DA; Rodionova, IA, 2013
)
1.43
"Myo-inositol (Myo-ins) is a marker of neuroglial cells, being present in the astrocytes of brain tissue, but also functions as an osmolyte. "( Myo-inositol metabolism in appropriately grown and growth-restricted fetuses: a proton magnetic resonance spectroscopy study.
Allsop, JM; Damodaram, MS; Kumar, S; Mcguinness, A; Patel, A; Rutherford, MA; Story, L; Supramaniam, V; Wylezinska, M, 2013
)
1.51
"Myo-inositol (MI) is an important polyol involved in cellular signal transduction, auxin storage, osmotic regulation, and membrane formation. "( Isolation and developmental expression analysis of L-myo-inositol-1-phosphate synthase in four Actinidia species.
Cui, M; Lei, Y; Liang, D; Ma, F; Wu, S, 2013
)
1.19
"Inositol is a cyclic sugar alcohol which occurs naturally in a variety of stereoisomers, the most common of which is myo-inositol. "( Myoinositol: a new marker of intrauterine growth restriction?
Dessì, A; Fanos, V, 2013
)
2.45
"Inositol is an important element of the follicular environment and data support that its higher level in follicular fluid correlates with the development of a good oocyte."( Inositol: effects on oocyte quality in patients undergoing ICSI. An open study.
Brusco, GF; Mariani, M, 2013
)
2.55
"Myo-Inositol (INO) is a biomolecule with crucial functions in many aspects. "( Inositol based non-viral vectors for transgene expression in human cervical carcinoma and hepatoma cell lines.
Fan, Y; Wu, Y; Zhang, L, 2014
)
2.4
"Inositol acts as a second messenger in insulin signaling pathway Literature data suggest inositol deficiency in insulin-resistant women with the polycystic ovary syndrome. "( [The role of inositol deficiency in the etiology of polycystic ovary syndrome disorders].
Jakimiuk, AJ; Szamatowicz, J, 2014
)
2.21
"myo-Inositol is an essential biomolecule that is synthesized by myo-inositol monophosphatase (IMPase) from inositol monophosphate species. "( Defective craniofacial development and brain function in a mouse model for depletion of intracellular inositol synthesis.
Gondo, Y; Hida, A; Iwayama, Y; Mishima, K; Murata, T; Ohba, H; Ohnishi, T; Watanabe, A; Yoshikawa, T, 2014
)
1.18
"Inositol is a physiological compound belonging to the sugar family. "( Inositol: history of an effective therapy for Polycystic Ovary Syndrome.
Bizzarri, M; Carlomagno, G, 2014
)
3.29
"Inositol is an essential metabolite that serves as a precursor for inositol lipids and inositol phosphates."( Inositol synthesis regulates the activation of GSK-3α in neuronal cells.
Greenberg, ML; Ye, C, 2015
)
2.58
"Inositol is an essential nutrient with important structural and signaling functions in eukaryotes. "( Finding the sweet spot: how human fungal pathogens acquire and turn the sugar inositol against their hosts.
Xue, C, 2015
)
2.09
"myo-Inositol is a building block for all inositol-containing phospholipids in eukaryotes. "( Trypanosoma brucei Bloodstream Forms Depend upon Uptake of myo-Inositol for Golgi Complex Phosphatidylinositol Synthesis and Normal Cell Growth.
Bütikofer, P; González-Salgado, A; Major, LL; Reymond, JL; Sigel, E; Smith, TK; Steinmann, M, 2015
)
1.21
"Inositol is an essential nutrient required by human cells in culture for growth and survival. "( Inositol in preterm infants at risk for or having respiratory distress syndrome.
Howlett, A; Ohlsson, A; Plakkal, N, 2015
)
3.3
"Inositol is a six-carbon sugar alcohol and is one of nine biologically significant isomers of hexahydroxycyclohexane. "( Quantification of myo-inositol, 1,5-anhydro- D-sorbitol, and D-chiro-inositol using high-performance liquid chromatography with electrochemical detection in very small volume clinical samples.
Cordle, CT; Leff, RD; Meek, CC; Phelps, DL; Schimpf, KJ; Schmitz, DJ, 2015
)
2.17
"Myo-inositol (Ins) is a major compatible osmolyte in many cells, including those of Mozambique tilapia (Oreochromis mossambicus). "( Direct Ionic Regulation of the Activity of Myo-Inositol Biosynthesis Enzymes in Mozambique Tilapia.
Kültz, D; Villarreal, FD, 2015
)
1.23
"Myo-inositol (MI) is a precursor for the synthesis of phosphatidylinositol polyphosphates (PIPs). "( Effect of treatment with myo-inositol on semen parameters of patients undergoing an IVF cycle: in vivo study.
Gulino, FA; Leanza, V; Leonardi, E; Marilli, I; Musmeci, G; Palumbo, MA; Vitale, SG, 2016
)
1.28
"Myo-inositol is a six-fold alcohol of cyclohexane, has already been proved to modulate different pathways: inflammatory, metabolic, oxidative and endocrine processes, in a wide array of human diseases, including cancer and the genesis of mammary gland and breast diseases, like fibrosis, as well as metabolic and endocrine cues."( An association of boswellia, betaine and myo-inositol (Eumastós) in the treatment of mammographic breast density: a randomized, double-blind study.
Alwasel, SH; Bizzarri, M; Cucina, A; Giuliani, A; Gullo, G; Harrath, AH; Pasta, V; Tartaglia, F, 2015
)
1.16
"Inositol is a polyalcohol, naturally occurring as nine stereoisomers, including D-chiro-inositol (DCI) and myo-inositol (MI), which have prominent roles in the metabolism of glucose and free fatty acids."( Inositol's and other nutraceuticals' synergistic actions counteract insulin resistance in polycystic ovarian syndrome and metabolic syndrome: state-of-the-art and future perspectives.
Brady, DM; Laganà, AS; Maniglio, P; Paul, C; Triolo, O, 2016
)
2.6
"Myoinositol is a promising supplement that may represent the first GDM-risk modifier that could be implemented on a population-level."( The Potential Role for Myoinositol in the Prevention of Gestational Diabetes Mellitus.
Froehlich, RJ; Werner, EF, 2016
)
1.25
"Myo-inositol is an important cellular osmolyte in autoregulation of cell volume and fluid balance, particularly for mammalian brain and kidney cells. "( Osmoregulatory inositol transporter SMIT1 modulates electrical activity by adjusting PI(4,5)P2 levels.
Dai, G; Hille, B; Kruse, M; Traynor-Kaplan, A; Yu, H, 2016
)
1.35
"Inositol is an organic compound of high biological importance that is widely distributed in nature. "( Inositol and human reproduction. From cellular metabolism to clinical use.
Czyzyk, A; Genazzani, AD; Meczekalski, B; Milewska, EM, 2016
)
3.32
"myo-Inositol is a sugarlike nutrient that is essential for life in most organisms. "( Functional Characterization of Pneumocystis carinii Inositol Transporter 1.
Collins, MS; Cushion, MT; Merino, EJ; Porollo, A; Sesterhenn, T; Vadukoot, AK, 2016
)
1.24
"Myoinositol (MI) is an organic osmolyte, with intracellular concentration changes depending on the extracellular osmolality."( Myoinositol as a Biomarker in Recurrent Glioblastoma Treated with Bevacizumab: A 1H-Magnetic Resonance Spectroscopy Study.
Bähr, O; Hattingen, E; Pilatus, U; Ronellenfitsch, MW; Steidl, E; Steinbach, JP; Zanella, F, 2016
)
1.57
"Inositol is a key cellular metabolite for many organisms. "( Computational modeling and in silico analysis of differential regulation of myo-inositol catabolic enzymes in Cryptococcus neoformans.
Klig, LS; Mackenzie, EA, 2008
)
2.02
"Myoinositol is an isomer of glucose that has chemopreventive activity in animal models of cancer. "( The chemopreventive agent myoinositol inhibits Akt and extracellular signal-regulated kinase in bronchial lesions from heavy smokers.
Dennis, PA; Gills, JJ; Han, W; Lam, S; Memmott, RM, 2009
)
1.27
"myo-Inositol (inositol) is an essential nutrient that is used for building phosphatidylinositol and its derivatives in eukaryotes and even in some eubacteria such as the mycobacteria. "( Strategies for acquiring the phospholipid metabolite inositol in pathogenic bacteria, fungi and protozoa: making it and taking it.
Reynolds, TB, 2009
)
1.16
"Inositol is a precursor of numerous phospholipids and signalling molecules essential for the cell. "( Calnexin regulates apoptosis induced by inositol starvation in fission yeast.
Beauregard, PB; Guérin, R; Leroux, A; Rokeach, LA, 2009
)
2.06
"Inositol is a component of the vitamin B complex. "( Effects of myoinositol on sperm mitochondrial function in-vitro.
Calogero, AE; Condorelli, RA; Di Bari, F; La Vignera, S; Unfer, V, 2011
)
2.17
"Inositol is a building block of phosphatidylinositol (PI), which is further elaborated to become PIMs, LM and LAM. "( Inositol lipid metabolism in mycobacteria: biosynthesis and regulatory mechanisms.
Fukuda, T; Kinoshita, T; McConville, MJ; Morita, YS; Sena, CB; Yamaryo-Botte, Y, 2011
)
3.25
"Myo-inositol (MI) is a stereoisomer of inositol and serves as a precursor of inositol phospholipids."( Evaluation of serum and urine 1,5-anhydro-D-glucitol and myo-inositol concentrations in healthy dogs.
Arai, T; Hayakawa, N; Ishioka, K; Miki, Y; Mori, A; Niki, T; Oda, H; Saeki, K; Sako, T; Sato, T; Tazaki, H, 2011
)
1.09
"Myo-inositol is a six carbon cyclitol that contains five equatorial and one axial hydroxyl groups. "( Inositol safety: clinical evidences.
Carlomagno, G; Unfer, V, 2011
)
2.37
"Myo-inositol is a versatile compound that generates diversified derivatives upon phosphorylation by lipid-dependent and -independent pathways. "( Myo-inositol and beyond--emerging networks under stress.
Valluru, R; Van den Ende, W, 2011
)
1.49
"Inositol is a polyalcohol existing as nine different stereoisomers, two of which have been shown to be insulin mediators: myo-inositol (MI) and D-chiro-inositol (DCI)."( Bye-bye chiro-inositol - myo-inositol: true progress in the treatment of polycystic ovary syndrome and ovulation induction.
Galletta, M; Grasso, S; Roseff, SJ; Vaiarelli, A, 2011
)
1.45
"myo-Inositol is an essential precursor for the production of inositol phosphates and inositol phospholipids in all eukaryotes. "( myo-Inositol uptake is essential for bulk inositol phospholipid but not glycosylphosphatidylinositol synthesis in Trypanosoma brucei.
Bütikofer, P; Gonzalez-Salgado, A; Greganova, E; Mäser, P; Rauch, M; Sigel, E; Steinmann, ME, 2012
)
1.5
"Inositol serves as a module for the generation of a high level of molecular diversity through the combinatorial attachment and removal of phosphate groups. "( Cell signalling by inositol pyrophosphates.
Saiardi, A, 2012
)
2.15
"Inositol is an essential nutrient required by human cells in culture for growth and survival. "( Inositol for respiratory distress syndrome in preterm infants.
Howlett, A; Ohlsson, A; Plakkal, N, 2012
)
3.26
"Myo-inositol is a 6-carbon cyclic polyalcohol also known as meso-inositol, meat sugar, inosite, and i-inositol. "( Determination of myo-inositol (free and bound as phosphatidylinositol) in infant formula and adult nutritionals by liquid chromatography/pulsed amperometry with column switching: first action 2011.18.
Baugh, S; Schimpf, K; Thompson, L,
)
1.01
"Myo-inositol (mIns) is a marker of glial cells proliferation and has been shown to increase in early Alzheimer's disease (AD) pathology. "( MICEST: a potential tool for non-invasive detection of molecular changes in Alzheimer's disease.
Cai, K; Crescenzi, R; Hariharan, H; Haris, M; Kogan, F; Nath, K; Reddy, R; Singh, A, 2013
)
0.95
"Inositol is an essential nutrient required by human cells in culture for growth and survival. "( Inositol for respiratory distress syndrome in preterm infants.
Howlett, A; Ohlsson, A, 2003
)
3.2
"Myo-inositol is a strongly coupled system and resonates at four chemical shift positions. "( A comparative study of myo-inositol quantification using LCmodel at 1.5 T and 3.0 T with 3 D 1H proton spectroscopic imaging of the human brain.
Hurd, R; Nelson, S; Sailasuta, N; Srinivasan, R; Vigneron, D, 2004
)
1.18
"myo-Inositol (mI) is a key metabolic precursor to the phospoinositide (PI) metabolic pathway as a key component of central G-protein coupled receptor signaling systems, including several subtypes of adrenergic, cholinergic, serotonergic and metabotropic glutamatergic receptors. "( Effects of myo-inositol versus fluoxetine and imipramine pretreatments on serotonin 5HT2A and muscarinic acetylcholine receptors in human neuroblastoma cells.
Brink, CB; de Kock, SE; Harvey, BH; Stein, DJ; Viljoen, SL, 2004
)
1.23
"Inositol is an essential precursor for the formation of glycosyl-phosphatidylinositol (GPI)-anchors found in the majority of surface molecules in trypanosomatids, in addition to its requirement for phoshatidylinositol signal transduction pathways. "( Substrate specificity of the Leishmania donovani myo-inositol transporter: critical role of inositol C-2, C-3 and C-5 hydroxyl groups.
Ganapasam, S; Hobbs, SB; Mongan, TP; Seyfang, A, 2004
)
2.02
"Myo-inositol is an important component of the phosphatidylinositol second messenger system (PI-cycle). "( Bipolar disorder and myo-inositol: a review of the magnetic resonance spectroscopy findings.
Kim, H; McGrath, BM; Silverstone, PH, 2005
)
1.19
"Myo-inositol is an important part of the phosphatidylinositol second messenger system (PI-cycle). "( A review of the possible relevance of inositol and the phosphatidylinositol second messenger system (PI-cycle) to psychiatric disorders--focus on magnetic resonance spectroscopy (MRS) studies.
Kim, H; McGrath, BM; Silverstone, PH, 2005
)
1.16
"Inositol is a simple polyol with eight naturally occurring stereoisomers. "( Properties of scyllo-inositol as a therapeutic treatment of AD-like pathology.
Brown, M; Fenili, D; McLaurin, J; Rappaport, R, 2007
)
2.1
"Myo-inositol is a simple and safe treatment that is capable of restoring spontaneous ovarian activity and consequently fertility in most patients with PCOS. "( Myo-inositol in patients with polycystic ovary syndrome: a novel method for ovulation induction.
Baillargeon, JP; Brigante, C; Cino, I; De Santis, L; Ferrari, A; Fusi, F; Marelli, G; Papaleo, E; Redaelli, A; Unfer, V, 2007
)
1.46
"Myo-inositol is a necessary component of the phospholipid phosphatidyl-inositol, which is an important membrane constituent."( Inositol as a lipotropic agent in dairy cattle diets.
Emery, RS; Gerloff, BJ; Herdt, TH; Wells, WW, 1984
)
2.19
"Inositol is a precursor for the synthesis of phosphatidylinositol (PI)."( Unusual effect of myo-inositol on phospholipid biosynthesis in Cryptococcus neoformans.
Klig, LS; Vincent, VL, 1995
)
1.33
"Inositol is a key metabolite in the phosphatidylinositol cycle, which is a second messenger system for serotonin-2 receptors that have been implicated in the pathophysiology of schizophrenia. "( CSF inositol in schizophrenia and high-dose inositol treatment of schizophrenia.
Agam, G; Belmaker, RH; Elizur, A; Goldberger, I; Levine, J; Rapaport, A; Schield, C; Schwartz, M; Shapiro, J, 1994
)
2.29
"Myo-inositol is an important precursor in cellular second-messenger synthesis. "( The effect of peripheral inositol injection on rat motor activity models of depression.
Alpert, C; Belmaker, RH; Bersudsky, Y; Kofman, O; Vinnitsky, I, 1993
)
1.15
"Inositol is a key precursor for synthesis of phosphatidylinositol in a major second messenger signalling system. "( Inositol treatment raises CSF inositol levels.
Agam, G; Belmaker, RH; Bersudsky, Y; Kofman, O; Lev, L; Levine, J; Rapaport, A; Shapiro, J, 1993
)
3.17
"myo-Inositol is a naturally occurring compound of particular interest because of its exceedingly low toxicity."( Chalcones, myo-inositol and other novel inhibitors of pulmonary carcinogenesis.
Wattenberg, L, 1995
)
1.13
"Myo-inositol (MI) is an important factor in the synthesis of phosphoinositides, and as an osmolyte, MI contributes to the regulation of cell volume. "( Osmotic regulation of Na-myo-inositol cotransporter mRNA level and activity in endothelial and neural cells.
Conner, CE; Dunlap, JA; Grzybowski, JA; Lowe, WL; Wiese, TJ; Yorek, MA, 1996
)
1.14
"Inositol is a simple polyol precursor in a second messenger system important in the brain. "( Controlled trials of inositol in psychiatry.
Levine, J, 1997
)
2.06
"Inositol is a simple dietary polyol that serves as a precursor in important second messenger systems. "( Inositol has behavioral effects with adaptation after chronic administration.
Belmaker, RH; Cohen, H; Kaplan, Z; Kofman, O; Kotler, M; Matar, MA, 1997
)
3.18
"Inositol is a precursor of the second messenger for some serotonin receptors, and has been reported effective in depression, panic disorder and obsessive-compulsive disorder."( Inositol treatment of autism.
Aviram, A; Barak, Y; Belmaker, RH; Holan, A; Levine, J; Ring, A, 1997
)
2.46
"Myo-inositol is a major compatible osmolyte in the renal medulla that is accumulated under hypertonic conditions via the Na+/myo-inositol cotransporter (SMIT). "( Inhibition of myo-inositol transport causes acute renal failure with selective medullary injury in the rat.
Hori, M; Horio, M; Imai, E; Kitamura, H; Matsuoka, Y; Shimada, S; Sugiura, T; Tohyama, M; Yamauchi, A, 1998
)
1.19
"Myo-inositol is an isomer of glucose that is a precursor in the phosphatidylinositol (PIP) cycle, a source of two second messengers: diacylglycerol (DAG) and inositol triphosphate (IP3). "( Inositol reduces depressive-like behaviors in two different animal models of depression.
Belmaker, RH; Einat, H; Karbovski, H; Korik, J; Tsalah, D, 1999
)
2.3
"myo-inositol is a growth factor for mammalian cells as well as for the pathogenic protozoa Trypanosoma cruzi. "( Characterization of the myo-inositol transport system in Trypanosoma cruzi.
Almeida, AC; Caruso-Neves, C; de Castro, SL; Einicker-Lamas, M; Oliveira, MM; Todorov, AG, 2000
)
1.16
"Inositol is an essential nutrient required by human cells in culture for growth and survival. "( Inositol for respiratory distress syndrome in preterm infants.
Howlett, A; Ohlsson, A, 2000
)
3.19
"Inositol is an essential nutrient required by human cells in culture for growth and survival. "( Inositol for respiratory distress syndrome in preterm infants.
Howlett, A; Ohlsson, A, 2000
)
3.19
"Inositol is a simple polyol precursor in a second messenger system important in brain myo-insitol, the natural isomer, which has been found to be therapeutically effective in depression, panic disorder, and obsessive-compulsive disorder in double-blind controlled trials. "( Epi-inositol and inositol depletion: two new treatment approaches in affective disorder.
Belmaker, RH; Bersudsky, Y; Einat, H; Stahl, Z, 1999
)
2.3
"Inositol is a constituent of the intracellular phosphatidyl inositol (PI) second messenger system, which is linked to various neurotransmitter receptors. "( Inositol as an add-on treatment for bipolar depression.
Buttenfield, J; Chengappa, KN; Gershon, S; Hardan, A; Kupfer, DJ; Levine, J; Luther, J; Mallinger, AG; Pollock, B; Vagnucci, A; Verfaille, S, 2000
)
3.19
"Myo-inositol is a 6-carbon alcohol which acquires new interest from its detection and quantitation in 1H spectra."( Biochemical considerations in 1H spectroscopy. Glutamate and glutamine; myo-inositol and related metabolites.
Ross, BD, 1991
)
0.99
"Inositol was found to be a potentiating factor of vir-inducing activity, which enhanced the vir-inducing activity of AS and HOAS in a synergistic manner, in particular at a low concentrations of AS and HOAS."( Synergistic action of phenolic signal compounds and carbohydrates in the induction of virulence gene expression of Agrobacterium tumefaciens.
Ebizuka, Y; Sankawa, U; Shibuya, M; Song, YN, 1991
)
1
"myo-Inositol was shown to be a long-living metabolite."( Competitive inhibition by glucose of myo-inositol incorporation into cultured porcine aortic endothelial cells.
Gerbitz, KD; Olgemöller, B; Schleicher, ED; Schwaabe, S, 1990
)
1.03
"Inositol is a major component of the intracellular mediators of insulin action. "( Low urinary chiro-inositol excretion in non-insulin-dependent diabetes mellitus.
Bogardus, C; Craig, J; Hansen, BC; Hill, CR; Kennington, AS; Larner, J; Ortmeyer, HK; Raz, I; Romero, G, 1990
)
2.06
"Myo-inositol is a precursor of inositol phospholipids (IPLs), whose metabolism is responsible for a number of signal transduction processes."( [Abnormal inositol phospholipid metabolism as a main factor causing pericyte drop-out in diabetic retinopathy].
Li, WY, 1989
)
1.16
"Myoinositol appears to be a competitive inhibitor of alpha-galactosidase activity in fibroblasts of normal human skin but not of the residual alpha-galactosidase activity of fibroblasts obtained from patients with Fabry's disease. "( Fabry's disease: differentiation between two forms of -galactosidase by myoinositol.
Banfalvi, M; Crawhall, JC, 1972
)
1.1

Effects

Myo-inositol (myoIns) has a positive role in mammalian development and human reproduction. Inositol deregulation has been found in a number of conditions mechanistically and epidemiologically associated to high-glucose diets or altered glucose metabolism.

ExcerptReferenceRelevance
"Myo-inositol (myoIns) has a positive role in mammalian development and human reproduction. "( Improvement of mouse embryo quality by myo-inositol supplementation of IVF media.
Bevilacqua, A; Carlomagno, G; Colazingari, S; Fiorenza, MT; Najjar, R, 2014
)
1.22
"Inositol depletion has been associated with diabetes and related complications. "( Inositol in Disease and Development: Roles of Catabolism via
Contreras, A; Eldon, ED; Jones, MK; Klig, LS, 2023
)
3.8
"Myo-inositol has emerged as one of the preventive therapies for the development of gestational diabetes mellitus in at-risk populations. "( The Efficacy and Safety of Myo-inositol Supplementation for the Prevention of Gestational Diabetes Mellitus in Overweight and Obese Pregnant Women: A Systematic Review and Meta-Analysis.
Corpuz, H; Factor, PA, 2023
)
1.75
"Myo-inositol (MI) has gained relevance in physiology research during the last decade. "( Myo-inositol: its metabolism and potential implications for poultry nutrition-a review.
Gonzalez-Uarquin, F; Huber, K; Rodehutscord, M, 2020
)
1.67
"Myo-inositol has been suggested to improve insulin resistance in women with polycystic ovary syndrome."( Effect of dietary myo-inositol supplementation on the insulin resistance and the prevention of gestational diabetes mellitus: study protocol for a randomized controlled trial.
Anastasiou, E; Antsaklis, P; Asimakopoulos, G; Daskalakis, G; Kallergi, A; Loutradis, D; Pergialiotis, V; Sindos, M; Theodora, M; Vogiatzi, E, 2020
)
1.35
"Inositol deregulation has been found in a number of conditions mechanistically and epidemiologically associated to high-glucose diets or altered glucose metabolism."( Nutritional and Acquired Deficiencies in Inositol Bioavailability. Correlations with Metabolic Disorders.
Bizzarri, M; Cucina, A; Dinicola, S; Minini, M; Unfer, V; Verna, R, 2017
)
1.44
"Inositol has been reported to improve insulin sensitivity since it works as a second messenger achieving insulin-like effects on metabolic enzymes. "( Combination of inositol and alpha lipoic acid in metabolic syndrome-affected women: a randomized placebo-controlled trial.
Botti, G; Brillante, G; Capasso, I; Cavalcanti, E; Ciliberto, G; Crispo, A; D'Aiuto, G; D'Aiuto, M; De Laurentiis, M; Esposito, E; Esposito, G; Frasci, G; Fucito, A; Grimaldi, M; Maurea, N; Montella, M, 2013
)
2.19
"Myo-inositol (myoIns) has a positive role in mammalian development and human reproduction. "( Improvement of mouse embryo quality by myo-inositol supplementation of IVF media.
Bevilacqua, A; Carlomagno, G; Colazingari, S; Fiorenza, MT; Najjar, R, 2014
)
1.22
"Myo-inositol has documented in clinical studies its effectiveness in improving the metabolic syndrome in post menopausal women."( Resveratrol, inositol, vitamin D and K in the prevention of cardiovascular and osteoporotic risk: a novel approach in peri- and postmenopause.
Parazzini, F, 2014
)
1.25
"Inositol has been proposed as a food supplement that might reduce gestational diabetes incidence in high-risk pregnant women."( Myo-Inositol Supplementation to Prevent Gestational Diabetes Mellitus.
Celentano, C; Liberati, M; Matarrelli, B; Mattei, PA; Pavone, G; Vitacolonna, E, 2016
)
1.71
"Myoinositol has promising therapeutic potential."( Inositol(s) in thyroid function, growth and autoimmunity.
Antonelli, A; Benvenga, S, 2016
)
2.39
"Myo-inositol has been trialed in humans for a range of conditions and appears safe for use in human pregnancy."( Inositol, neural tube closure and the prevention of neural tube defects.
Copp, AJ; Greene, ND; Leung, KY, 2017
)
2.38
"Myo-inositol has been observed to have anti-oxidant properties and be present in much greater concentrations specifically in seminal liquid than in the blood."( In vitro effect of myo-inositol on sperm motility in normal and oligoasthenospermia patients undergoing in vitro fertilization.
Artini, PG; Carletti, E; Casarosa, E; Di Berardino, OM; Di Noia, A; Monteleone, P, 2017
)
1.25
"Myo-inositol has been classified as an insulin sensitizing agent and it is commonly used in the treatment of the Polycystic Ovary Syndrome (PCOS)."( Inositol safety: clinical evidences.
Carlomagno, G; Unfer, V, 2011
)
2.29
"Some inositol isomers have been reported to possess insulin-mimetic activity and to be efficient in lowering blood glucose level."( Chronic treatment with myo-inositol reduces white adipose tissue accretion and improves insulin sensitivity in female mice.
Croze, ML; Guichardant, M; Hadji, L; Pillon, NJ; Soula, HA; Soulage, CO; Vella, RE, 2013
)
1.14
"myo-Inositol biosynthesis has been examined in hypophysectomized and thyroidectomized male rats. "( Selective hormonal control of myo-inositol biosynthesis in reproductive organs and liver of the male rat.
Eisenberg, F; Hasegawa, R, 1981
)
1.1
"Inositol levels have been studied in cellular cultures and recently by perfusion of isolated hearts. "( A new method to measure cardiac inositol levels in intact animals.
Antona, A; Bellanca, L; Bucca, V; D'Amico, C; Di Pasquale, P; Licata, G; Palazzoadriano, M; Paterna, S, 1996
)
2.02
"Oral inositol has been reported to have antidepressant and antipanic properties in humans. "( Differential uptake of myo-inositol in vivo into rat brain areas.
Belmaker, RH; Berger, M; Kofman, O; Lubrich, B; Patishi, Y; van Calker, D, 1996
)
1.1
"myo-Inositol has been believed to be a sole inositol isomer existing in phosphatidylinositol (PI) and related derivatives. "( Identification of chiro-inositol and its formation by isomerization of myo-inositol during hydrolysis of glycosylphosphatidylinositol-anchored proteins.
Ikezawa, H; Taguchi, R; Tsutsui, Y; Yamazaki, J, 1997
)
1.16
"myo-Inositol has been found to be clinically effective in depression, obsessive compulsive disorder (OCD) and panic disorder when given chronically per os. "( Chronic dietary inositol enhances locomotor activity and brain inositol levels in rats.
Agam, G; Kofman, O; Shapiro, J; Spencer, A, 1998
)
1.2
"Inositol has been reported to be effective in treating central nervous system disorders such as depression, Alzheimer's disease, panic disorder, and obsessive-compulsive disorder."( Inositol--clinical applications for exogenous use.
Colodny, L; Hoffman, RL, 1998
)
2.46
"Inositol has been cited as being essential for the growth of micro-organisms and animals. "( Effects of fluorinated inositols on the phosphoinositide metabolism and the proliferation of Trypanosoma cruzi.
de Castro, SL; Einicker-Lamas, M; Malaquias, AT; Oliveira, MM; Smith, GA, 1999
)
2.06
"Inositol has been reported to be an effective treatment in depression, and we hypothesized that inositol addition might enhance or speed up response to serotonin selective reuptake inhibitors (SSRI)."( Combination of inositol and serotonin reuptake inhibitors in the treatment of depression.
Belmaker, RH; Levine, J; Martin, M; Mishori, A; Susnosky, M, 1999
)
2.1
"Inositol acylation has to precede the mannosylation of GPIs because, in the absence of acyl-CoA or CoA, mannosylated GPIs were not detected."( Biosynthesis of glycosylphosphatidylinositols of Plasmodium falciparum in a cell-free incubation system: inositol acylation is needed for mannosylation of glycosylphosphatidylinositols.
Azzouz, N; Freiberg, N; Gerold, P; Jung, N; Kobe, S; Schwarz, RT, 1999
)
1.3
"Inositol has 8 stereoisomers, four of which are physiologically active. "( Inositol stereoisomers stabilize an oligomeric aggregate of Alzheimer amyloid beta peptide and inhibit abeta -induced toxicity.
Antel, JP; Fraser, PE; Golomb, R; Jurewicz, A; McLaurin, J, 2000
)
3.19
"Inositol has demonstrated antidepressant effects but in a controlled double blind augmentation trial did not improve depression in SSRI treatment failures."( Inositol addition does not improve depression in SSRI treatment failures.
Belmaker, RH; Levine, J; Mishory, A; Nemets, B, 1999
)
2.47

Actions

Myoinositol supplement increase clinical pregnancy rate in infertile women undergoing ovulation induction for ICSI or IVF-ET. Myo-inositol is related to lower incidence of GDM, as well as fasting, 1h, and 2h OGTT value, in pregnant women with high risk of this condition.

ExcerptReferenceRelevance
"Inositol plays a significant role in cellular function and signaling. "( Inositol depletion regulates phospholipid metabolism and activates stress signaling in HEK293T cells.
Case, KC; Greenberg, ML; Lazcano, P; Onu, CJ; Schmidtke, MW; Suliman, M, 2022
)
3.61
"Myo-inositol may enhance the inhibitory effect of metformin on gonadotropin production in postmenopausal women."( Myo-Inositol Enhances the Inhibitory Effect of Metformin on Gonadotropin Levels in Postmenopausal Women.
Kowalcze, K; Krysiak, R; Okopień, B, 2022
)
1.84
"Myoinositol supplement increase clinical pregnancy rate in infertile women undergoing ovulation induction for ICSI or IVF-ET. "( Inositol supplement improves clinical pregnancy rate in infertile women undergoing ovulation induction for ICSI or IVF-ET.
Li, S; Lin, D; Lin, Y; Song, J; Sun, Y; Zhang, Y; Zheng, X, 2017
)
2.52
"Myo-inositol is related to lower incidence of GDM, as well as fasting, 1h, and 2h OGTT value, in pregnant women with high risk of this condition. "( Myo-inositol lowers the risk of developing gestational diabetic mellitus in pregnancies: A systematic review and meta-analysis of randomized controlled trials with trial sequential analysis.
Guo, S; Guo, X; Li, Z; Miao, Z; Zhang, H, 2018
)
1.6
"Myo-inositol (Myo-Ins) plays an important role in thyroid function and autoimmunity. "( Myo-inositol in autoimmune thyroiditis, and hypothyroidism.
Antonelli, A; Caruso, C; Elia, G; Fallahi, P; Ferrari, SM; Guglielmi, G; Paparo, SR; Ragusa, F, 2018
)
1.6
"Inositol promotes maturation of several components of surfactant and may play a critical role in fetal and early neonatal life."( Inositol in preterm infants at risk for or having respiratory distress syndrome.
Howlett, A; Ohlsson, A; Plakkal, N, 2019
)
2.68
"Inositol promotes maturation of several components of surfactant and may play a critical role in fetal and early neonatal life."( Inositol in preterm infants at risk for or having respiratory distress syndrome.
Howlett, A; Ohlsson, A; Plakkal, N, 2015
)
2.58
"Inositol displays multi-targeted effects on many biochemical pathways involved in epithelial-mesenchymal transition (EMT). "( Inositol induces mesenchymal-epithelial reversion in breast cancer cells through cytoskeleton rearrangement.
Alwasel, SH; Bizzarri, M; Catizone, A; Cucina, A; Dinicola, S; Fabrizi, G; Harrath, AH; Masiello, MG; Minini, M; Palombo, A; Proietti, S; Ricci, G, 2016
)
3.32
"myo-Inositol (MI) plays an essential role in several important processes of cell physiology, is involved in the neural system, and provides an effective treatment for some psychiatric disorders. "( Sodium/myo-inositol cotransporter 1 and myo-inositol are essential for osteogenesis and bone formation.
Chan, AW; Chung, SK; Dai, Z; Kung, AW; Lau, KS; Miao, D, 2011
)
1.32
"Myo-inositol plays key physiological functions, necessitating development of methodology for quantification in biological matrices. "( Quantitative analysis of myo-inositol in urine, blood and nutritional supplements by high-performance liquid chromatography tandem mass spectrometry.
Burren, KA; Copp, AJ; Greene, ND; Leung, KY; Mills, K, 2011
)
1.22
"Inositol promotes maturation of several components of surfactant and may play a critical role in fetal and early neonatal life."( Inositol for respiratory distress syndrome in preterm infants.
Howlett, A; Ohlsson, A; Plakkal, N, 2012
)
2.54
"Myo-inositol plays a key role in an important intracellular signalling pathway. "( Kinetics of myo-inositol loading in women of reproductive age.
Groenen, PM; Janssen, FS; Merkus, HM; Steegers-Theunissen, RP; Sweep, FC; Wevers, RA, 2003
)
1.22
"Inositol promotes maturation of several components of surfactant and may play a critical role in fetal and early neonatal life."( Inositol for respiratory distress syndrome in preterm infants.
Howlett, A; Ohlsson, A, 2003
)
2.48
"Inositol plays a major role in the regulation of phospholipid synthesis."( Phospholipid synthesis in yeast: regulation by phosphorylation.
Carman, GM; Kersting, MC, 2004
)
1.04
"Inositol plays a key role in dopamine, serotonin, noradrenaline and acetylcholine neurotransmission, and inositol treatment is reported to have beneficial effects in depression and anxiety. "( Behavioural phenotyping of sodium-myo-inositol cotransporter heterozygous knockout mice with reduced brain inositol.
Agam, G; Belmaker, RH; Berry, GT; Bersudsky, Y; Buccafusca, R; Johanson, RA; Shaldubina, A, 2007
)
2.05
"myo-Inositol plays a key role in signal transduction and osmotic regulation events in the CNS. "( Differentiated human NT2-N neurons possess a high intracellular content of myo-inositol.
Agranoff, BW; Fisher, SK; Novak, JE; Turner, RS, 1999
)
1.09
"Myo-inositol did not cause any undesirable metabolic changes in the rats."( The effect of myo-inositol on ethanol-induced metabolic changes and insulin concentration in the rat.
Kandulska, K; Szkudelski, T, 1999
)
1.12
"Inositol promotes maturation of several components of surfactant and may play a critical role in fetal and early neonatal life."( Inositol for respiratory distress syndrome in preterm infants.
Howlett, A; Ohlsson, A, 2000
)
2.47
"Inositol promotes maturation of several components of surfactant and may play a critical role in fetal and early neonatal life."( Inositol for respiratory distress syndrome in preterm infants.
Howlett, A; Ohlsson, A, 2000
)
2.47
"Inositol promotes endothelial cell growth, enhances glucocorticoid-mediated lung epithelial cell differentiation, and may serve as an antioxidant."( Inositol supplementation in respiratory distress syndrome.
Bry, K; Hallman, M; Pohjavuori, M, 1990
)
2.44
"Inositol was found to inhibit glycerolphosphate phosphatidyltransferase in the microsomal fraction but not in the mitochondrial fraction derived from the type II cells, indicating that the competition between phosphatidylglycerol and phosphatidylinositol synthesis for CDP diacylglycerol takes place in the endoplasmic reticulum."( Regulation and location of phosphatidylglycerol and phosphatidylinositol synthesis in type II cells isolated from fetal rat lung.
Batenburg, JJ; Klazinga, W; van Golde, LM, 1985
)
1.23

Treatment

Myo-inositol treatment resulted in positive modulation of PINK1/Parkin pathway as well as PHB2 and NIX. Myoinositol-treated animals had significantly fewer demyelinating lesions than mannitol.

ExcerptReferenceRelevance
"Myo-inositol treatment resulted in positive modulation of PINK1/Parkin pathway as well as PHB2 and NIX."( Renoprotective potential of myo-inositol on diabetic kidney disease: Focus on the role of the PINK1/Parkin pathway and mitophagy receptors.
Arruri, VK; Kalvala, AK; Khatri, DK; Sherkhane, B; Singh, SB, 2022
)
1.49
"Inositol treatments should be evaluated on the patients' specific conditions and needs, as long-term supplementation of high doses of DCI may cause detrimental effects on the ovarian functionality."( Inositols in the ovaries: activities and potential therapeutic applications.
Alkatout, I; Bianco, B; Bizzarri, M; Forte, G; Gitas, G; Kamenov, ZA; Kaya, C; Laganà, AS; Terzic, M; Unfer, V, 2022
)
2.89
"Myo-inositol treatment ameliorated the decreased expression of ZO-1 and synaptopodin in an in vitro FSGS model, and as myo-inositol increased, myo-inositol oxygenase tissue expression decreased proportionally to eGFR."( Urinary myo-inositol is associated with the clinical outcome in focal segmental glomerulosclerosis.
An, JN; Cho, JH; Choi, YW; Ha, H; Hwang, GS; Hyeon, JS; Jung, Y; Kim, DK; Kim, JH; Kwon, S; Lee, JP; Lee, SH; Oh, S; Park, SH; Yang, SH, 2019
)
1.37
"Myo-inositol treatment in early pregnancy is associated with a reduction in the rate of gestational diabetes mellitus and in the risk of preterm birth and macrosomia in women who are at risk for gestational diabetes mellitus."( Clinical and metabolic outcomes in pregnant women at risk for gestational diabetes mellitus supplemented with myo-inositol: a secondary analysis from 3 RCTs.
Alibrandi, A; Corrado, F; D'Anna, R; Di Benedetto, A; Facchinetti, F; Pintaudi, B; Santamaria, A, 2018
)
1.25
"Myo-inositol treatment ameliorates insulin resistance and body weight, and improves ovarian activity in PCOS patients."( Ovulation induction with myo-inositol alone and in combination with clomiphene citrate in polycystic ovarian syndrome patients with insulin resistance.
Carlomagno, G; Gateva, A; Genazzani, AD; Kamenov, Z; Kolarov, G, 2015
)
1.27
"Myo-inositol treatment was associated with a 67% risk reduction of developing GDM (OR 0.33; 95% CI 0.15-0.70)."( Myo-inositol may prevent gestational diabetes onset in overweight women: a randomized, controlled trial.
Corrado, F; D'Anna, R; Di Benedetto, A; Facchinetti, F; Neri, I; Petrella, E; Pintaudi, B; Santamaria, A, 2016
)
1.47
"Myoinositol-treated animals had significantly fewer demyelinating lesions than mannitol (2.25 +/- 1.1 versus 6.42 +/- 1.4 lesions/brain, p < 0.03)."( Myoinositol administration improves survival and reduces myelinolysis after rapid correction of chronic hyponatremia in rats.
Rojiani, AM; Schroeder, BM; Silver, SM; Sterns, RH, 2006
)
1.47
"Myo-Inositol treatment at 650 mg ."( Myo-inositol and sorbitol metabolism in relation to peripheral nerve function in experimental diabetes in the rat: the effect of aldose reductase inhibition.
Gillon, KR; Hawthorne, JN; Tomlinson, DR, 1983
)
1.3
"Myoinositol treatment affected neither content nor labeling of phosphatidylcholine or disaturated phosphatidylcholine as studied within 50 h of administration."( Analysis of labeling and clearance of lung surfactant phospholipids in rabbit. Evidence of bidirectional surfactant flux between lamellar bodies and alveolar lavage.
Epstein, BL; Gluck, L; Hallman, M, 1981
)
0.78
"Oral inositol treatment of 8 patients is shown to significantly increase CSF inositol by almost 70%, suggesting possible CNS therapeutic applications of this compound and possible CNS side-effects of systemic therapy."( Inositol treatment raises CSF inositol levels.
Agam, G; Belmaker, RH; Bersudsky, Y; Kofman, O; Lev, L; Levine, J; Rapaport, A; Shapiro, J, 1993
)
2.18
"Inositol treatment had no significant effect on levels of monoamines, their metabolites, or turnover rates compared to controls."( Rat brain monoamines after acute and chronic myo-inositol treatment.
Belmaker, RH; Ben-Shachar, D; Einat, H; Gazawi, H; Klein, E; Kopilov, M, 1999
)
1.28
"Inositol treatment was not observed to have any effect on amphetamine-induced hyperactivity, apomorphine-induced stereotypy, or on the performance of memory tasks by monkeys."( The effects of inositol treatment in animal models of psychiatric disorders.
Belmaker, RH; Einat, H, 2001
)
1.38
"Myo-inositol treatment could not improve Ca2(+)-uptake activity in diabetic rats."( Calcium uptake activity of cardiac sarcoplasmic reticulum in myo-inositol-treated diabetic rats.
McNeill, JH; Xiang, H, 1990
)
1
"Myo-inositol treatment also partially prevented the rise in adrenal adrenaline."( Tissue noradrenaline and the polyol pathway in experimentally diabetic rats.
Lucas, PD; Qirbi, A, 1989
)
0.76
"Myo-inositol treatment did not affect nerve levels."( The effect of aldose reductase inhibition on the pattern of nerve conduction deficits in diabetic rats.
Cameron, NE; Cotter, MA; Robertson, S, 1989
)
0.76
"Myo-inositol treatment leads to a normalization of blood-brain barrier permeability; it is suggested that myo-inositol exerts a restituting effect upon Na+/K+-ATPase activity of the cerebral endothelial cells."( Myo-inositol normalizes decreased sodium permeability of the blood-brain barrier in streptozotocin diabetes.
Barry, DI; Compton, AM; Jakobsen, J; Knudsen, GM; Tomlinson, DR, 1989
)
1.32
"myo-inositol treatment partially improved cardiac performance in STZ-D rats."( Effect of myo-inositol and T3 on myocardial lipids and cardiac function in streptozocin-induced diabetic rats.
Heyliger, CE; McNeill, JH; Xiang, H, 1988
)
1.12
"Treatment with inositol significantly downregulated ASS1 deficiency-mediated signaling pathways and reduced cell invasiveness in IPF lung fibroblasts."( Inositol possesses antifibrotic activity and mitigates pulmonary fibrosis.
Chang, WH; Chen, CH; Hsu, SW; Kenyon, NJ; Li, JM; Li, L; Yang, DC, 2023
)
2.69
"Heat-treatment of inositol-rich frozen solutions resulted in high crystallinity stable-form inositol solids, leaving dextran in the amorphous state."( Effect of co-solutes and process variables on crystallinity and the crystal form of freeze-dried myo-inositol.
Arai, R; Goda, Y; Ito, M; Izutsu, KI; Kusano, R; Shibata, H; Sugano, K; Terada, K; Yoshida, H, 2016
)
0.97
"Oral treatment with inositol nicotinate (Hexopal) was followed by an initial rise in the thermographic index in both areas."( Quantitative thermographic assessment of inositol nicotinate therapy in Raynaud's phenomena.
Bacon, PA; Ring, EF, 1977
)
0.84

Toxicity

Inositol is an effective and safe treatment in PCOS. Adverse events and comorbidities were fewer in the inositol groups, but not significantly so.

ExcerptReferenceRelevance
" The toxic compounds could be separated by column chromatography or methanol solubility, but were unstable and could not be isolated in pure form."( Toxicity of fractions obtained from the legume species Astragalus lusitanicus Lam. lusitanicus.
Sanz, F; Tarazona, JV, 1990
)
0.28
"To determine whether so-called uraemic toxins exhibit direct toxic effects on Schwann cells, the latter were cultured in a monolayer with the addition of uraemic toxins."( Myoinositol inhibits proliferation of cultured Schwann cells: evidence for neurotoxicity of myoinositol.
Maeda, K; Mitsuma, T; Niwa, T; Sobue, G, 1989
)
0.9
" Toxicity studies allowed us to establish the LD50 (750 mg/kg body weight)."( A synthetic, nitrogenated antimetastatic and anti-angiogenic compound with low toxicity in vivo.
Cerutti, ML; Colombo, L; D'Orio, E; Davel, L; Diament, M; Eiján, AM; Gelpi, ME; Leicach, SR; Parma, P; Stillitani, I, 1999
)
0.3
" It was therefore investigated whether pilocarpine was also toxic to retinal ganglion cells."( Pilocarpine toxicity in retinal ganglion cells.
Dreyer, EB; Gorla, M; Katowitz, W; Levin, LA; Simon, P; Vorwerk, CK; Zurakowski, D, 1999
)
0.3
"Pilocarpine was toxic to retinal ganglion cells in a dose-dependent fashion."( Pilocarpine toxicity in retinal ganglion cells.
Dreyer, EB; Gorla, M; Katowitz, W; Levin, LA; Simon, P; Vorwerk, CK; Zurakowski, D, 1999
)
0.3
"Pilocarpine is toxic to retinal ganglion cells in a mixed culture assay."( Pilocarpine toxicity in retinal ganglion cells.
Dreyer, EB; Gorla, M; Katowitz, W; Levin, LA; Simon, P; Vorwerk, CK; Zurakowski, D, 1999
)
0.3
" Adverse drug events were more commonly reported in acarbose-treated patients (P<0."( Efficacy and safety of voglibose in comparison with acarbose in type 2 diabetic patients.
Ploybutr, S; Tunlakit, M; Vichayanrat, A; Watanakejorn, P, 2002
)
0.31
" No serious adverse effects such as hypoglycemia, liver impairment or rhabdomyolysis were observed in any of the patients."( Combination therapy of pioglitazone with voglibose improves glycemic control safely and rapidly in Japanese type 2-diabetic patients on hemodialysis.
Abe, M; Kaizu, K; Kikuchi, F; Matsumoto, K, 2007
)
0.34
"Pioglitazone was safe and effective as a treatment for diabetics on dialysis therapy."( Combination therapy of pioglitazone with voglibose improves glycemic control safely and rapidly in Japanese type 2-diabetic patients on hemodialysis.
Abe, M; Kaizu, K; Kikuchi, F; Matsumoto, K, 2007
)
0.34
" Yet, if this metabolic pathway is perturbed due to congenital deficiencies of the three associated enzymes, or an overwhelming presence of galactose, this monosaccharide which is abundantly present in milk and many non-dairy foodstuffs, will become highly toxic to humans and animals."( Galactose toxicity in animals.
Elsas, LJ; Lai, K; Wierenga, KJ, 2009
)
0.35
" An understanding of structure-activity relationships (SARs) of chemicals can make a significant contribution to the identification of potential toxic effects early in the drug development process and aid in avoiding such problems."( Developing structure-activity relationships for the prediction of hepatotoxicity.
Fisk, L; Greene, N; Naven, RT; Note, RR; Patel, ML; Pelletier, DJ, 2010
)
0.36
" After 12 weeks, the incidences of clinical adverse experiences (AEs), drug-related AEs and gastrointestinal AEs in the sitagliptin group (48."( Efficacy and safety of sitagliptin monotherapy compared with voglibose in Japanese patients with type 2 diabetes: a randomized, double-blind trial.
Amatruda, JM; Arjona Ferreira, JC; Iwamoto, Y; Kadowaki, T; Nishii, M; Nonaka, K; Tajima, N; Taniguchi, T, 2010
)
0.36
" Overall adverse events (AEs) were lower in the vildagliptin-treated patients compared with that in the voglibose-treated patients (61."( Efficacy and safety of vildagliptin and voglibose in Japanese patients with type 2 diabetes: a 12-week, randomized, double-blind, active-controlled study.
Iwamoto, Y; Kashiwagi, A; Mimori, N; Suzuki, M; Tachibana, H; Terao, S; Yamada, N, 2010
)
0.36
" Drug-related adverse event rates were comparable across treatment groups over 12 weeks (9."( Linagliptin monotherapy provides superior glycaemic control versus placebo or voglibose with comparable safety in Japanese patients with type 2 diabetes: a randomized, placebo and active comparator-controlled, double-blind study.
Araki, E; Dugi, KA; Gong, Y; Hayashi, N; Horie, Y; Inagaki, N; Kawamori, R; Sarashina, A; von Eynatten, M; Watada, H; Woerle, HJ, 2012
)
0.38
" This loss appears due to the synaptic accumulation of toxic Aβ oligomers (ADDLs), which damages synapse structure and function."( Protection against the synaptic targeting and toxicity of Alzheimer's-associated Aβ oligomers by insulin mimetic chiro-inositols.
Brautigan, D; Klein, WL; Larner, J; Pitt, J; Thorner, M, 2013
)
0.6
" Long-term treatment with linagliptin was well tolerated; adverse events (AEs) of special interest and serious AEs occurred in small percentages of patients."( Long-term safety of linagliptin monotherapy in Japanese patients with type 2 diabetes.
Araki, E; Dugi, K; Hayashi, N; Horie, Y; Inagaki, N; Kawamori, R; Sarashina, A; Thiemann, S; von Eynatten, M; Watada, H; Woerle, HJ, 2013
)
0.39
"Lithium is the most effective mood stabilizer for the treatment of bipolar disorder, but it is toxic at only twice the therapeutic dosage and has many undesirable side effects."( A safe lithium mimetic for bipolar disorder.
Aley, PK; Antoniadou, I; Baldwin, R; Churchill, GC; Halliday, AC; Kuznetsova, OV; Sharp, T; Singh, N; Thomas, JM; Vasudevan, SR; Woon, EC, 2013
)
0.39
"Teneligliptin is a novel DPP-4 inhibitor in development for treating type 2 diabetes mellitus that does not require dose adjustment for diabetic patients with end-stage renal disease; however, it had not been known whether or not teneligliptin is safe or potent in dialysis patients."( Safety and efficacy of teneligliptin: a novel DPP-4 inhibitor for hemodialysis patients with type 2 diabetes.
Kosaka, T; Kuwahara, Y; Nakamura, K; Otsuki, H; Shimomura, F; Tsukamoto, T, 2014
)
0.4
" The prevalence of adverse events and the risk of hypoglycemia were similar for both groups."( A prospective, randomized, multicenter trial comparing the efficacy and safety of the concurrent use of long-acting insulin with mitiglinide or voglibose in patients with type 2 diabetes.
Baik, SH; Cha, BS; Jang, HC; Lee, IK; Lee, KW; Park, TS; Son, JW; Sung, YA; Woo, JT; Yoo, SJ; Yoon, KH, 2015
)
0.42
" The adverse event frequency in the therapy groups was similar to that in the placebo group."( Efficacy and Safety of "URSA Complex" in Subjects with Physical Fatigue: A Multicenter, Randomized, Double-blind, Placebo-controlled Trial.
Cho, DY; Kim, KM; Kim, KS; Kim, MJ; Kim, YS; Park, KC; Song, SW; Yang, SW, 2016
)
0.43
" Adverse events and comorbidities were fewer in the inositol groups, but not significantly so."( Safety and pharmacokinetics of multiple dose myo-inositol in preterm infants.
Ball, MB; Bell, EF; Carlo, WA; Carlton, DP; Chess, PR; Cotten, CM; Das, A; Ehrenkranz, RA; Faix, RG; Fennell, T; Frantz, ID; Goedecke, M; Hallman, M; Higgins, RD; Lacy, CB; Nolen, TL; Oh, W; Phelps, DL; Poindexter, BB; Sánchez, PJ; Shankaran, S; Walsh, MC; Ward, RM; Watterberg, KL; Williams, RL; Zaterka-Baxter, KM, 2016
)
0.94
"Multiple dose inositol at 80 mg/kg/d was not associated with increased adverse events, achieves previously effective serum levels, and is appropriate for investigation in a phase III trial."( Safety and pharmacokinetics of multiple dose myo-inositol in preterm infants.
Ball, MB; Bell, EF; Carlo, WA; Carlton, DP; Chess, PR; Cotten, CM; Das, A; Ehrenkranz, RA; Faix, RG; Fennell, T; Frantz, ID; Goedecke, M; Hallman, M; Higgins, RD; Lacy, CB; Nolen, TL; Oh, W; Phelps, DL; Poindexter, BB; Sánchez, PJ; Shankaran, S; Walsh, MC; Ward, RM; Watterberg, KL; Williams, RL; Zaterka-Baxter, KM, 2016
)
1.05
" We performed a random-effects meta-analysis of depression ratings, response, remission, and adverse effects calculating standardized mean difference (SMD) and risk ratio (RR) ±95% confidence intervals (CIs)."( Lamotrigine compared to placebo and other agents with antidepressant activity in patients with unipolar and bipolar depression: a comprehensive meta-analysis of efficacy and safety outcomes in short-term trials.
Anghelescu, IG; Correll, CU; Gao, K; Normann, C; Reis, C; Schaffer, A; Solmi, M; van der Loos, ML; Veronese, N; Zaninotto, L, 2016
)
0.43
" Adverse effects and all-cause/specific-cause discontinuation were similar across all comparisons."( Lamotrigine compared to placebo and other agents with antidepressant activity in patients with unipolar and bipolar depression: a comprehensive meta-analysis of efficacy and safety outcomes in short-term trials.
Anghelescu, IG; Correll, CU; Gao, K; Normann, C; Reis, C; Schaffer, A; Solmi, M; van der Loos, ML; Veronese, N; Zaninotto, L, 2016
)
0.43
"Lamotrigine was superior to placebo in improving unipolar and bipolar depressive symptoms, without causing more frequent adverse effects/discontinuations."( Lamotrigine compared to placebo and other agents with antidepressant activity in patients with unipolar and bipolar depression: a comprehensive meta-analysis of efficacy and safety outcomes in short-term trials.
Anghelescu, IG; Correll, CU; Gao, K; Normann, C; Reis, C; Schaffer, A; Solmi, M; van der Loos, ML; Veronese, N; Zaninotto, L, 2016
)
0.43
"Vogmet is a safe antihyperglycemic agent that controls blood glucose level effectively, yields weight loss, and is superior to metformin in terms of various key glycemic parameters without increasing the risk of hypoglycemia."( Efficacy and Safety of Voglibose Plus Metformin in Patients with Type 2 Diabetes Mellitus: A Randomized Controlled Trial.
Baik, SH; Cha, BS; Choi, SH; Jeong, IK; Kim, DM; Kim, IJ; Kim, SR; Kim, YS; Lee, IK; Lee, KW; Lee, MK; Min, KW; Oh, TJ; Park, JH; Park, JY; Park, SW; Park, TS; Son, HS; Song, YD; Yoon, KH; Yu, JM, 2019
)
0.51
"Arsenic is awfully toxic metalloid responsible for many human diseases all over the world."( Investigating the protective actions of D-pinitol against arsenic-induced toxicity in PC12 cells and the underlying mechanism.
Akter, M; Hosokawa, T; Kurasaki, M; Rahaman, MS; Rahman, MM; Saito, T; Sikder, MT, 2020
)
0.56
" Long-term exposure to arsenic has strong adverse health effects on liver and kidney disorders, and various forms of cancer."( Effects of curcumin, D-pinitol alone or in combination in cytotoxicity induced by arsenic in PC12 cells.
Binte Hossain, KF; Hosokawa, T; Kurasaki, M; Rahaman, MS; Saito, T; Yamasaki, S, 2020
)
0.56
"Raw materials for making dried shrimp (a type of foodstuff) are mostly from farmed shrimp and preliminary findings indicated that head copper (Cu) concentrations in some commercial dried shrimp products exceeded the safe limit specified in pollution-free aquatic products (50 mg/kg), which may influence food safety."( Role of myo-inositol supplementation against toxicity of excessive dietary copper in Pacific white shrimp Litopenaeus vannamei.
Chen, S; Gan, L; Guo, Y; Huang, R; Liu, Y; Meng, B; Tian, L; Wei, Y; Xie, S; Xu, Q; Yang, H; Ye, T, 2022
)
1.1
"This pilot study demonstrated that the dosage of 4 gr/daily of inositol is safe in patients taking Li/VPA, as we recorded no interference with the pharmacological therapy."( Safety of inositol supplementation in patients taking lithium or valproic acid: a pilot clinical study.
Cantelmi, T; Lepore, E; Unfer, V; Unfer, VR, 2022
)
1.36
" However, its therapeutic index is narrow, and it is prone to adverse side effects, along with an increased risk of toxicity, namely, cardio-, nephro-, hepato-, and neurotoxicity."( The effect of tacrolimus-induced toxicity on metabolic profiling in target tissues of mice.
Dang, R; Guo, J; Han, W; Li, Y; Meng, J; Si, Q; Wang, S; Wei, N; Wu, L; Xie, D, 2022
)
0.72
"Inositol is an effective and safe treatment in PCOS."( Inositol is an effective and safe treatment in polycystic ovary syndrome: a systematic review and meta-analysis of randomized controlled trials.
Ács, N; Greff, D; Hegyi, P; Horváth, EM; Juhász, AE; Nyirády, P; Park, S; Sipos, Z; Szinte, J; Váncsa, S; Váradi, A; Várbíró, S, 2023
)
3.8
" No adverse effects were noted."( The Efficacy and Safety of Myo-inositol Supplementation for the Prevention of Gestational Diabetes Mellitus in Overweight and Obese Pregnant Women: A Systematic Review and Meta-Analysis.
Corpuz, H; Factor, PA, 2023
)
1.2
" While studies show that 4 g myo-inositol per day may decrease the incidence of GDM, pregnancy-induced hypertension and pre-term birth with no associated risk of serious adverse events, the certainty of evidence is low to very low."( The Efficacy and Safety of Myo-inositol Supplementation for the Prevention of Gestational Diabetes Mellitus in Overweight and Obese Pregnant Women: A Systematic Review and Meta-Analysis.
Corpuz, H; Factor, PA, 2023
)
1.48

Pharmacokinetics

ExcerptReferenceRelevance
" Tolrestat was administered by gavage (1 x 150 mg/kg, or 5, and 15 mg/kg/day for 15 days to attain steady state as estimated from the 53-h half-life of tolrestat determined in rat nerve); subsequently, at six time intervals, ranging from 4 to 59 days, rats were given access for 4 days to a 20% galactose diet, and killed."( Tolrestat pharmacokinetics in rat peripheral nerve.
Dvornik, D; Hicks, DR; Kraml, M; Millen, J,
)
0.13
" Blood samples were taken to determine the pharmacokinetic characteristics of glibenclamide and the test/reference ratios were evaluated according to bioequivalence criteria."( Concomitant administration of the alpha-glucosidase inhibitor voglibose (AO-128) does not alter the pharmacokinetics of glibenclamide.
Ehrlich, A; Fuder, H; Kleist, P; Lücker, PW; Suzuki, Y; Timmer, W; Wetzelsberger, N, 1997
)
0.3
"Voglibose did not interact with glibenclamide on a pharmacokinetic level."( Concomitant administration of the alpha-glucosidase inhibitor voglibose (AO-128) does not alter the pharmacokinetics of glibenclamide.
Ehrlich, A; Fuder, H; Kleist, P; Lücker, PW; Suzuki, Y; Timmer, W; Wetzelsberger, N, 1997
)
0.3
" The prothrombin time was determined on days 10 and 11 (reference) and on days 15 and 16 (test), and the steady-state pharmacokinetic characteristics of the warfarin enantiomers were determined on days 10 (reference) and 15 (test)."( The alpha-glucosidase inhibitor voglibose (AO-128) does not change pharmacodynamics or pharmacokinetics of warfarin.
Birkel, M; Ehrlich, A; Emeklibas, S; Fuder, H; Kleist, P; Lücker, PW; Maslak, W; Stridde, E; Wetzelsberger, N; Wieckhorst, G, 1997
)
0.3
"To assess the extent of pharmacokinetic and pharmacodynamic interaction between vildagliptin, a potent and selective inhibitor of dipeptidyl peptidase IV (DPP-4) enzyme, and voglibose, an α-glucosidase inhibitor widely prescribed in Japan, when coadministered in Japanese patients with Type 2 diabetes."( Pharmacokinetic and pharmacodynamic interaction of vildagliptin and voglibose in Japanese patients with Type 2 diabetes.
Furihata, K; He, YL; Kulmatycki, K; Mita, S; Saji, T; Sekiguchi, K; Yamaguchi, M, 2013
)
0.39
" Co-administration led to significantly better pharmacodynamic response compared with each treatment alone, including higher active GLP-1 and lower glucose levels."( Pharmacokinetic and pharmacodynamic interaction of vildagliptin and voglibose in Japanese patients with Type 2 diabetes.
Furihata, K; He, YL; Kulmatycki, K; Mita, S; Saji, T; Sekiguchi, K; Yamaguchi, M, 2013
)
0.39
" Pharmacokinetic (PK) studies in extremely preterm infants are needed before efficacy trials."( Pharmacokinetics and safety of a single intravenous dose of myo-inositol in preterm infants of 23-29 wk.
Backstrom Lacy, C; Bell, EF; Bethany Ball, M; Das, A; Ehrenkranz, RA; Faix, RG; Fennell, TR; Frantz, ID; Hallman, MK; Higgins, RD; Laptook, AR; Michael Cotten, C; Michael O'Shea, T; Nolen, TL; Phelps, DL; Poindexter, BB; Sánchez, PJ; Shankaran, S; Walsh, MC; Ward, RM; Watterberg, KL; Williams, RL; Wrage, LA; Zaterka-Baxter, KM, 2013
)
0.63
" Plasma concentrations of metformin on day 7 were measured using high performance liquid chromatography (HPLC) with UV detection for pharmacokinetic assessment Vital signs and adverse events were monitored, and physical examinations and laboratory tests were conducted to evaluate safety."( Effect of voglibose on the pharmacokinetics of metformin in healthy Korean subjects.
Ghim, JL; Kim, DH; Kim, EJ; Kim, HS; Oh, M; Shin, JG; Shon, JH; Song, GS, 2014
)
0.4
" The pharmacodynamic interaction study to evaluate the effect of metformin on the pharmacodynamics of voglibose is in progress."( Effect of voglibose on the pharmacokinetics of metformin in healthy Korean subjects.
Ghim, JL; Kim, DH; Kim, EJ; Kim, HS; Oh, M; Shin, JG; Shon, JH; Song, GS, 2014
)
0.4
"The aim of this study was to compare the pharmacokinetic characteristics of metformin between a fixed-dose combination (FDC) of voglibose/metformin and coadministered individual voglibose and metformin tablets in healthy Korean volunteers under fasting conditions."( Pharmacokinetic study of metformin to compare voglibose/metformin fixed-dose combination with coadministered voglibose and metformin.
Choi, HK; Ghim, JL; Kim, EJ; Kim, HS; Oh, M; Shin, JG; Shon, JH; Song, GS, 2015
)
0.42

Compound-Compound Interactions

ExcerptReferenceRelevance
" The purpose of this study was to investigate metabolic changes in the rabbit lens after long-term dexamethasone treatment in combination with UVB exposure, using high-resolution magic angle spinning proton nuclear magnetic resonance (HR-MAS (1)H NMR) spectroscopy to analyse intact lens tissues."( High-resolution magic angle spinning 1H NMR spectroscopy of metabolic changes in rabbit lens after treatment with dexamethasone combined with UVB exposure.
Cejková, J; Krane, J; Midelfart, A; Risa, O; Saether, O, 2004
)
0.32
" Long-term treatment with dexamethasone combined with UVB exposure induced substantial metabolic changes, dominated by osmolytic regulation processes and loss of glutathione."( High-resolution magic angle spinning 1H NMR spectroscopy of metabolic changes in rabbit lens after treatment with dexamethasone combined with UVB exposure.
Cejková, J; Krane, J; Midelfart, A; Risa, O; Saether, O, 2004
)
0.32
"In the present study, we have used metabonomics combined with magnetic resonance imaging (MRI) to investigate an orphan neurological disease, Australian stringhalt, described in horse-ingesting inflorescences of Hypochoeris radicata (HR), without any knowledge on the toxic principle and without any practical possibility to perform experiments on the target species."( Orthologous metabonomic qualification of a rodent model combined with magnetic resonance imaging for an integrated evaluation of the toxicity of Hypochoeris radicata.
Biélicki, G; Canlet, C; Domange, C; Keller, C; Paris, A; Priymenko, N; Traore, A, 2008
)
0.35
" In hens fed either the CSM diets with phytase B alone, or in combination with 6-phytase A, enhanced feed intakes, egg mass, and hen-day egg production were recorded."( Effects of inositol, inositol-generating phytase B applied alone, and in combination with 6-phytase A to phosphorus-deficient diets on laying performance, eggshell quality, yolk cholesterol, and fatty acid deposition in laying hens.
Duliński, R; Koreleski, J; Mika, M; Piironen, J; Pustkowiak, H; Swiatkiewicz, S; Zyla, K, 2012
)
0.77
"The effects of the dipeptidyl peptidase-4 (DPP-4) inhibitor, linagliptin, alone and in combination with voglibose or exendin-4, on glycaemic control and body weight were assessed in an animal model of type 2 diabetes."( Effect of linagliptin, alone and in combination with voglibose or exendin-4, on glucose control in male ZDF rats.
Cheetham, SC; Headland, KR; Jones, RB; Klein, T; Mark, M; Vickers, SP, 2014
)
0.4
"The aim of the present study is to evaluate the effectiveness of myo-inositol alone or in combination with clomiphene citrate for (1) induction of ovulation and (2) pregnancy rate in anovulatory women with PCOS and proven insulin resistance."( Ovulation induction with myo-inositol alone and in combination with clomiphene citrate in polycystic ovarian syndrome patients with insulin resistance.
Carlomagno, G; Gateva, A; Genazzani, AD; Kamenov, Z; Kolarov, G, 2015
)
0.94
"Sitagliptin or voglibose combined with SAP can improve glucose control and protect islet function for patients with newly diagnosed T2DM."( [Comparison of therapeutic effects between sitagliptin and voglibose both combined with sensor-augmented insulin pump in newly diagnosed type 2 diabetes].
Bai, R; Du, JL; Liu, D; Shi, CH; Wang, H; Wang, L; Wang, YB; Yang, Y; Zhang, XY, 2016
)
0.43

Bioavailability

Myo-inositol soft gelatin capsules should be considered for the preventive treatment of NTDs in folate-resistant subjects.

ExcerptReferenceRelevance
" "Amsoy") on the bioavailability of 59Fe to iron-depleted rats."( Iron availability to rats from soybeans.
Van Campen, R; Welch, RM, 1975
)
0.25
" Hence, it is suggested that the impact of dietary phytate on trace mineral bioavailability will depend upon the presence of factors, including excess calcium, that alter the absorption and utilization of phytate."( Metabolism of 14C-phytate in rats: effect of low and high dietary calcium intakes.
Nahapetian, A; Young, VR, 1980
)
0.26
" There are no differences between mice fed linoleate and those that were not in: the rate of absorption of palmitoyl glycerol, oxidative phosphorylation by liver or heart mitochondria, excretion of carbon dioxide and tissue distribution of radioactivity following gavage of rac-1(3)-[1-14C]palmitoyl glycerol."( Interstitial pneumonitis induced by ingestion of palmitoyl glycerol.
Kanich, RE; Schnitzer-Polokoff, R; Tove, SB, 1980
)
0.26
"The clinical efficacy of an aldose reductase (AR) inhibitor in diabetic polyneuropathy depends on its bioavailability at the site(s) of AR in peripheral nerves."( Tolrestat pharmacokinetics in rat peripheral nerve.
Dvornik, D; Hicks, DR; Kraml, M; Millen, J,
)
0.13
"Despite progress in defining a pathogenic role for amyloid beta protein (Abeta) in Alzheimer's disease, orally bioavailable compounds that prevent its effects on hippocampal synaptic plasticity and cognitive function have not yet emerged."( Orally available compound prevents deficits in memory caused by the Alzheimer amyloid-beta oligomers.
Cleary, JP; Hofmeister, J; Lesne, S; Mehta, T; O'Hare, E; Selkoe, DJ; Townsend, M; Walsh, DM, 2006
)
0.33
" Increasing the bioavailability of arginine, the precursor of nitric oxide, thus potentially offers protection against end-stage disease."( Metabolic effects of a novel silicate inositol complex of the nitric oxide precursor arginine in the obese insulin-resistant JCR:LA-cp rat.
Kelly, SE; Proctor, SD; Russell, JC; Vine, DF, 2007
)
0.61
" Identification of small molecule inhibitors that are orally available, have low toxicity and high central nervous system bioavailability is one approach to the potential development of a disease-modifying treatment for Alzheimer's disease."( Modulation of amyloid-beta aggregation and toxicity by inosose stereoisomers.
Cousins, JE; Darabie, AA; Fenili, D; McLaurin, J; Nitz, M; Wu, L, 2008
)
0.35
" PK profiles related to the two pharmaceutical forms were obtained by analysis of MI plasma concentration, and the respective MI bioavailability was compared."( Myo-inositol in a new pharmaceutical form: a step forward to a broader clinical use.
Carlomagno, G; De Grazia, S; Manna, F; Unfer, V, 2012
)
0.94
" These interactions may have important implications on the absorption and metabolism and thus the overall oral bioavailability of atazanavir."( Interactions between phytochemical components of Sutherlandia frutescens and the antiretroviral, atazanavir in vitro: implications for absorption and metabolism.
Bendayan, R; Kanfer, I; Kis, O; Müller, AC; Patnala, S, 2012
)
0.38
"In order to evaluate coffee possible negative effects on inositol gastrointestinal absorption, a single-dose bioavailability trial was conducted."( Myo-inositol soft gel capsules may prevent the risk of coffee-induced neural tube defects.
Carlomagno, G; Cavalli, P; De Grazia, S; Unfer, V, 2012
)
1.18
" Furthermore, it was observed that MI soft gelatin capsule administration resulted in improved bioavailability compared to the MI powder form."( Myo-inositol soft gel capsules may prevent the risk of coffee-induced neural tube defects.
Carlomagno, G; Cavalli, P; De Grazia, S; Unfer, V, 2012
)
0.94
"Myo-inositol soft gelatin capsules should be considered for the preventive treatment of NTDs in folate-resistant subjects due to their higher bioavailability and to the capability to reduce espresso interference."( Myo-inositol soft gel capsules may prevent the risk of coffee-induced neural tube defects.
Carlomagno, G; Cavalli, P; De Grazia, S; Unfer, V, 2012
)
1.5
" Furthermore, the CE-mediated relaxation rate can be readily determined with a relatively short irradiation pulse and without approaching the steady state, therefore, reducing the limitations on hardware and specific absorption rate requirements."( Quantitative chemical exchange sensitive MRI using irradiation with toggling inversion preparation.
Jin, T; Kim, SG, 2012
)
0.38
" Critical evaluation of the interaction data suggested that the absorption and bioavailability of many coadministered drugs were not meaningfully affected from a clinical perspective."( Reappraisal and perspectives of clinical drug-drug interaction potential of α-glucosidase inhibitors such as acarbose, voglibose and miglitol in the treatment of type 2 diabetes mellitus.
Babu, RJ; Dash, RP; Srinivas, NR, 2018
)
0.48
" Reduced bioavailability of inositol in living organisms could arise from reduced food supply or from metabolism deregulation."( Nutritional and Acquired Deficiencies in Inositol Bioavailability. Correlations with Metabolic Disorders.
Bizzarri, M; Cucina, A; Dinicola, S; Minini, M; Unfer, V; Verna, R, 2017
)
1.02
"The bioavailability of myo-inositol was modified by the concomitant administration of α- lactalbumin."( Alpha-lactalbumin Effect on Myo-inositol Intestinal Absorption: In vivo and In vitro.
Ferrari, D; Ferruzza, S; Monastra, G; Ranaldi, G; Sambuy, Y, 2018
)
1.06
"The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs."( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019
)
0.51

Dosage Studied

Myo-inositol can reduce the numbers of mature oocytes and the dosage of rFSH whilst maintaining clinical pregnancy rate. A controlled dosage of inositols, up to 6 grams/daily, may reduce the side effects caused by lithium therapy.

ExcerptRelevanceReference
" The dose-response relationship between feed intake, liver hemorrhagic score and liver lipid content was again demonstrated."( Effect of inositol, lecithin, vitamins (B12 with choline and E), and iodinated casein on induced fatty liver-hemorrhagic syndrome in laying chickens.
Polin, D; Wolford, JH, 1975
)
0.66
"Clofibrate and m-Inositolnicotinate in a daily dosage of 1,5 g Clofibrate and 1,2 g m-Inositolnicotinate during long term treatment effected a good triglyceride fall in all three lipoprotein fractions, especially in VLDL."( [Combination or monotherapy of hyperlipoproteinemia typus IIb, IV, V with clofibrate and m-inositolnicotinate or clofibrinic acid (author's transl)].
Schwartzkopff, W; Zschiedrich, M, 1978
)
0.82
" Sixteen newborn Swiss mice received a daily subcutaneous dosage of 100 mg/kg of body weight of conduritol-B-epoxide from one day after birth to 28 days."( Gaucher disease in mice induced by conduritol-B-epoxide: morphologic features.
Adachi, M; Volk, BW, 1977
)
0.26
" The dosage of the single components is this combined therapy is significantly lower than the doses usually used for clofibrate or mesoinositol-hexanicotinate."( [Clinical study with a new antihyperlipemic combination].
Pistautz, H, 1977
)
0.46
" Comparison between the values before and with up to nine weeks of dosing revealed no alteration in conduction velocity."( Influence of dietary myoinositol on nerve conduction and inositol phospholipids in normal and diabetic rats.
Jefferys, JG; Palmano, KP; Sharma, AK; Thomas, PK, 1978
)
0.57
"The absorption, blood level and renal excretion of chlorphenoxyisobutyric acid (clofibric acid) were examined following oral dosage of the magnesium salt (magnesium clofibrate) in a combination preparation containing meso-inositol hexanicotinate."( [Pharmacokinetics of a combination of magnesium-chlorophenoxy-isobutyrate and meso-inositol hexanicotinate].
el Eisch, IA; Paltauf, F; Pristautz, H, 1977
)
0.67
" The dose-response curve for this suppression was very similar to that for stimulation of inositol monophosphate (IP1) formation and for stimulation of the initial rise of [Ca2+]i elicited by carbachol."( Suppressive effect of carbachol on forskolin-stimulated neurite outgrowth in human neuroblastoma NB-OK1 cells.
Nakagawa-Yagi, Y; Nakamura, H; Saito, Y; Takada, Y, 1992
)
0.5
" Phase-resetting curves and dose-response curves indicated that cultures maintained on low inositol (25 microM) were several orders of magnitude more sensitive to light than those maintained on high inositol (250 microM)."( Phase resetting of the Neurospora crassa circadian oscillator: effects of inositol depletion on sensitivity to light.
Lakin-Thomas, PL, 1992
)
0.74
" Spantide, [D-Arg1, D-Trp7,9, Leu11]SP, a SP antagonist, used at a concentration of 10(-5) M, competitively shifted the dose-response curve of SP."( [Reduction induced by substance P of the initial accumulation of myo(3H)inositol in acinar cells of the parotid gland in rats].
Beaujouan, JC; Dietl, M; Glowinski, J; Torrens, Y, 1989
)
0.51
"9, Leu11]SP), a SP antagonist, used at a concentration of 10(-5) M, gave a competitive shift of the dose-response curve to SP."( Substance P-induced reduction in the initial accumulation of cytosolic myo-[3H]inositol in rat parotid acinar cells mediated by the NK1 tachykinin receptor.
Beaujouan, JC; Dietl, MM; Glowinski, J; Torrens, Y, 1989
)
0.5
" Dose-response curves to carbachol and 5-HT showed that lithium treatment reduced the maximal agonist response without altering the EC50 value."( Subacute and chronic in vivo lithium treatment inhibits agonist- and sodium fluoride-stimulated inositol phosphate production in rat cortex.
Godfrey, PP; Grahame-Smith, DG; McClue, SJ; White, AM; Wood, AJ, 1989
)
0.5
" However, the effect of carbamazepine (100 microM) on the respective dose-response curves suggests that the mechanism of inhibition of the carbachol response differs from the inhibition of the histamine and veratrin responses."( Inhibition of agonist-stimulated inositol lipid metabolism by the anticonvulsant carbamazepine in rat hippocampus.
Logan, SD; McDermott, EE, 1989
)
0.56
" Labelling muscle slices with [3H]inositol in the presence of carbachol or labelling for longer periods (greater than 6 h) prevented subsequent carbachol-stimulated effects on incorporation without significantly altering the dose-response relationship for carbachol-stimulated [3H]InsP formation and resulted in steady-state labelling conditions confirmed by the ability of atropine to reverse fully the [3H]InsP response to carbachol."( Characterization of agonist-stimulated incorporation of myo-[3H]inositol into inositol phospholipids and [3H]inositol phosphate formation in tracheal smooth muscle.
Barnes, PJ; Chilvers, ER; Nahorski, SR, 1989
)
0.79
" Dose-response curves for inositol phospholipid synthesis stimulated by carbachol and CCK-8 in mouse acini were biphasic and superimposable with those of amylase secretion."( The effects of gamma-hexachlorocyclohexane on amylase secretion and inositol phospholipid metabolism in mouse pancreatic acini.
Crouch, MF; Roberts, ML, 1985
)
0.8
"We have recently shown by dose-response analyses with resealed erythrocyte ghosts that the channel formed by complement is a monomer of C5b-9 of the composition C5b61C71C81C9n, in which n = 1 for channels permitting passage of sucrose (0."( The relationship between channel size and the number of C9 molecules in the C5b-9 complex.
Mayer, MM; Ramm, LE; Whitlow, MB, 1985
)
0.27
" Comparison of the dependence of the turnover on carbamoylcholine concentration revealed that in neonates, the dose-response curve was shifted to the left, giving a half-maximal effect at concentrations approximately tenfold lower than that in the adult."( Enhanced coupling of neonatal muscarinic receptors in rat brain to phosphoinositide turnover.
Agranoff, BW; Fisher, SK; Heacock, AM, 1987
)
0.27
" Dose-response curves revealed that reduction in the response to carbachol was due to a fall in maximal response and not in EC50."( Acute and chronic lithium treatments influence agonist and depolarization-stimulated inositol phospholipid hydrolysis in rat cerebral cortex.
Kendall, DA; Nahorski, SR, 1987
)
0.5
" Time-course and dose-response evaluations of the 1,25-(OH)2D3 effect revealed that the decrease in [14C]choline incorporation was seen within 12 h of incubation and occurred with as little as 10(-9) M, respectively."( Effect of 1,25-dihydroxyvitamin D3 on phospholipid metabolism in cultured bovine parathyroid cells.
Morrissey, J; Ritter, C; Slatopolsky, E; Sugimoto, T, 1988
)
0.27
" The dose-response relationship for the TRH-stimulated phospholipase C was elucidated as was the relationship between the various inositol phosphates formed during the first few seconds after stimulation."( Thyrotropin-releasing hormone-stimulated inositol trisphosphate formation is liable to thyrotropin-releasing hormone-induced desensitization by a calcium-dependent mechanism.
Bjøro, T; Haug, E; Ostberg, BC; Torjesen, PA, 1988
)
0.75
" A high concentration of the L isomer (10 microM) did not significantly shift the dose-response curve for the D isomer in Swiss 3T3 cells, suggesting that the less active isomer is probably a very weak agonist."( Stereospecific mobilization of intracellular Ca2+ by inositol 1,4,5-triphosphate. Comparison with inositol 1,4,5-trisphosphorothioate and inositol 1,3,4-trisphosphate.
Cooke, AM; Gigg, R; Nahorski, SR; Potter, BV; Strupish, J, 1988
)
0.52
" Dose-response experiments showed that this increase was due to an increase in the maximal response to carbachol after lesion with no change in EC50 values."( Increased polyphosphoinositide responsiveness in the cerebral cortex induced by cholinergic denervation.
de Belleroche, J; Reed, LJ, 1988
)
0.27
" Similar temporal and dose-response relationships were observed for LH-stimulated IP3 and cAMP accumulation."( Luteinizing hormone increases inositol trisphosphate and cytosolic free Ca2+ in isolated bovine luteal cells.
Davis, JS; Farese, RV; Weakland, LL; West, LA, 1987
)
0.56
" These effects of myo-inositol, as well as the dose-response relationship between ambient inositol levels and increments in cell number, were not significantly modified by 20 mmol/L glucose with the exceptions of a transient lesser effect of the physiologic doses during rapid proliferation (day 6) and a larger effect of all doses of myo-inositol in later stages of growth curve (day 12)."( Myo-inositol enhances the proliferation of human endothelial cells in culture but fails to prevent the delay induced by high glucose.
Lorenzi, M; Toledo, S, 1986
)
1.14
" With lesser concentrations of glucose, the flush exhibits dose-response relationships, and with 3 mg/ml glucose, a second flush can be elicited by restoring basal conditions and stimulating anew with 3 mg/ml glucose."( Rapid transient efflux of phosphate ions from pancreatic islets as an early action of insulin secretagogues.
Bonnar, J; Dawson, RM; Freinkel, N; Younsi, CE, 1974
)
0.25
" The degree of 32PO4 incorporation into these phospholipids paralleled the dose-response curves for histamine release."( Enhanced phospholipid metabolism in rat mast cells stimulated to release histamine.
Schellenberg, RR, 1980
)
0.26
" 2 The parent compound 5-HT was found to stimulate both cyclic AMP formation and the related parameters of PI hydrolysis and calcium transport with similar dose-response relationships."( Separate 5-hydroxytryptamine receptors on the salivary gland of the blowfly are linked to the generation of either cyclic adenosine 3',5'-monophosphate or calcium signals.
Berridge, MJ; Heslop, JP, 1981
)
0.26
" Very low concentrations of atropine shifted the carbachol dose-response curve to the right and allowed inhibition constants for the antagonist to be easily calculated."( Inositol phospholipid hydrolysis in rat cerebral cortical slices: I. Receptor characterisation.
Brown, E; Kendall, DA; Nahorski, SR, 1984
)
1.71
" The dose-response curve for the initial rate of cytosolic free Ca2+ increase was very similar to those obtained for the initial rates of Ins-P3 production and PtdIns-4,5-P2 breakdown."( Relationship between inositol polyphosphate production and the increase of cytosolic free Ca2+ induced by vasopressin in isolated hepatocytes.
Alexander, J; Thomas, AP; Williamson, JR, 1984
)
0.59
" The position of the dose-response curve for histamine in cerebral cortical slices was similar to that of the curve for the receptor binding of histamine deduced from histamine inhibition of [3H]mepyramine binding."( Histamine stimulation of inositol 1-phosphate accumulation in lithium-treated slices from regions of guinea pig brain.
Daum, PR; Downes, CP; Young, JM, 1984
)
0.57
" Dose-response studies were performed using potassium chloride with and without inhibitors of cytosolic calcium oscillation mechanisms."( Potassium chloride effects on the hormonal signal transduction mechanisms underlying phasic myometrial contractions.
Chien, EK; Phillippe, M, 1995
)
0.29
" The dose-response curve for carbachol showed a significantly lower maximal response in the striatum of senescent rats, whereas the time course of [3H]inositol incorporation into inositol metabolites and the accumulation of free [3H]inositol in tissues from young and old animals were not different."( Decreased phospholipase C-beta immunoreactivity, phosphoinositide metabolism, and protein kinase C activation in senescent F-344 rat brain.
Friedman, E; Undie, AS; Wang, HY,
)
0.33
" Following 2-months untreated diabetes, examination of 1 month ZD5522 treatment dose-response relationships for correction of nerve sorbitol and fructose accumulations and reduction in myo-inositol concentration, sciatic motor and saphenous sensory conduction velocity and sciatic blood flow by laser-Doppler flowmetry revealed poor agreement between nerve function and biochemical indices."( Aldose reductase inhibition, nerve perfusion, oxygenation and function in streptozotocin-diabetic rats: dose-response considerations and independence from a myo-inositol mechanism.
Cameron, NE; Carey, F; Cotter, MA; Dines, KC; Maxfield, EK; Mirrlees, DJ, 1994
)
0.68
" The dose-response for calcium release induced by sphingosine-1-phosphate correlated closely with the concentration required for stimulation of DNA synthesis."( Sphingosine-1-phosphate, a putative second messenger, mobilizes calcium from internal stores via an inositol trisphosphate-independent pathway.
Brooker, G; Mattie, M; Spiegel, S, 1994
)
0.5
" Dose-response studies disclosed that incremental increases in [3H]InsP1 (129-420%) are observed over a concentration range of 10-1,000 nM."( Glucose and scyllo-inositol impair phosphoinositide hydrolysis in the 10.5-day cultured rat conceptus: a role in dysmorphogenesis?
Metzger, BE; Strieleman, PJ, 1993
)
0.61
"Chronic dosing with the glycine partial NMDA agonist, 1-aminocyclopropanecarboxylic acid (ACPC) elicited an altered allosteric regulation of cortical NMDA receptor binding."( Chronic dosing with 1-aminocyclopropanecarboxylic acid, a glycine partial agonist, modulates NMDA inhibition of muscarinic-coupled PI hydrolysis in rat cortical slices.
Boje, KM; Lakhman, SS, 1998
)
0.3
" Nevertheless, SNF2 in increased gene dosage did not suppress ino80 mutant phenotypes."( The product of the SNF2/SWI2 paralogue INO80 of Saccharomyces cerevisiae required for efficient expression of various yeast structural genes is part of a high-molecular-weight protein complex.
Birkmann, A; Ebbert, R; Schüller, HJ, 1999
)
0.3
" We have tested this hypothesis by: 1) demonstrating an extremely high potency of nordidemnin as an inhibitor of myo-inositol uptake in primary cultures of mouse astrocytes; and 2) determining the dose-response correlation of a nordidemnin-induced decrease in the latency before appearance of seizures in the lithium-pilocarpine test after intracerebroventricular injection of minute samples (10 microl) of virtually isotonic saline solution."( Nordidemnin potently inhibits inositol uptake in cultured astrocytes and dose-dependently augments lithium's proconvulsant effect in vivo.
Belmaker, RH; Berkin, V; Bersudsky, Y; Einat, H; Hertz, L; Wolfson, M, 2000
)
0.8
" In conclusion, this approach is a novel use of ceramic delivery systems in tissue culture that gives breakthrough information for basic research on limiting and eliminating contamination and the logistical problems associated with intermittent dosing in tissue culture."( Development of sustained delivery system as a novel technique for tissue culture.
Benghuzzi, H; Higdon, KK; Hughes, JL; Puckett, A; Scott, A; Tucci, M, 2000
)
0.31
"Dietary myo-inositol is an effective inhibitor of lung tumor induction in mice, but no dose-response studies have been reported."( Dose-response study of myo-inositol as an inhibitor of lung tumorigenesis induced in A/J mice by benzo.
Hecht, SS; Kenney, PM; Upadhyaya, P; Wang, M, 2001
)
0.99
" They were challenged on the eighth day with one dosage and sacrificed 3 h later."( Activation of metabotropic glutamate receptor 5 is associated with effect of amphetamine on brain neurons.
Li, LT; Lin, WW; Yin, HS; Yu, MF, 2003
)
0.32
"Although no difference was found between groups with RBD and IPD without dream enactment behavior in demographic characteristics, duration of disease, mean levodopa dosage and duration of levodopa use, all UPDRS scores (total, motor and cognitive) were worse in RBD group (p<0."( Brainstem 1H-MR spectroscopy in patients with Parkinson's disease with REM sleep behavior disorder and IPD patients without dream enactment behavior.
Dincer, A; Hanoglu, L; Meral, H; Ozer, F, 2006
)
0.33
" Our work provides a revised genetic map of IP metabolism in yeast and evidence for dosage compensation between IPs and PP-IPs downstream of I(1,4,5)P3 in the regulation of nucleocytoplasmic processes."( Molecular definition of a novel inositol polyphosphate metabolic pathway initiated by inositol 1,4,5-trisphosphate 3-kinase activity in Saccharomyces cerevisiae.
Bastidas, RJ; Seeds, AM; York, JD, 2005
)
0.61
" Because findings from the animal literature have indicated that specific dosage regimens of MDMA can produce long-lasting alterations in serotonergic function, existing studies of MDMA effects in humans have examined brain serotonin (5-HT) transporters (5-HTT) and receptors or have examined brain structures or functions potentially affected by MDMA."( Neuroimaging research in human MDMA users: a review.
Cowan, RL, 2007
)
0.34
"DM2 patients were dosed with losartan (100 mg/d) and urines were collected at week 8 and 12."( [Assessment of therapeutic effect of losartan on diabetes mellitus with gas chromatography-based metabonomics].
Gao, P; Lu, X; Shi, XZ; Xu, GW; Yuan, KL, 2007
)
0.34
" However, a systematic spectroscopic study on short-term exposure to corticosteroids, in a dosage sufficient to impair memory performance, is lacking."( Effects of short-term stress-like cortisol on cerebral metabolism: a proton magnetic resonance spectroscopy study at 3.0 T.
Bruhn, H; Scheel, M; Ströhle, A, 2010
)
0.36
" On such basis, we investigated the efficacy on insulin sensitivity and hormonal parameters of 8 weeks treatment with myo-inositol (MYO) (Inofert, ItalPharmaco, Milano, Italy) at the dosage of 2 g day in a group (n = 42) of obese PCOS patients,."( Differential insulin response to myo-inositol administration in obese polycystic ovary syndrome patients.
Artini, PG; Campedelli, A; Chierchia, E; Genazzani, AD; Prati, A; Rattighieri, E; Ricchieri, F; Santagni, S; Simoncini, T, 2012
)
0.86
" Maxillary taste neurons of the two strains had similar dose-response relationships for sucrose, inositol, and strychnine nitrate, but the deterrent cell of Sawa-J·lem showed a remarkably low sensitivity to salicin."( Genetic analysis of the electrophysiological response to salicin, a bitter substance, in a polyphagous strain of the silkworm Bombyx mori.
Asaoka, K; Iizuka, T; Mase, K; Okada, E; Sezutsu, H; Tamura, T, 2012
)
0.6
"Our findings suggest that the addition of myo-inositol to folic acid in non PCOS-patients undergoing multiple follicular stimulation for in-vitro fertilization may reduce the numbers of mature oocytes and the dosage of rFSH whilst maintaining clinical pregnancy rate."( Pretreatment with myo-inositol in non polycystic ovary syndrome patients undergoing multiple follicular stimulation for IVF: a pilot study.
Carfagna, P; Caserta, D; Lisi, F; Lisi, R; Manna, C; Marci, R; Moscarini, M; Oliva, MM; Poverini, R; Rago, R; Raparelli, V; Vaquero, E, 2012
)
0.95
"Lithium is the most effective mood stabilizer for the treatment of bipolar disorder, but it is toxic at only twice the therapeutic dosage and has many undesirable side effects."( A safe lithium mimetic for bipolar disorder.
Aley, PK; Antoniadou, I; Baldwin, R; Churchill, GC; Halliday, AC; Kuznetsova, OV; Sharp, T; Singh, N; Thomas, JM; Vasudevan, SR; Woon, EC, 2013
)
0.39
" Therefore, we concluded that the proposed dissolution method was particularly suitable for evaluating the dissolution of ODFs and should also be applicable to other fast-dissolving solid dosage forms."( A new method for evaluating the dissolution of orodispersible films.
Chen, F; Luo, C; Xia, Y; Zhang, H, 2015
)
0.42
" Male Zucker Diabetic Fatty (ZDF) rats were dosed for 3 days, fasted overnight and a sucrose/glucose tolerance test was performed."( Effect of linagliptin, alone and in combination with voglibose or exendin-4, on glucose control in male ZDF rats.
Cheetham, SC; Headland, KR; Jones, RB; Klein, T; Mark, M; Vickers, SP, 2014
)
0.4
" The subjects were divided into two groups: Group A, treated with an association of 1 g myo-inositol, 5 mg monacolin K and 400 mg lipoic acid for 6 months; Group B, treated with a double dosage of 2 g myo-inositol, 10 mg monacolin K, 800 mg lipoic acid for 6 months."( Polycystic ovary syndrome (PCOS) and hyperandrogenism: the role of a new natural association.
Cappelli, V; De Leo, V; Di Sabatino, A; Massaro, MG; Morgante, G, 2015
)
0.64
"The results have shown good efficacy of both dosages, although women treated with a double dosage of myo-inositol, monacolin K and lipoic acid showed a significantly greater improvement in terms of lipid parameters and those connected with hyperandrogenism."( Polycystic ovary syndrome (PCOS) and hyperandrogenism: the role of a new natural association.
Cappelli, V; De Leo, V; Di Sabatino, A; Massaro, MG; Morgante, G, 2015
)
0.63
"DCI is able to reduce the gene expression of CYP19A1, P450scc and insulin-like growth factor 1 receptor (IGF-1R) in dose-response manner."( Modulation of gonadotrophin induced steroidogenic enzymes in granulosa cells by d-chiroinositol.
Argento, C; Giulini, S; La Marca, A; Lui, J; Marinaro, F; Marsella, T; Sacchi, S; Tagliasacchi, D; Tirelli, A; Tondelli, D; Xella, S, 2016
)
0.66
" Hence, dosage adjustment is not warranted in the use of AGIs in T2DM patients in situations of comorbidity."( Reappraisal and perspectives of clinical drug-drug interaction potential of α-glucosidase inhibitors such as acarbose, voglibose and miglitol in the treatment of type 2 diabetes mellitus.
Babu, RJ; Dash, RP; Srinivas, NR, 2018
)
0.48
" This analysis found no advantage in terms of PK for single 4 g dosing of myo-ins compared to 2 g twice a day, which allowed to get a 24-hour coverage, contrary to the singular dose."( Finding the best therapeutic approach for PCOS: the importance of inositol(s) bioavailability.
Carlomagno, G; Circo, R; Logoteta, P; Orrù, B; Petousis, S, 2017
)
0.69
" Clinical studies of SI showed promising benefits on mild to moderate AD, however, with limitations on dosage regime."( A guanidine-appended scyllo-inositol derivative AAD-66 enhances brain delivery and ameliorates Alzheimer's phenotypes.
Chung, SK; Das, S; Jung, HY; Kim, KT; Kim, YK; Lee, D; Lee, J; Lee, WS; Lim, S; Luo, W, 2017
)
0.75
" Patients and methods In an open, prospective, non-blinded, non-comparative observational study, 3602 infertile women used myo-inositol and folic acid between 2 and 3 months in a dosage of 2 × 2000 mg myo-inositol +2 × 200 μg folic acid per day."( Management of women with PCOS using myo-inositol and folic acid. New clinical data and review of the literature.
Druckman, R; Lesoine, B; Regidor, PA; Schindler, AE, 2018
)
0.95
"Fixed-dose combination (FDC) medicines containing two or more active pharmaceutical ingredients (APIs) in a single dosage form have been reported to improve patient adherence to a greater extent than single dosages of individual components (ICs)."( Ease of Taking and Palatability of Fixed-Dose Orally Disintegrating Mitiglinide/Voglibose Tablets.
Hakamata, A; Inui, N; Kamiya, C; Kashiwagura, Y; Namiki, N; Odagiri, K; Sotoyama, M; Tanaka, S; Uchida, S; Watanabe, H, 2019
)
0.51
"The objective of this present study was to determine the effects of phytase dosing on growth performance, mineral digestibility, phytate breakdown, and the level of glucose transporter type 4 (GLUT4) in muscle plasma membranes of weanling pigs."( Effect of phytase on intestinal phytate breakdown, plasma inositol concentrations, and glucose transporter type 4 abundance in muscle membranes of weanling pigs1.
Adeola, O; Ajuwon, KM; Bedford, MR; Brearley, C; Kühn, I; Lu, H; Whitfield, H, 2019
)
0.76
" Furthermore, a controlled dosage of inositols, up to 6 grams/daily, may reduce the side effects caused by lithium therapy, without hindering its central therapeutic role on patients' mood."( Combined treatment of myo-inositol and d-chiro-inositol (80:1) as a therapeutic approach to restore inositol eumetabolism in patients with bipolar disorder taking lithium and valproic acid.
D'Ambrosio, F; Di Lorenzo, C; Janiri, L, 2021
)
1.19
" The clinical dosage of inositols used as dietary supplementation is 4 grams/daily, and it may allow the recovery of the side effects and improve patients' QoL, without reducing the central therapeutic effect of the pharmacological therapy."( Combined treatment of myo-inositol and d-chiro-inositol (80:1) as a therapeutic approach to restore inositol eumetabolism in patients with bipolar disorder taking lithium and valproic acid.
D'Ambrosio, F; Di Lorenzo, C; Janiri, L, 2021
)
1.23
"Compared with metformin, the suitable supplemental dosage of myo-ins may be helpful in lowering levels of TG and avoiding adverse events (AEs)."( Short period-administration of myo-inositol and metformin on hormonal and glycolipid profiles in patients with polycystic ovary syndrome: a systematic review and updated meta-analysis of randomized controlled trials.
He, B; Xing, C; Zhang, JQ, 2022
)
1
"This study strove to investigate the hypothesis that a low dosage of myo-inositol supplementation might decrease the likelihood of gestational diabetes in overweight, pregnant women."( The effect of myo-inositol supplementation on the prevention of gestational diabetes in overweight pregnant women: a randomized, double-blind, controlled trial.
Basirat, Z; Delavar, MA; Esmaeilzadeh, S; Ghadimi, R; Mashayekh-Amiri, S, 2023
)
1.48
" This study adds new insights on this aspect, highlighting the safety of a tailored dosage of inositol in patients taking Li or VPA."( Safety of inositol supplementation in patients taking lithium or valproic acid: a pilot clinical study.
Cantelmi, T; Lepore, E; Unfer, V; Unfer, VR, 2022
)
1.34
"This pilot study demonstrated that the dosage of 4 gr/daily of inositol is safe in patients taking Li/VPA, as we recorded no interference with the pharmacological therapy."( Safety of inositol supplementation in patients taking lithium or valproic acid: a pilot clinical study.
Cantelmi, T; Lepore, E; Unfer, V; Unfer, VR, 2022
)
1.36
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Occurs in Manufacturing (331 Product(s))

Product Categories

Product CategoryProducts
Other109
Succo di ananas1
Aliments et boissons à base de végétaux, Aliments d'origine végétale, Légumineuses et dérivés, Légumineuses, Fruits à coques et dérivés, Fruits à coques, Cacahuètes1
Boissons, Boissons alcoolisées, Vins, Vins français1
Produits de la mer, Poissons et dérivés, Poissons, Filets de poissons, Filets de merlan, Filets de merlan pané1
Milchprodukte, Fermentierte Lebensmittel, Desserts, Fermentierte Milch, Milchnachspeisen, en:Fermented dairy desserts, Joghurt1
Pflanzliche Lebensmittel und Getränke, Pflanzliche Lebensmittel, Getreide und Kartoffeln, Getreideprodukte1
Desayunos, Untables, Untables dulces, Productos apícolas, Productos agrícolas, Endulzantes, Mieles2
Snacks, Snacks sucrés, Confiseries, Nougats2
Viandes et dérivés, Viandes, Porc et dérivés, Porc1
Alimentos y bebidas de origen vegetal, Alimentos de origen vegetal, Cereales y patatas, Panes, Colines, Picos de pan1
en:peanut-butters1
Plant-based foods and beverages, Plant-based foods, Legumes and their products, Snacks, Legumes, Salty snacks, Nuts and their products, Nuts, Peanuts, Salted nuts, Salted peanuts, Salted-peanuts-and-cashews1
Aliments et boissons à base de végétaux, Boissons, Boissons chaudes, Boissons à base de végétaux, Thés1
Produits laitiers, Produits fermentés, Produits laitiers fermentés, Fromages, Produits de montagne, Fromages de montagne, Tommes1
Aliments et boissons à base de végétaux, Boissons, Boissons à base de végétaux, Smoothies1
Produits laitiers, Produits fermentés, Desserts, Produits laitiers fermentés, Desserts lactés, Desserts lactés fermentés, Yaourts, Yaourts au lait de brebis1
Aliments et boissons à base de végétaux, Aliments d'origine végétale, Matières grasses, Produits à tartiner, Pâtes à tartiner végétales, Produits à tartiner salés, Matières grasses à tartiner, Matières grasses végétales, Margarines1
Fertiggerichte1
Aliments et boissons à base de végétaux, Boissons, Aliments d'origine végétale, Cafés, Boissons instantanées, Cafés solubles1
Snacks, Snacks sucrés, Biscuits et gâteaux, Gâteaux1
Aliments et boissons à base de végétaux, Aliments d'origine végétale, Fruits à coques et dérivés1
Aliments et boissons à base de végétaux, Aliments d'origine végétale, Cafés, Café Arabica, Cafés moulus, Café Arabica moulu, Café du Honduras1
Frutti di mare, en:Fishes and their products, Alimenti in scatola, Pesci, en:Fatty fishes, Pesce in scatola, Tonno, Tonno in scatola, Tonno sott'olio, Tonno sott'olio di oliva1
Condiments, Sauces, Mayonnaises1
Produits de la mer, Poissons et dérivés, Poissons, Plats préparés, Préparations de poisson, Produits panés, Poissons panés, Nuggets de poisson1
Aliments et boissons à base de végétaux, Aliments d'origine végétale, Petit-déjeuners, Produits à tartiner, Pâtes à tartiner végétales, Produits à tartiner sucrés, Confitures et marmelades, Confitures, Confitures d'agrumes, Confitures-d-oranges-ameres1
Produits laitiers,Produits fermentés,Produits laitiers fermentés,Yaourts,Yaourts natures1
Snack, Snack dolci, Cacao e i suoi derivati, Cioccolato, Cioccolato fondente, Cioccolato di Modica IGP1
Condiments, Sauces, Vegetarian sauces, Vegan sauces, Egg-free mayonnaises1
Alimentos y bebidas de origen vegetal, Alimentos de origen vegetal, Frutos de cáscara y derivados, Frutos de cáscara1
Alimentos y bebidas de origen vegetal, Alimentos de origen vegetal, Frutas y verduras y sus productos, Verduras y hortalizas y sus productos, Hortalizas, Verduras de tallo, Cardos1
ca:Fuet1
Productos a base de carne, Carnes, Embutidos, Jamón, en:cured-ham1
Productos del mar, en:Fishes and their products, Pescados, Crustáceos, Camarones1
Botanas, Snacks dulces, Galletas y pasteles, Pasteles, Magdalenas1
Snacks, Snacks sucrés, Popcorn1
Compléments alimentaires, Compléments pour le Bodybuilding, Protéines en poudre1
Aides culinaires, Aides à la pâtisserie, Pâtes à sucre1
Lácteos, Comidas fermentadas, Productos fermentados de la leche, Quesos1
Lácteos,Comidas fermentadas,Productos fermentados de la leche,Quesos,Quesos de leche de oveja,Quesos españoles,Manchego1
Milchprodukte, Fermentierte Lebensmittel, Fermentierte Milch, Käse1
Bebidas,Lácteos,Bebida lácteas1
Aliments et boissons à base de végétaux, Aliments d'origine végétale, Petit-déjeuners, Céréales et pommes de terre, Céréales et dérivés, Céréales pour petit-déjeuner, Mueslis, Mueslis croustillants1
Stuffing1
Aliments et boissons à base de végétaux, Boissons, Boissons à base de végétaux, Boissons aux fruits, Jus et nectars, Jus de fruits1
Plantaardige levensmiddelen en dranken, Plantaardige levensmiddelen, Granen en aardappels, Granen en graanproducten, Pasta1
Pflanzliche Lebensmittel und Getränke, Pflanzliche Lebensmittel, Frucht- und gemüsebasierte Lebensmittel, Hülsenfrüchte und Hülsenfruchtprodukte, Konserven, Hülsenfrüchte, Gemüsebasierte Lebensmittel, Konserven-Produkte auf pflanzlicher Basis, Gemüse, Gem1
en:sweet-snacks1
Snacks, Snacks sucrés, Biscuits et gâteaux, Biscuits, Biscuits secs1
Aliments et boissons à base de végétaux, Boissons, Boissons à base de végétaux, Boissons aux fruits, Jus et nectars, Jus de fruits, Jus multifruits1
Botanas, Snacks dulces, Galletas y pasteles, Pasteles, en:filled-sponge-cake-rolls1
Plant-based foods and beverages, Plant-based foods, Cereals and potatoes, Cereals and their products, Pastas, Cereal pastas, Durum wheat pasta, Spaghetti, Whole durum wheat pasta, Durum wheat spaghetti, Whole durm wheat spaghetti, en:dry-pastas1
Snacks, Zoute snacks, Voorgerechten, Crackers1
Aliments et boissons à base de végétaux, Aliments d'origine végétale, Aliments à base de fruits et de légumes, Petit-déjeuners, Produits à tartiner, Fruits et produits dérivés, Pâtes à tartiner végétales, Produits à tartiner sucrés, Confitures et marmelad1
Petit-déjeuners, Produits à tartiner, Produits à tartiner sucrés, Produits de la ruche, Produits d'élevages, Édulcorants, Miels1
Aliments et boissons à base de végétaux, Aliments d'origine végétale, Cafés1
Productos del mar, Pescados, en:Fatty fishes, Atunes, Bonito del Norte1
Plant-based foods and beverages,Plant-based foods,Cereals and potatoes,Chips and fries,Fries,Frozen fries,Sweet potato crisps1
Aliments et boissons à base de végétaux, Boissons, Boissons à base de végétaux, Boissons aux fruits, Jus et nectars, Jus de fruits, Boissons sans sucre ajouté, Jus de pomme, Jus de fruits pur jus, Jus de pommes pur jus1
Plant-based foods and beverages, Plant-based foods, Legumes and their products, Canned foods, Legumes, Canned plant-based foods, Meals, Prepared vegetables, Canned legumes, Baked beans in tomato sauce, Canned common beans1
en:Plant-based foods and beverages, ผลิตภัณฑ์จากพืชทั้งหมด, ธัญพืชและมันฝรั่ง, ผลิตภัณฑ์จากผักและผลไม้, ผลิตภัณฑ์จากธัญพืช, ผลิตภัณฑ์จากพืช, พาสตา, en:Noodles1
Professional Supplements20
Active Lifestyle & Fitness15
Vitamins & Supplements106
Beauty & Personal Care6
Baby & Kids Products9
Herbs, Botanicals & Homeopathy1
Pet Supplies1
Weight Management1

Products

ProductBrandCategoryCompounds Matched from IngredientsDate Retrieved
Turkey Flavored Stuffing MixHill Country FareStuffingriboflavin,niacin2024-02-09
Allergy Research Group Super Vitamin B Complex -- 120 Vegetarian CapsulesAllergy Research GroupProfessional SupplementsPABA, Biotin, Folic Acid, Inositol, Niacin, PABA, Pantothenic Acid, Vitamin B6, Riboflavin, Thiamin, Vitamin B12, Vitamin B62024-11-29 10:47:42
ALLMAX Nutrition TestoFX Testosterone Booster and Cortisol Blocker -- 90 CapsulesALLMAX NutritionActive Lifestyle & FitnessMyo-Inositol, Alpha-Lipoic Acid, Withania somnifera2024-11-29 10:47:42
Amazing Nutrition Amazing Formulas Inositol -- 1000 mg - 120 TabletsAmazing NutritionVitamins & SupplementsInositol2024-11-29 10:47:42
Amazing Nutrition Amazing Formulas Inositol -- 1000 mg - 250 TabletsAmazing NutritionVitamins & SupplementsInositol2024-11-29 10:47:42
Amy Myers MD The Myers Way Multivitamin -- 180 CapsulesAmy Myers MDProfessional SupplementsVitamin C, Biotin, Boron, Choline, Chromium, Vitamin E, Folate, Vitamin E, myo-Inositol, Iodine, Manganese, Molybdenum, Niacin, Pantothenic Acid, Vitamin B6, Vitamin A, Riboflavin, Selenium, Thiamine, Vanadium, Vitamin B12, Vitamin B6, Vitamin K2024-11-29 10:47:42
Animal PAK - The Ultimate Training Pack -- 30 PacksAnimalActive Lifestyle & FitnessLipase, Alanine, Arginine, Vitamin C, Aspartic Acid, Biotin, Carnitine, Choline, Chromium, Coenzyme Q10, Cystine, Vitamin E, Folate, Vitamin E, Glutamic Acid, Glutamine, Glycine, Histidine, Hydroxyproline, Inositol, Iodine, Isoleucine, Leucine, Lutein, Lycopene, Lysine, Manganese, menaquinone-4, Methionine, Niacin, Ornithine, Pantothenic Acid, Phenylalanine, Phosphorus, Proline, Vitamin B6, Vitamin A, Riboflavin, Selenium, Serine, L-Taurine, Thiamin, Alpha Lipoic Acid, Threonine, Tryptophan, Tyrosine, Valine, Vitamin B12, Vitamin B6, phytonadione, Vitamin K2024-11-29 10:47:42
Animal PAK - The Ultimate Training Pack -- 44 PacksAnimalActive Lifestyle & FitnessLipase, Alanine, Arginine, Vitamin C, Aspartic Acid, Biotin, Carnitine, Choline, Chromium, Coenzyme Q10, Cystine, Vitamin E, Folate, Vitamin E, Glutamic Acid, Glutamine, Glycine, Histidine, Hydroxyproline, Inositol, Iodine, Isoleucine, Leucine, Lutein, Lycopene, Lysine, Manganese, menaquinone-4, Methionine, Niacin, Ornithine, Pantothenic Acid, Phenylalanine, Phosphorus, Proline, Vitamin B6, Vitamin A, Riboflavin, Selenium, Serine, L-Taurine, Thiamin, Alpha Lipoic Acid, Threonine, Tryptophan, Tyrosine, Valine, Vitamin B12, Vitamin B6, phytonadione, Vitamin K2024-11-29 10:47:42
Animal Pak Ultimate Foundation Powder Cherry Bomb -- 30 ServingsAnimalActive Lifestyle & FitnessLipase, Vitamin C, Betaine Anhydrous, Biotin, dicalcium phosphate, Choline, Chromium, Coenzyme Q10, Vitamin E, Folate, Vitamin E, L-Glutamine, L-Histidine, Inositol, Iodine, L-Isoleucine, calcium carbonate, Lutein, Lycopene, Manganese, menaquinone-4, Niacin, Pantothenic Acid, L-Phenylalanine, Phosphorus, Vitamin B6, Vitamin A, Riboflavin, Selenium, L-Taurine, Thiamin, L-Valine, Vitamin B12, Vitamin B6, Vitamin K2024-11-29 10:47:42
Animal Pak Ultimate Foundation Powder Fruit Punch -- 14.7 ozAnimalActive Lifestyle & FitnessLipase, Vitamin C, Betaine Anhydrous, Biotin, dicalcium phosphate, Choline, Chromium, Coenzyme Q10, Vitamin E, Folate, Vitamin E, L-Glutamine, L-Histidine, Inositol, Iodine, L-Isoleucine, calcium carbonate, Lutein, Lycopene, Manganese, menaquinone-4, Niacin, Pantothenic Acid, L-Phenylalanine, Phosphorus, Vitamin B6, Vitamin A, Riboflavin, Selenium, L-Taurine, Thiamin, L-Valine, Vitamin B12, Vitamin B6, Vitamin K2024-11-29 10:47:42
Animal Pak Ultimate Foundation Powder Orange Crushed -- 14.5 ozAnimalActive Lifestyle & FitnessLipase, Vitamin C, Betaine Anhydrous, Biotin, dicalcium phosphate, Choline, Chromium, Coenzyme Q10, Vitamin E, Folate, Vitamin E, L-Glutamine, L-Histidine, Inositol, Iodine, L-Isoleucine, calcium carbonate, Lutein, Lycopene, Manganese, menaquinone-4, Niacin, Pantothenic Acid, L-Phenylalanine, Phosphorus, Vitamin B6, Vitamin A, Riboflavin, Selenium, L-Taurine, Thiamin, L-Valine, Vitamin B12, Vitamin B6, Vitamin K2024-11-29 10:47:42
Beauty Without Cruelty Conditioner Rosemary Mint Tea Tree -- 16 fl ozBeauty Without CrueltyBeauty & Personal Carecitric acid, chamomile, ascorbic acid, biotin, cetearyl alcohol, citric acid, panthenol, ethylhexyl glycerin, glycerin, inositol, sodium benzoate2024-11-29 10:47:42
Beauty Without Cruelty Conditioner Volume Plus -- 16 fl ozBeauty Without CrueltyBeauty & Personal Carecitric acid, chamomile, ascorbic acid, cetyl alcohol, citric acid, panthenol, palmarosa, glycerin, dimethicone, inositol, sodium benzoate2024-11-29 10:47:42
Beauty Without Cruelty Moisture Plus Conditioner -- 16 fl ozBeauty Without CrueltyBeauty & Personal Carecitric acid, chamomile, ascorbic acid, cetearyl alcohol, citric acid, panthenol, glyceryl stearate, glycerin, dimethicone, inositol, sodium benzoate2024-11-29 10:47:42
Best Naturals B-100 Complex -- 120 TabletsBest NaturalsVitamins & SupplementsPABA, Biotin, Choline, Folate, Inositol, Niacin, PABA, Pantothenic Acid, Vitamin B6, Vitamin B2, Vitamin B1, Vitamin B12, Vitamin B62024-11-29 10:47:42
Best Naturals Inositol -- 1000 mg - 120 TabletsBest NaturalsVitamins & SupplementsInositol2024-11-29 10:47:42
Beverly International Lean Out -- 120 CapsulesBeverly InternationalActive Lifestyle & FitnessBiotin, Choline, Chromium, Coenzyme Q10, Inositol, L-Carnitine, Vitamin B122024-11-29 10:47:42
Beverly International Super Pak -- 30 PacketsBeverly InternationalActive Lifestyle & FitnessPara-Aminobenzoic Acid, Vitamin C, Betaine HCl, Biotin, Chloride, Vitamin D3, Choline, Chromium, Vitamin E, Folate, Vitamin E, L-Glutamic Acid, Pepsin, Inositol, Iodine, Manganese, Niacin, Pantothenic Acid, Vitamin B6, Vitamin A, Riboflavin, Rutin, Selenium, Thiamin, Vitamin B12, Vitamin B62024-11-29 10:47:42
BioRepublic Skincare Ultra Hydration Mask -- 1.05 fl ozBioRepublic SkincareBeauty & Personal Carebutylene glycol, citric acid, ascorbyl palmitate, betaine, chlorphenesin, citric acid, panthenol, hydroxyphenyl propamidobenzoic acid, beta-glucan, ethylhexylglycerin, glycerin, dimethicone, inositol, o-cymen-5-ol, phenoxyethanol, propylene glycol, sodium citrate2024-11-29 10:47:42
BioSchwartz Advanced B-Complex -- 60 Veggie CapsBioSchwartzVitamins & Supplements ascorbyl palmitate, Vitamin C, Biotin, calcium ascorbate, Choline, Folate, Inositol, Niacin, Pantothenic Acid, pyridoxal-5-phosphate, pyridoxine HCl, Vitamin B6, Riboflavin, Thiamin, Vitamin B12, Vitamin B62024-11-29 10:47:42
BioSil Bone Collagenizer Ultra -- 60 Vegetarian CapsulesBioSilVitamins & SupplementsCholine, Inositol, Vitamin K2, Vitamin K2, Silicon, Vitamin B122024-11-29 10:47:42
Bluebonnet Nutrition B-Complex 100 -- 100 Vegetable CapsulesBluebonnet NutritionVitamins & SupplementsPABA, Biotin, Choline, Folate, Inositol, Vitamin B3, PABA, Pantothenic Acid, Vitamin B6, Vitamin B2, Vitamin B1, Vitamin B12, Vitamin B62024-11-29 10:47:42
Bluebonnet Nutrition B-Complex 50 -- 100 Vegetable CapsulesBluebonnet NutritionVitamins & SupplementsPABA, Biotin, Choline, Folate, Inositol, Vitamin B3, PABA, Pantothenic Acid, Vitamin B6, Vitamin B2, Vitamin B1, Vitamin B12, Vitamin B62024-11-29 10:47:42
Bluebonnet Nutrition CellularActive® Coenzyme B-Complex -- 100 Vcaps®Bluebonnet NutritionVitamins & SupplementsPABA, Biotin, Choline, riboflavin 5' phosphate, inositol hexanicotinate, Inositol, Vitamin B3, niacinamide, PABA, Pantothenic Acid, pyridoxal 5' phosphate, pyridoxine HCl, Vitamin B6, Vitamin B2, cocarboxylase, Vitamin B1, Vitamin B12, Vitamin B62024-11-29 10:47:42
Bluebonnet Nutrition Multi One Single Daily Multiple -- 120 Vegetable CapsulesBluebonnet NutritionVitamins & SupplementsPABA, Vitamin C, Biotin, Vitamin D3, Choline, Chromium, Vitamin E, Folate, Vitamin E, Inositol, Iodine, Lutein, Manganese, Molybdenum, Vitamin B3, PABA, Pantothenic Acid, Vitamin B6, Vitamin A, Vitamin B2, Selenium, Vitamin B1, Vitamin B12, Vitamin B62024-11-29 10:47:42
Bluebonnet Nutrition Super Earth Lecithin Granules Natural Soya -- 25.4 ozBluebonnet NutritionVitamins & SupplementsLinolenic Acid, Choline, Inositol, Linoleic Acid, Phosphorus2024-11-29 10:47:42
CeliAct Optimizing Nutrition for People with Celiac Disease -- 180 TabletsCeliActVitamins & Supplements Lipase, Para Aminobenzoic Acid, Vitamin C, Biotin, Boron, Chromium, Vitamin E, Folic Acid, Vitamin E, L-Glutamic Acid, Inositol, Manganese, Molybdenum, Niacin, Pantothenic Acid, Vitamin B6, Vitamin A, Vitamin B2, Selenium, Vitamin B1, Vanadium, Vitamin B12, Vitamin B6, Vitamin K12024-11-29 10:47:42
Chapter One One Multi Gummies -- 60 GummiesChapter OneVitamins & SupplementsVitamin C, Biotin, Choline, Vitamin E, Folic Acid, Vitamin E, Inositol, Iodine, Pantothenic Acid, Vitamin B6, Vitamin A, Vitamin B12, Vitamin B62024-11-29 10:47:42
Childlife Multi Vitamin and Mineral Natural Orange Mango -- 8 fl ozChildlifeVitamins & SupplementsVitamin C, Biotin, Vitamin D3, Chromium, Vitamin E, Folic Acid, Vitamin E, Inositol, Iodine, Manganese, Niacin, Pantothenic Acid, Vitamin B6, Vitamin A, Riboflavin, Selenium, Thiamin, Vitamin B12, Vitamin B62024-11-29 10:47:42
Codeage Hair Vitamins - Biotin 10000 mcg Keratin Collagen Zinc Inositol Supplement -- 120 CapsulesCodeageProfessional SupplementsVitamin C, Biotin, Omega-3, Vitamin D3, Vitamin E, Folate, Vitamin E, Inositol, Iodine, Niacin, Pantothenic Acid, Vitamin B6, Vitamin A, Selenium, Vitamin B12, Vitamin B62024-11-29 10:47:42
Codeage Teen Daily Multivitamin - Vitamins A B C D E K Zinc Biotin & Probiotics Vegan Supplement -- 60 CapsulesCodeageProfessional SupplementsVitamin C, Astaxanthin, Biotin, Boron, Omega-3, Vitamin D3, Chromium, Coenzyme Q10, Vitamin E, Vitamin E, Inositol, Iodine, Lutein, Lycopene, Manganese, Vitamin K2, Vitamin K2, Molybdenum, Niacin, Pantothenic Acid, Phosphorus, Vitamin B6, Vitamin A, Riboflavin, Rutin, Selenium, Thiamin, Vitamin B12, Vitamin B6, Zeaxanthin2024-11-29 10:47:42
Codeage Teen Daily Multivitamin - Vitamins A B C D E K Zinc Biotin & Probiotics Vegan Supplement -- 60 Capsules Each / Pack of 2CodeageProfessional SupplementsVitamin C, Astaxanthin, Biotin, Boron, Omega-3, Vitamin D3, Chromium, Coenzyme Q10, Vitamin E, Vitamin E, Inositol, Iodine, Lutein, Lycopene, Manganese, Vitamin K2, Vitamin K2, Molybdenum, Niacin, Pantothenic Acid, Phosphorus, Vitamin B6, Vitamin A, Riboflavin, Rutin, Selenium, Thiamin, Vitamin B12, Vitamin B6, Zeaxanthin2024-11-29 10:47:42
Comforts Advantage Premium Milk-Based Infant Formula -- 34 ozComfortsBaby & Kids ProductsVitamin C, Biotin, Chloride, Choline, Vitamin E, Folic Acid, Vitamin E, Inositol, Iodine, Linoleic Acid, Manganese, Niacin, Fat, Pantothenic Acid, Phosphorus, Vitamin B6, Vitamin A, Riboflavin, Selenium, Thiamine, Vitamin B12, Vitamin B6, Vitamin K2024-11-29 10:47:42
Comforts Gentle Premium Milk Based Infant Formula -- 33.2 ozComfortsBaby & Kids ProductsVitamin C, Biotin, Chloride, Choline, Vitamin E, Folic Acid, Vitamin E, Inositol, Iodine, Linoleic Acid, Manganese, Niacin, Fat, Pantothenic Acid, Phosphorus, Vitamin B6, Vitamin A, Riboflavin, Selenium, Thiamine, Vitamin B12, Vitamin B6, Vitamin K2024-11-29 10:47:42
Comforts Infant Premium Milk Based Formula with Iron -- 34 ozComfortsBaby & Kids ProductsVitamin C, Biotin, Chloride, Choline, Vitamin E, Folic Acid, Vitamin E, Inositol, Iodine, Linoleic Acid, Manganese, Niacin, Fat, Pantothenic Acid, Phosphorus, Vitamin B6, Vitamin A, Riboflavin, Selenium, Thiamine, Vitamin B12, Vitamin B6, Vitamin K2024-11-29 10:47:42
Country Life Chewable Adult Multi -- 60 WafersCountry LifeVitamins & SupplementsPABA, Vitamin C, Biotin, calcium ascorbate, calcium citrate, Choline, Chromium, Vitamin E, riboflavin 5' phosphate, Folic Acid, Vitamin E, Inositol, Manganese, Niacin, niacinamide, PABA, Pantothenic Acid, pyridoxal 5' phosphate, pyridoxine hydrochloride, Vitamin B6, Vitamin A, Riboflavin, Selenium, Thiamin, Vitamin B12, Vitamin B62024-11-29 10:47:42
Country Life Coenzyme B-Complex -- 120 Vegan CapsulesCountry LifeVitamins & SupplementsPABA, Biotin, d-calcium pantothenate, Choline, dibencozide, riboflavin 5' phosphate, Folate, Inositol, Niacin, PABA, pantethine, Pantothenic Acid, pyridoxal 5' phosphate, pyridoxine hydrochloride, Vitamin B6, Riboflavin, thiamine hydrochloride, Thiamin, alpha-Lipoic Acid, Vitamin B12, Vitamin B62024-11-29 10:47:42
Country Life Coenzyme B-Complex -- 60 Vegan CapsulesCountry LifeVitamins & SupplementsPABA, Biotin, Choline, dibencozide, riboflavin 5' phosphate, Folate, Inositol, Niacin, PABA, pantethine, Pantothenic Acid, pyridoxal 5' phosphate, pyridoxine hydrochloride, Vitamin B6, Riboflavin, thiamine hydrochloride, Thiamin, Alpha-Lipoic Acid, Vitamin B12, Vitamin B62024-11-29 10:47:42
Country Life Core Daily-1 for Men 50 + -- 60 TabletsCountry LifeVitamins & SupplementsLipase, Vitamin C, beta carotene, Betaine, Biotin, Calcium fructoborate, d-calcium pantothenate, Cellulase, Choline, Chromium, Vitamin E, riboflavin 5' phosphate, Folic Acid, Vitamin E, inositol hexanicotinate, Inositol, Lactose, Manganese, Molybdenum, Niacin, pantethine, Pantothenic Acid, Phosphorus, pyridoxal 5' phosphate, pyridoxine hydrochloride, Vitamin B6, Vitamin A, Riboflavin, Selenium, citrate, citrate, thiamine hydrochloride, Thiamin, cyanocobalamin, Vitamin B6, Vitamin K2024-11-29 10:47:42
Country Life Core Daily™ 1 for Women 50 Plus -- 60 TabletsCountry LifeVitamins & SupplementsLipase, Vitamin C, beta carotene, Betaine, Biotin, Calcium fructoborate, d-calcium pantothenate, Cellulase, Choline, Chromium, Vitamin E, riboflavin 5' phosphate, Folic Acid, Vitamin E, inositol hexanicotinate, Inositol, Lactose, Manganese, Molybdenum, Niacin, pantethine, Pantothenic Acid, Phosphorus, pyridoxal 5' phosphate, pyridoxine hydrochloride, Vitamin B6, Vitamin A, Riboflavin, Selenium, citrate, citrate, thiamine hydrochloride, Thiamin, cyanocobalamin, Vitamin B6, Vitamin K2024-11-29 10:47:42
Country Life Daily Total One™ Iron Free -- 60 Vegetarian CapsulesCountry LifeVitamins & Supplements ascorbyl palmitate, Vitamin C, beta carotene, Betaine, Biotin, Boron, calcium ascorbate, calcium citrate, d-calcium pantothenate, di-calcium phosphate, Chromium, Vitamin E, riboflavin 5' phosphate, Folate, Vitamin E, inositol hexanicotinate, Inositol, magnesium citrate, Manganese, Molybdenum, Niacin, niacinamide, pantethine, Pantothenic Acid, Phosphorus, pyridoxal 5' phosphate, pyridoxine hydrochloride, Vitamin B6, retinyl palmitate, Vitamin A, Riboflavin, Selenium, thiamine hydrochloride, Thiamin, Vitamin B12, Vitamin B6, Vitamin K2024-11-29 10:47:42
Cymbiotika Heart Health With CoQ10 Organic Orange Cream -- 30 ServingsCymbiotikaVitamins & SupplementsCoenzyme Q10, Inositol2024-11-29 10:47:42
DaVinci Laboratories B Complex-75 -- 60 CapsulesDaVinci LaboratoriesProfessional SupplementsPABA, Biotin, Choline, Folic Acid, Inositol, Niacinamide, PABA, Pantothenic Acid, Vitamin B6, Riboflavin, Thiamin, Vitamin B12, Vitamin B62024-11-29 10:47:42
DaVinci Laboratories Daily Best™ Ultra Multivitamin -- 60 CapsulesDaVinci LaboratoriesProfessional SupplementsVitamin C, Biotin, Boron, Vitamin D3, Choline, Chromium, Coenzyme Q10, Vitamin E, Folate, Vitamin E, Inositol, Iodine, Lutein, Lycopene, Manganese, Vitamin K2, Vitamin K2, Molybdenum, Niacin, Pantothenic Acid, Vitamin B6, Vitamin A, Riboflavin, Selenium, Thiamin, Alpha-Lipoic Acid, Vitamin B12, Vitamin B6, Zeaxanthin2024-11-29 10:47:42
DaVinci Laboratories Spectra Man Multi -- 120 TabletsDaVinci LaboratoriesProfessional Supplements Lipase, Octacosanol, PABA, Vitamin C, L-Aspartic Acid, Betaine HCl, Biotin, Boron, Vitamin D3, Choline, Chromium, L-Cysteine, Vitamin E, Folic Acid, Gamma Linolenic Acid, Vitamin E, L-Glutamine, Hesperidin, Inositol, Iodine, Lycopene, Manganese, Molybdenum, Niacin, PABA, Pantothenic Acid, Vitamin B6, Vitamin A, Riboflavin, Rutin, Selenium, Silicon, Thiamin, Alpha-Lipoic Acid, Vanadium, Vitamin B12, Vitamin B6, Vitamin K12024-11-29 10:47:42
DaVinci Laboratories Spectra™ Multivitamins for Adults -- 240 TabletsDaVinci LaboratoriesProfessional Supplements Lipase, Octacosanol, PABA, Vitamin C, L-Aspartic Acid, Betaine HCl, Biotin, Boron, Vitamin D3, Choline, Chromium, L-Cysteine, Vitamin E, Folic Acid, Vitamin E, L-Glutamine, Hesperidin, Inositol, Iodine, Linoleic Acid, Manganese, Molybdenum, Niacin, Nickel, PABA, Pantothenic Acid, Vitamin B6, Vitamin A, Riboflavin, Rutin, Selenium, Silicon, Thiamin, Vanadium, Vitamin B12, Vitamin B6, Vitamin K12024-11-29 10:47:42
DaVinci Laboratories Spectra™ Senior Multi -- 180 TabletsDaVinci LaboratoriesProfessional Supplements lipase, Octacosanol, PABA, Vitamin C, L-Aspartic Acid, Betaine HCl, Biotin, Boron, Vitamin D3, Choline, Chromium, Coenzyme Q10, L-Cysteine, Vitamin E, Folic Acid, Gamma Linolenic Acid, Vitamin E, Glutamic Acid, Hesperidin, Inositol, Iodine, Lutein, Lycopene, Manganese, Molybdenum, Niacin, PABA, Pantothenic Acid, Vitamin B6, Vitamin A, Riboflavin, Rutin, Selenium, Silicon, Thiamin, Alpha-Lipoic Acid, Vanadium, Vitamin B12, Vitamin B6, Vitamin K12024-11-29 10:47:42
DaVinci Laboratories Spectra™ Woman -- 120 TabletsDaVinci LaboratoriesProfessional Supplements lipase, Octacosanol, PABA, Vitamin C, L-Aspartic Acid, Biotin, Boron, Vitamin D3, Choline, Chromium, L-Cysteine, Vitamin E, Folic Acid, Gamma Linolenic Acid, Vitamin E, L-Glutamine, Hesperidin, Inositol, Iodine, Manganese, Molybdenum, Niacin, Nickel, PABA, Pantothenic Acid, Vitamin B6, Vitamin A, Riboflavin, Rutin, Selenium, Silicon, Thiamin, Vanadium, Vitamin B12, Vitamin B6, Vitamin K12024-11-29 10:47:42
DaVinci Laboratories Ultimate Prenatal Multi -- 150 TabletsDaVinci LaboratoriesProfessional Supplements lipase, Octacosanol, PABA, Vitamin C, L-Aspartic Acid, Betaine HCl, Biotin, Boron, Vitamin D3, Choline, Chromium, L-Cysteine, Vitamin E, Folic Acid, Vitamin E, L-Glutamine, Hesperidin, Inositol, Iodine, Linoleic Acid, Manganese, Molybdenum, Niacin, PABA, Pantothenic Acid, Vitamin B6, Vitamin A, Riboflavin, Rutin, Selenium, Silicon, Thiamin, Vitamin B12, Vitamin B6, Vitamin K12024-11-29 10:47:42
Deva Vegan Hair Nails and Skin -- 90 TabletsDevaVitamins & SupplementsPABA, Vitamin C, Biotin, Choline, L-cysteine, Vitamin E, Folate, Vitamin E, Inositol, Iodine, Vitamin B3, PABA, Vitamin B5, Vitamin B6, Vitamin B2, Beta Sitosterol, Vitamin B1, Alpha Lipoic Acid, Vitamin B12, Vitamin B6, Vitamin D22024-11-29 10:47:42
Deva Vegan Multivitamin & Mineral Supplement -- 90 Coated TabletsDevaVitamins & SupplementsVitamin C, Beta Carotene, Betaine HCL, Biotin, Boron, Choline, Chromium, Vitamin E, Folic Acid, Vitamin E, Inositol, Iodine, Calcium Carbonate, Lutein, Manganese, Molybdenum, Vitamin B3, Vitamin B5, Vitamin B6, Vitamin A, Vitamin B2, Rutin, Selenium, Vitamin B1, Vitamin B12, Vitamin B6, Vitamin D22024-11-29 10:47:42
Deva Vegan Multivitamin & Mineral Tiny Tablets -- 90 TabletsDevaVitamins & SupplementsVitamin C, Biotin, Boron, Choline, Chromium, Vitamin E, Folate, Vitamin E, Inositol, Iodine, Manganese, Molybdenum, Vitamin B3, Vitamin B5, Vitamin B6, Vitamin A, Vitamin B2, Selenium, Vitamin B1, Vitamin B12, Vitamin B6, Vitamin D22024-11-29 10:47:42
Deva Vegan Multivitamin and Mineral Supplement Iron Free -- 90 Coated TabletsDevaVitamins & SupplementsVitamin C, Beta Carotene, Biotin, Boron, Choline, Chromium, Vitamin E, Folic Acid, Vitamin E, Inositol, Iodine, Lutein, Manganese, Molybdenum, Vitamin B3, Vitamin B5, Vitamin B6, Vitamin A, Vitamin B2, Rutin, Selenium, Vitamin B1, Vitamin B12, Vitamin B6, Vitamin D22024-11-29 10:47:42
Deva Vegan Prenatal One Daily Multivitamin and Mineral -- 90 Coated TabletsDevaVitamins & SupplementsChamomile, Vitamin C, Biotin, Boron, Choline, Chromium, Vitamin E, Folate, Vitamin E, Inositol, Iodine, Lutein, Manganese, Molybdenum, Vitamin B3, Vitamin B5, Vitamin B6, Vitamin A, Vitamin B2, Selenium, Vitamin B1, Vitamin B12, Vitamin B6, Vitamin D2, Vitamin K2024-11-29 10:47:42
Dr. Mercola Whole Food Multivitamin Plus -- 240 TabletsDr. MercolaProfessional SupplementsPABA, Ascorbyl Palmitate, Vitamin C, Betaine, Biotin, Boron, Vitamin D3, Choline, Chromium, Folate, Glutamic Acid, Hesperidin, Inositol, Iodine, Manganese, Molybdenum, Niacin, Niacinamide, PABA, Pantothenic Acid, Vitamin B6, Vitamin A, Riboflavin, Rutin, Selenium, Strontium, Thiamin, Vanadium, Vitamin B12, Vitamin B62024-11-29 10:47:42
Dr. Mercola Whole-Food Multivitamin for Women -- 240 TabletsDr. MercolaProfessional SupplementsPABA, Ascorbyl Palmitate, Vitamin C, Betaine, Biotin, Boron, Vitamin D3, Choline, Chromium, Folate, Glutamic Acid, Hesperidin, Inositol, Iodine, Manganese, Molybdenum, Niacin, PABA, Pantothenic Acid, Vitamin B6, Vitamin A, Riboflavin, Rutin, Selenium, Strontium, Thiamin, Vanadium, Vitamin B12, Vitamin B62024-11-29 10:47:42
Else Kids Complete Nutrition Shake RTD Plant Powered 2+ Years Chocolate -- 4 PackElseBaby & Kids ProductsVitamin C, Biotin, Chloride, Choline, Vitamin E, Folate, Vitamin E, Inositol, Iodine, Manganese, Niacin, Pantothenic Acid, Phosphorus, Vitamin B6, Vitamin A, Riboflavin, Selenium, Thiamine, Vitamin B12, Vitamin B6, Vitamin K2024-11-29 10:47:42
Emerald Labs CoEnzymated B Healthy -- 120 Vegetable CapsulesEmerald LabsVitamins & SupplementsBiotin, Inositol, Vitamin B3, Vitamin B5, Vitamin B1, Vitamin B122024-11-29 10:47:42
Emerald Labs CoEnzymated B-Healthy -- 60 Vegetable CapsulesEmerald LabsVitamins & SupplementsBiotin, Inositol, Vitamin B3, Vitamin B5, Vitamin B1, Vitamin B122024-11-29 10:47:42
Emerald Labs CoEnzymated Complete plus 2-Daily Multi -- 60 Vegetable CapsulesEmerald LabsVitamins & SupplementsLipase, Beta Carotene, Biotin, Boron, Cellulase, Vitamin D3, Chromium, Inositol, Iodine, Lutein, Lycopene, Manganese, Molybdenum, Vitamin B3, Vitamin B5, P-5-P, Pyridoxine HCl, Vitamin B6, Vitamin A, Vitamin B2, R-5-P, Rutin, Selenium, Vitamin B1, Alpha Lipoic Acid, Vanadium, Vitamin B12, Vitamin B62024-11-29 10:47:42
Emerald Labs Complete Clinical Plus Multi -- 120 Vegetable CapsulesEmerald LabsVitamins & SupplementsBeta Carotene, Biotin, Boron, Vitamin D3, Chromium, CoQ10, Inositol, Iodine, Lutein, Lycopene, Manganese, Molybdenum, Vitamin B3, Vitamin B5, P-5-P, Pyridoxine HCl, Vitamin B6, Vitamin A, Vitamin B2, R-5-P, Rutin, Selenium, Vitamin B1, Alpha Lipoic Acid, Vanadium, Vitamin B12, Vitamin B62024-11-29 10:47:42
Emerald Labs Prenatal 1-Daily Multi -- 30 Vegetable CapsulesEmerald LabsVitamins & SupplementsBiotin, Boron, Vitamin D3, Chromium, Inositol, Iodine, Lutein, Lycopene, Manganese, Molybdenum, Vitamin B3, Vitamin B5, Vitamin B6, Vitamin A, Vitamin B2, Rutin, Selenium, Vitamin B1, Alpha-Lipoic Acid, Vanadium, Vitamin B12, Vitamin B62024-11-29 10:47:42
Emerald Labs Prenatal 1-Daily Multi -- 60 Vegetable CapsulesEmerald LabsVitamins & SupplementsLipase, Beta Carotene, Biotin, Boron, cellulase, Vitamin D3, Chromium, Vitamin E, Vitamin E, Inositol, Iodine, Lutein, Lycopene, Manganese, Vitamin K2, Vitamin K2, Molybdenum, Vitamin B3, Vitamin B5, Vitamin B6, Vitamin A, Vitamin B2, Rutin, Selenium, Vitamin B1, Alpha-Lipoic Acid, Vitamin B12, Vitamin B6, Vitamin K12024-11-29 10:47:42
Equazen VitaSpectrum Powder Unflavored -- 5.04 ozEquazenProfessional SupplementsVitamin C, Trimethylglycine, Trimethylglycine, Biotin, Boron, Vitamin D3, Choline, Chromium, Vitamin E, Folate, Vitamin E, Inositol, Iodine, Manganese, Vitamin K2, Vitamin K2, Molybdenum, Niacin, Pantothenic Acid, Vitamin B6, vitamin A acetate, Vitamin A, Riboflavin, Selenium, Thiamin, Vanadium, Vitamin B12, Vitamin B62024-11-29 10:47:42
Evlution Nutrition VitaMode -- 120 TabletsEvlution NutritionActive Lifestyle & Fitness Lipase, PABA, Vitamin C, Biotin, Boron, Choline, Chromium, Vitamin E, Folic Acid, Vitamin E, Inositol, Iodine, Lutein, Lycopene, Manganese, Molybdenum, Niacin, PABA, Pantothenic Acid, Vitamin B6, Vitamin A, Riboflavin, Selenium, Thiamin, Alpha-Lipoic Acid, Vanadium, Vitamin B12, Vitamin B6, Vitamin K, Zeaxanthin2024-11-29 10:47:42
Fitcode Fit Multi Complete Multivitamin Complex -- 90 TabletsFitcodeVitamins & SupplementsVitamin C, Biotin, Chloride, Choline, Vitamin E, Folate, Vitamin E, Inositol, Lutein, Lycopene, Manganese, Niacin, Pantothenic Acid, Vitamin B6, Vitamin A, Riboflavin, Selenium, Thiamin, Vitamin B12, Vitamin B6, Zeaxanthin2024-11-29 10:47:42
Futurebiotics Hair Skin & Nails® for Men -- 135 TabletsFuturebioticsVitamins & Supplementspara-Aminobenzoic Acid, Vitamin C, Biotin, Vitamin D3, Choline, Vitamin E, Folate, Vitamin E, Inositol, Iodine, Manganese, Niacin, Pantothenic Acid, Phosphorus, Vitamin B6, Vitamin A, Riboflavin, Selenium, Thiamin, Vitamin B12, Vitamin B62024-11-29 10:47:42
Futurebiotics Hair, Skin and Nails® -- 75 TabletsFuturebioticsVitamins & SupplementsPara Aminobenzoic Acid, Vitamin C, Betaine, Biotin, Vitamin E, Folic Acid, Vitamin E, Inositol, Iodine, Manganese, Methionine, Niacin, Pantothenic Acid, Phosphorus, Vitamin B6, Vitamin A, Riboflavin, Rutin, Selenium, Thiamin, Vitamin B12, Vitamin B62024-11-29 10:47:42
Futurebiotics Hi-Energy Multi For Men™ -- 120 TabletsFuturebioticsVitamins & SupplementsPara Aminobenzoic Acid, Vitamin C, Biotin, Chloride, Chromium, Vitamin E, Folate, Vitamin E, Inositol, Iodine, Manganese, Molybdenum, Niacin, Pantothenic Acid, Phosphorus, Vitamin B6, Vitamin A, Riboflavin, Selenium, Thiamin, Vitamin B12, Vitamin B62024-11-29 10:47:42
Futurebiotics Multi Vitamin Energy Plus® For Women -- 60 TabletsFuturebioticsVitamins & SupplementsPara Aminobenzoic Acid, Vitamin C, Biotin, Choline, Chromium, Vitamin E, Folate, Vitamin E, Inositol, Iodine, Niacin, Pantothenic Acid, Vitamin B6, Vitamin A, Riboflavin, Selenium, Thiamin, Vitamin B12, Vitamin B62024-11-29 10:47:42
Futurebiotics Silymarin Plus™ -- 120 Vegetarian TabletsFuturebioticsHerbs, Botanicals & HomeopathyCholine, Inositol2024-11-29 10:47:42
Greens First Female - ConceEVE -- 180 CapsulesGreens FirstVitamins & SupplementsCellulose, Folate, microcrystalline cellulose, D-Chiro-Inositol2024-11-29 10:47:42
Happy Baby Organic Infant Formula A2 Milk Powder 0-12 Months Stage 1 -- 22.9 ozHappy BabyBaby & Kids Productsascorbyl palmitate, Vitamin C, beta-carotene, Biotin, calcium pantothenate, Chloride, cholecalciferol, Choline, cupric sulfate, Vitamin E, ferrous sulfate, folic acid, vitamin e, Inositol, Iodine, Linoleic Acid, Manganese, Niacin, niacinamide, Fat, Pantothenic Acid, Phosphorus, potassium chloride, vitamin A palmitate, Vitamin A, Riboflavin, Selenium, sodium citrate, Vitamin B1, calcium phosphate, Vitamin B12, phytonadione, Vitamin K, zinc sulfate2024-11-29 10:47:42
Happy Baby Organic Infant Formula Powder 0-12 Months Stage 1 -- 21 ozHappy BabyBaby & Kids Productsascorbyl palmitate, dl-alpha tocopheryl acetate, Vitamin C, betacarotene, Biotin, calcium pantothenate, Chloride, cholecalciferol, Choline, cupric sulfate, Vitamin E, ferrous sulfate, folic acid, vitamin E, Inositol, Iodine, Linoleic Acid, Manganese, Niacin, niacinamide, Fat, Pantothenic Acid, Phosphorus, potassium bicarbonate, potassium chloride, potassium iodide, pyridoxine hydrochloride, Vitamin B6, vitamin A palmitate, Vitamin A, Riboflavin, Selenium, sodium citrate, sodium selenite, thiamine hydrochloride, Thiamine, calcium phosphate, Vitamin B12, Vitamin B6, phytonadione, Vitamin K, zinc sulfate2024-11-29 10:47:42
Happy Baby Organic Infant Formula Powder 6-12 Months Stage 2 -- 21 ozHappy BabyBaby & Kids Productsascorbyl palmitate, dl-alpha tocopheryl acetate, Vitamin C, betacarotene, Biotin, calcium pantothenate, Chloride, cholecalciferol, Choline, cupric sulfate, Vitamin E, ferrous sulfate, folic acid, vitamin E, Inositol, Iodine, Linoleic Acid, Manganese, Niacin, niacinamide, Fat, Pantothenic Acid, Phosphorus, potassium bicarbonate, potassium chloride, potassium iodide, pyridoxine hydrochloride, Vitamin B6, vitamin A palmitate, Vitamin A, Riboflavin, Selenium, sodium citrate, sodium selenite, thiamine hydrochloride, Thiamine, calcium phosphate, Vitamin B12, Vitamin B6, phytonadione, Vitamin K, zinc sulfate2024-11-29 10:47:42
Heaven Sent Wellgenix Balanced Essentials + Plus Liquid Vitamins Berry -- 32 fl ozHeaven SentVitamins & Supplementscitric acid, Antimony, Arginine, Vitamin C, Aspartic Acid, Kelp, Barium, Beryllium, Biotin, Bismuth, Boron, Bromide, Omega 3, Cerium, Cesium, Chromium, citric acid, Cobalt, Cystine, Vitamin E, fructose, Dysprosium, Erbium, Europium, Fluoride, Folate, Gadolinium, Gallium, Vitamin E, Glycine, Gold, Hafnium, Histidine, Holmium, Inositol, Iodine, Iodine, Isoleucine, Lanthanum, Leucine, Calcium Carbonate, Lithium, Lutetium, Lysine, Manganese, Methionine, Molybdenum, Neodymium, Niacin, Nickel, Niobium, Pantothenic Acid, Phenylalanine, Phosphorus, Praseodymium, Proline, Vitamin B6, Vitamin A, Rhenium, Riboflavin, Rubidium, Samarium, Scandium, Selenium, Serine, Silicon, Silver, Strontium, Tantalum, Tellurium, Terbium, Thallium, Thiamin, Thorium, Threonine, Thulium, Tin, Titanium, Tryptophan, Tungsten, Tyrosine, Valine, Vanadium, Vitamin B12, Vitamin B6, Vitamin K, Ytterbium, Yttrium, Zirconium2024-11-29 10:47:42
Integrative Therapeutics Active B-Complex -- 60 CapsulesIntegrative TherapeuticsProfessional Supplementsascorbyl palmitate, Biotin, cellulose, Choline, Folate, Inositol, Niacin, Pantothenic Acid, Vitamin B6, Riboflavin, Thiamin, Vitamin B12, Vitamin B62024-11-29 10:47:42
Jarrow Formulas B-Right Complex -- 100 Veggie CapsulesJarrow FormulasVitamins & SupplementsBiotin, Choline, microcrystalline cellulose, Inositol, Niacin, Pantethine, Pantothenic Acid, Vitamin B6, Riboflavin, Thiamin, calcium phosphate, Vitamin B12, Vitamin B62024-11-29 10:47:42
Jigsaw Health Activated B with SRT® -- 120 TabletsJigsaw HealthVitamins & SupplementsPABA, Biotin, Choline, Folate, Microcrystalline cellulose, Inositol, Niacin, PABA, Pantothenic Acid, Vitamin B6, Riboflavin, Thiamin, Vitamin B12, Vitamin B62024-11-29 10:47:42
Kabrita Goat Milk Toddler Formula 12-24 Months -- 14 ozKabritaBaby & Kids Productsvitamin E acetate, Vitamin C, Biotin, tri calcium citrate, calcium pantothenate, dicalcium phosphate, vitamin D3, choline chloride, copper sulfate, Vitamin E, ferrous sulfate, folic acid, Vitamin E, inositol, Iodine, Lactose, L-carnitine, calcium carbonate, Niacin, niacinamide, Pantothenic Acid, Phosphorus, vitamin B6 hydrochloride, Vitamin B6, retinyl acetate, Vitamin A, Riboflavin, sodium selenite, taurine, thiamine hydrochloride, Thiamin, tri calcium phosphate, Vitamin B12, Vitamin B6, vitamin K1, zinc sulfate2024-11-29 10:47:42
Kal GABA L-Thenine Stress B Lozenge Natural Mango Tangerine -- 100 LozengesKALVitamins & SupplementsVitamin C, cellulose, fructose, Folate, GABA, Inositol, Niacin, Pantothenic Acid, Vitamin B6, stearic acid, Thiamine, Cyanocobalamin, Vitamin B6, Xylitol2024-11-29 10:47:42
KAL Stress B-Complex -- 100 TabletsKALVitamins & SupplementsPABA, Vitamin C, Biotin, Cellulose, Choline, Folate, Inositol, Niacin, PABA, Pantothenic Acid, Vitamin B6, Riboflavin, stearic acid, Thiamin, Vitamin B12, Vitamin B62024-11-29 10:47:42
Klean Athlete B-Complex - NSF Certified for Sport -- 60 Vegetarian CapsulesKlean AthleteProfessional SupplementsBiotin, Choline, Folate, microcrystalline cellulose, Inositol, Niacin, Pantothenic Acid, Vitamin B6, Riboflavin, Thiamin, Vitamin B12, Vitamin B62024-11-29 10:47:42
Klean Athlete Klean Multivitamin - NSF Certified for Sport -- 60 TabletsKlean AthleteProfessional SupplementsL-methylfolate, Vitamin C, Astaxanthin, Biotin, Cellulose, Vitamin D3, Choline, Chromium, leaf, Vitamin E, Folate, Vitamin E, glycerin, Inositol, Iodine, Lutein, Lycopene, Molybdenum, Pantothenic Acid, Pterostilbene, Vitamin B6, Vitamin A, Riboflavin, Selenium, stearic acid, Thiamine, titanium dioxide, Vitamin B12, Vitamin B6, Zeaxanthin2024-11-29 10:47:42
Life Extension BioActive Complete B-Complex -- 60 Vegetarian CapsulesLife ExtensionVitamins & SupplementsPABA, Biotin, D-calcium pantothenate, dicalcium phosphate, calcium sulfate, Folate, Inositol, Niacin, PABA, Pantothenic Acid, Vitamin B6, Riboflavin, stearic acid, Thiamine, Vitamin B12, Vitamin B62024-11-29 10:47:42
Life Extension Two-Per-Day Capsules -- 120 CapsulesLife ExtensionVitamins & SupplementsD-alpha tocopheryl succinate, Apigenin, Vitamin C, Biotin, Boron, dicalcium phosphate, Vitamin D3, Vitamin E, riboflavin 5'-phosphate, Folate, Vitamin E, gluconate, Inositol, Iodine, maltodextrin, Manganese, Molybdenum, Niacin, niacinamide, Pantothenic Acid, pyridoxal 5'-phosphate, pyridoxine HCl, Vitamin B6, Vitamin A, Riboflavin, Thiamine, Alpha-Lipoic Acid, beta, Vitamin B12, Vitamin B62024-11-29 10:47:42
Life Extension Two-Per-Day Tablets -- 120 TabletsLife ExtensionVitamins & SupplementsD-alpha tocopheryl succinate, Apigenin, Vitamin C, Biotin, Boron, dicalcium phosphate, Vitamin D3, Vitamin E, riboflavin 5'-phosphate, Folate, Vitamin E, gluconate, glycerin, Microcrystalline cellulose, Inositol, Iodine, maltodextrin, Manganese, Molybdenum, Niacin, niacinamide, Pantothenic Acid, pyridoxal 5'-phosphate, pyridoxine HCI, Vitamin B6, Vitamin A, Riboflavin, stearic acid, Thiamine, Alpha-Lipoic Acid, beta, Vitamin B12, Vitamin B62024-11-29 10:47:42
Lifetime All One Rice Base Multiple Vitamin & Mineral Powder Unflavored -- 2.2 lbsLifetimeVitamins & SupplementsPara Aminobenzoic Acid, Vitamin C, Kelp, Beta Carotene, Betaine HCl, Biotin, Calcium Pantothenate, Dicalcium Phosphate, Choline, Chromium, Vitamin E, Folate, Vitamin E, Inositol, Iodine, Calcium Carbonate, Manganese, Molybdenum, Niacin, Pantothenic Acid, Phosphorus, Potassium Iodide, Vitamin B6, Retinol Acetate, Vitamin A, Riboflavin, Selenium, Thiamine, Vitamin B12, Vitamin B6, Vitamin D2, Vitamin K2024-11-29 10:47:42
Lifetime Multiple Vitamin & Mineral Powder Unflavored -- 2.2 lbsLifetimeVitamins & SupplementsPara Aminobenzoic Acid, Vitamin C, Kelp, Biotin, Calcium Pantothenate, Dicalcium Phosphate, Choline, Chromium, Vitamin E, Folate, Vitamin E, Inositol, Iodine, Calcium Carbonate, Manganese, Molybdenum, Niacin, Pantothenic Acid, Phosphorus, Vitamin B6, Vitamin A, Riboflavin, Selenium, Vitamin B1, Vitamin B12, Vitamin B6, Vitamin D2, Vitamin K2024-11-29 10:47:42
Lifetime Supreme Vital Hair -- 120 CapsulesLifetimeVitamins & SupplementsVitamin C, Biotin, L-Cysteine, Folic Acid, Inositol, Vitamin B3, Vitamin B5, Vitamin B6, Vitamin A, Vitamin B2, Vitamin B1, Vitamin B62024-11-29 10:47:42
Mason Natural Advanced Ear Health Formula -- 100 CapletsMason NaturalVitamins & SupplementsVitamin C, Choline, microcrystalline cellulose, Inositol, Vitamin B3, Pantothenic Acid, Vitamin B6, Vitamin B2, stearic acid, tartrazine, Vitamin B1, titanium dioxide, glyceryl triacetate, Vitamin B12, Vitamin B62024-11-29 10:47:42
MegaFood Kids B Complex Vitamins -- 30 Mini TabletsMegaFoodVitamins & SupplementsBiotin, Folate, microcrystalline cellulose, Inositol, Niacin, Pantothenic Acid, Vitamin B6, Riboflavin, stearic acid, Thiamin, Vitamin B12, Vitamin B62024-11-29 10:47:42
Mill Creek Biotene H-24® Natural Shampoo -- 8.5 fl ozMill CreekBeauty & Personal Carecitric acid, annatto, ascorbic acid, biotin, citric acid, panthenol, provitamin b5, inositol, retinyl palmitate, vitamin a, sodium benzoate2024-11-29 10:47:42
Mill Creek Biotene H-24® Tri-Pack Shampoo Conditioner Scalp Emulsion -- 1 SetMill CreekBeauty & Personal CareCitric Acid, Vitamin C, Benzoicacid, Biotin, Calcium Pantothenate, Ethoxydiglycol, Carbomer, Cetearyl Alcohol, Cetyl Alcohol, Citric Acid, Panthenol, provitamin B5, Dicetyldimonium Chloride, Glycerin, Inositol, Methylparaben, Niacin, Retinyl Palmitate, vitamin A, Sodium Hydroxide, Stearyl Alcohol, Triethanolamine2024-11-29 10:47:42
Mt Angel Vitamins Super Enzymes+ -- 200 CapsulesMt Angel VitaminsProfessional Supplements Inositol, magnesium trisilicate2024-11-29 10:47:42
Natrol Daily Stress Relief -- 30 TabletsNatrolVitamins & Supplements5-HTP, glycerin, microcrystalline cellulose, Inositol, Methylcellulose, Vitamin B6, stearic acid, Vitamin B12, Vitamin B62024-11-29 10:47:42
Natural Dog Company Multivitamin Supplements For Dogs -- 90 Soft ChewsNatural Dog CompanyPet Suppliesascorbic acid, beta carotene, vitamin B7, Choline, Vitamin E, ferrous gluconate, Folic Acid, vitamin E, inositol, Iodine, Manganese, Niacin, Pantothenic Acid, potassium iodate, pyridoxine hydrochloride, vitamin B6, vitamin A acetate, Vitamin A, vitamin B2, Selenium, vitamin B1, Vitamin B12, vitamin B6, vitamin K2024-11-29 10:47:42
NutraBio MultiSport for Men -- 120 CapsulesNutraBioActive Lifestyle & FitnessVitamin C, Biotin, Boron, Choline, Chromium, Vitamin E, Folate, Vitamin E, Inositol, Iodine, Manganese, Molybdenum, Niacin, Pantothenic Acid, Phosphorus, Vitamin B6, Vitamin A, Riboflavin, Selenium, Thiamin, Alpha-Lipoic Acid, Vanadium, Vitamin B12, Vitamin B62024-11-29 10:47:42
NutraBio MultiSport for Women -- 120 CapsulesNutraBioActive Lifestyle & FitnessVitamin C, Biotin, Boron, Choline, Chromium, Vitamin E, Folate, Vitamin E, Inositol, Iodine, Manganese, Molybdenum, Niacin, Pantothenic Acid, Phosphorus, Vitamin B6, Vitamin A, Riboflavin, Selenium, Thiamin, Alpha-Lipoic Acid, Vanadium, Vitamin B12, Vitamin B62024-11-29 10:47:42
NutriBiotic Broken Cell Wall Chlorella Microalgae -- 500 mg - 300 Vegan TabletsNutriBioticVitamins & SupplementsPABA, Biotin, Chlorophyll, Inositol, Iodine, Niacin, PABA, Phosphorus, Vitamin B6, Vitamin A, Riboflavin, stearic acid, Thiamine, Vitamin B12, Vitamin B62024-11-29 10:47:42
NutriBiotic Multi Vitamins & Minerals -- 180 CapsulesNutriBioticVitamins & SupplementsPara Aminobenzoic Acid, Vitamin C, Glucono delta lactone, Biotin, Vitamin D3, Choline, Chromium, Vitamin E, Folate, Vitamin E, Inositol, calcium carbonate, Manganese, Molybdenum, Niacin, Pantothenic Acid, Vitamin B6, Vitamin A, Vitamin B2, Selenium, montmorillonite, Thiamin, Vanadium, Vitamin B12, Vitamin B62024-11-29 10:47:42
NutriCology Super B Vitamins Non Yeast or Corn Derived -- 120 Vegetarian CapsulesNutriCologyVitamins & SupplementsPABA, Biotin, Folate, Inositol, Niacin, PABA, Pantothenic Acid, Vitamin B6, Riboflavin, Thiamin, Vitamin B12, Vitamin B62024-11-29 10:47:42
One-A-Day VitaCraves Adult Multi Gummies -- 150 GummiesOne-A-DayVitamins & Supplementscitric acid, vitamin E acetate, Vitamin C, d-biotin, d-calcium pantothenate, vitamin D3, Choline, citric acid, Vitamin E, folic acid, Vitamin E, Inositol, Iodine, Pantothenic Acid, potassium iodide, pyridoxine hydrochloride, Vitamin B6, vitamin A acetate, Vitamin A, sucrose, vitamin B12, Vitamin B62024-11-29 10:47:42
Optimum Nutrition Opti-Men Multivitamin for Men -- 150 TabletsOptimum NutritionActive Lifestyle & Fitness Lipase, PABA, Alpha-Carotene, Vitamin C, beta carotene, Biotin, Boron, Choline, Chromium, Cryptoxanthin, L-Cystine, Vitamin E, Folic Acid, Vitamin E, L-Glutamine, Microcrystalline cellulose, Inositol, Iodine, L-Isoleucine, Lutein, Lycopene, L-Lysine, Manganese, Molybdenum, Niacin, PABA, Pantothenic Acid, Vitamin B6, Vitamin A, Riboflavin, Selenium, stearic acid, Thiamin, Alpha-Lipoic Acid, L-Valine, Vanadium, Vitamin B12, Vitamin B6, Vitamin K, Zeaxanthin2024-11-29 10:47:42
Optimum Nutrition Opti-Men Multivitamin for Men -- 240 TabletsOptimum NutritionActive Lifestyle & Fitness Lipase, PABA, Alpha-Carotene, Vitamin C, beta carotene, Biotin, Boron, Choline, Chromium, Cryptoxanthin, L-Cystine, Vitamin E, Folate, Vitamin E, L-Glutamine, Microcrystalline cellulose, Inositol, Iodine, L-Isoleucine, Lutein, Lycopene, Manganese, Molybdenum, Niacin, PABA, Pantothenic Acid, Vitamin B6, Vitamin A, Riboflavin, Selenium, stearic acid, Thiamin, Alpha-Lipoic Acid, L-Valine, Vanadium, Vitamin B12, Vitamin B6, Vitamin K, Zeaxanthin2024-11-29 10:47:42
Optimum Nutrition Opti-Men Multivitamin for Men -- 90 TabletsOptimum NutritionActive Lifestyle & FitnessPABA, Alpha-Carotene, Vitamin C, beta carotene, Biotin, Boron, Chromium, Cryptoxanthin, L-Cystine, Vitamin E, Folate, Vitamin E, L-Glutamine, glycerine, Microcrystalline cellulose, Inositol, Iodine, L-Isoleucine, Lutein, Lycopene, L-Lysine, Manganese, Molybdenum, Niacin, PABA, Pantothenic Acid, Vitamin B6, Vitamin A, Riboflavin, Selenium, stearic acid, Thiamin, Alpha-Lipoic Acid, L-Valine, Vanadium, Vitamin B12, Vitamin B6, Vitamin K, Zeaxanthin2024-11-29 10:47:42
Optimum Nutrition Serious Mass Protein Powder Supplement Chocolate -- 16 ServingsOptimum NutritionActive Lifestyle & FitnessPABA, acesulfame potassium, acesulfame potassium, d-alpha tocopheryl succinate, Vitamin C, beta carotene, Biotin, calcium citrate, d-calcium pantothenate, di-calcium phosphate, cholecalciferol, Choline, Chromium, copper gluconate, Vitamin E, ferrous fumarate, folic acid, Vitamin E, L-Glutamine, Inositol, Iodine, Maltodextrin, Manganese, Molybdenum, Niacin, niacinamide, PABA, Pantothenic Acid, Phosphorus, potassium iodide, pyridoxine hydrochloride, Vitamin B6, Vitamin A, Riboflavin, Selenium, selenomethionine, Thiamin, cyanocobalamin, Vitamin B62024-11-29 10:47:42
Serenity Kids Grass Fed A2 Whole Milk Toddler Formula Powder 12-36 Months -- 21 ozSerenity KidsBaby & Kids ProductsL-methylfolate, ascorbyl palmitate, adenosine-5-monophosphate, alpha-tocopheryl acetate, Vitamin C, Biotin, calcium pantothenate, dicalcium phosphate, Chloride, vitamin D3, Choline, copper sulfate, cytidine-5-monophosphate, Vitamin E, ferrous sulfate, Folate, Vitamin E, inositol, Iodine, lacto-n-neotetraose, calcium carbonate, magnesium phosphate, Niacin, niacinamide, Pantothenic Acid, Phosphorus, potassium chloride, pyridoxine hydrochloride, Vitamin B6, vitamin A palmitate, Vitamin A, Riboflavin, Selenium, sodium selenite, Thiamin, Vitamin B12, Vitamin B6, phylloquinone, Vitamin K, zinc sulfate2024-11-29 10:47:42
SFI Health VitaSpectrum -- 180 Vegetarian CapsulesSFI HealthProfessional SupplementsVitamin C, beta-carotene, Biotin, Boron, cellulose, Vitamin D3, Choline, Chromium, Vitamin E, Folate, Vitamin E, Inositol, Iodine, Manganese, Molybdenum, Niacin, Pantothenic Acid, Vitamin B6, Vitamin A, Riboflavin, Selenium, Thiamin, Vanadium, Vitamin B12, Vitamin B6, Vitamin K2024-11-29 10:47:42
SmartyPants Kids Formula Cherry Berry -- 120 GummiesSmartyPantsVitamins & Supplementscitric acid, L-methylfolate, Vitamin C, Choline, citric acid, Vitamin E, EPA, Folate, Vitamin E, Inositol, Iodine, Pantothenic Acid, Vitamin B6, Vitamin A, Thiamin, Vitamin B12, Vitamin B62024-11-29 10:47:42
SmartyPants Kids Multi and Fiber Gummies -- 120 GummiesSmartyPantsVitamins & Supplementscitric acid, L-methylfolate, Vitamin C, Biotin, citric acid, Vitamin E, Folate, Vitamin E, Inositol, Iodine, Vitamin B6, Vitamin A, Riboflavin, Thiamin, Vitamin B12, Vitamin B6, Vitamin K2024-11-29 10:47:42
SmartyPants Organic Prenatal Multi & Omegas Gummies -- 120 Vegetarian GummiesSmartyPantsVitamins & SupplementsL-methylfolate, Vitamin C, Biotin, Omega-3, Choline, Vitamin E, Folate, Vitamin E, Inositol, Iodine, Vitamin K2, Vitamin K2, Niacin, Vitamin B6, retinyl palmitate, Vitamin A, Riboflavin, Selenium, sodium citrate, Thiamin, Vitamin B12, Vitamin B62024-11-29 10:47:42
SmartyPants Prenatal Multi & Omegas Gummies -- 120 GummiesSmartyPantsVitamins & Supplementscitric acid, Vitamin C, Biotin, Choline, citric acid, Vitamin E, Folate, Vitamin E, Inositol, Iodine, Niacin, Vitamin B6, Vitamin A, Riboflavin, Thiamin, Vitamin B12, Vitamin B6, Vitamin K2024-11-29 10:47:42
SmartyPants Sugar Free Kids Multi & Omegas -- 44 GummiesSmartyPantsVitamins & Supplementscitric acid, L-methylfolate, Vitamin C, Biotin, Omega-3, citric acid, Vitamin E, Folate, Vitamin E, Inositol, Iodine, allulose, Vitamin B6, Vitamin A, Riboflavin, sodium citrate, Thiamin, Vitamin B12, Vitamin B6, Vitamin K2024-11-29 10:47:42
SmartyPants Teen Girl Multi & Omegas Gummies -- 120 GummiesSmartyPantsVitamins & Supplementscitric acid, L-methylfolate, Vitamin C, Biotin, Choline, Chromium, citric acid, Vitamin E, Folate, Vitamin E, Inositol, Iodine, Lutein, Manganese, Vitamin K2, Vitamin K2, Molybdenum, Niacin, Vitamin B6, retinyl palmitate, Vitamin A, Riboflavin, Selenium, Thiamin, Vitamin B12, Vitamin B6, Vitamin K, Zeaxanthin2024-11-29 10:47:42
SmartyPants Teen Guy Multi & Omegas Gummies -- 120 GummiesSmartyPantsVitamins & Supplementscitric acid, L-methylfolate, Vitamin C, Biotin, Choline, Chromium, citric acid, Vitamin E, Folate, Vitamin E, Inositol, Iodine, Lutein, Manganese, Vitamin K2, Vitamin K2, Molybdenum, Niacin, Vitamin B6, retinyl palmitate, Vitamin A, Riboflavin, Selenium, Thiamin, Vitamin B12, Vitamin B6, Vitamin K, Zeaxanthin2024-11-29 10:47:42
SmartyPants Toddler Multi & Omegas Gummies -- 90 GummiesSmartyPantsVitamins & Supplementscitric acid, L-methylfolate, Vitamin C, Biotin, Choline, citric acid, Vitamin E, Folate, Vitamin E, Inositol, Iodine, Vitamin K2, Vitamin K2, Pantothenic Acid, Vitamin B6, retinyl palmitate, Vitamin A, Riboflavin, Thiamin, Vitamin B12, Vitamin B62024-11-29 10:47:42
Solaray B-Complex 100 -- 100 VegCapsSolarayVitamins & SupplementsPABA, Biotin, Chlorine, Folate, Inositol, Niacin, PABA, Pantothenic Acid, Vitamin B6, Riboflavin, Thiamine, Vitamin B12, Vitamin B62024-11-29 10:47:42
Solgar B-Complex 100 -- 100 Vegetable CapsulesSolgarVitamins & SupplementsBiotin, Choline, Folic Acid, Inositol, Niacin, Pantothenic Acid, Vitamin B6, Riboflavin, Thiamin, Vitamin B12, Vitamin B62024-11-29 10:47:42
Solgar B-Complex 50 -- 100 Vegetable CapsulesSolgarVitamins & SupplementsBiotin, Choline, Folic Acid, Inositol, Niacin, niacinamide, Pantothenic Acid, Vitamin B6, Riboflavin, Thiamin, Vitamin B12, Vitamin B62024-11-29 10:47:42
Solgar B-Complex with Vitamin C Stress Formula -- 250 TabletsSolgarVitamins & SupplementsVitamin C, Biotin, Choline, Folic Acid, Microcrystalline cellulose, Inositol, Niacin, Pantothenic Acid, Vitamin B6, Riboflavin, Thiamin, titanium dioxide, Vitamin B12, Vitamin B62024-11-29 10:47:42
Solgar Formula VM-75® Iron-Free -- 180 TabletsSolgarVitamins & Supplementsalpha carotene, Vitamin C, Betaine HCl, Biotin, Boron, Choline, Chromium, cryptoxanthin, Vitamin E, Folic Acid, Vitamin E, Hesperidin, Microcrystalline cellulose, Inositol, Iodine, calcium carbonate, lutein, Manganese, Molybdenum, Niacin, Pantothenic Acid, Vitamin B6, Vitamin A, Riboflavin, Rutin, Selenium, Thiamin, titanium dioxide, Vitamin B12, Vitamin B6, zeaxanthin, zinc oxide2024-11-29 10:47:42
Source Naturals Life Force™ Multiple No Iron -- 180 CapsulesSource NaturalsVitamins & SupplementsN-Acetyl L-Cysteine, Vitamin C, Astaxanthin, Biotin, Boron, Vitamin D3, Choline, Chromium, Coenzyme Q10, Vitamin E, DMAE, Folate, Vitamin E, microcrystalline cellulose, Inositol, Iodine, calcium carbonate, Lutein, Lycopene, Manganese, Molybdenum, N-Acetyl-L-Tyrosine, Niacin, Pantethine, Pantothenic Acid, Vitamin B6, Quercetin, Vitamin A, Riboflavin, Rutin, Selenium, Thiamin, Vitamin B12, Vitamin B6, Vitamin K12024-11-29 10:47:42
SUKU Vitamins Teen Boy Total Multi Blueberry & Grape -- 60 Pectin GummiesSUKU VitaminsVitamins & Supplementscitric acid, L-5-Methyltetrahydrofolate, agar, Vitamin C, Biotin, Vitamin D3, Choline, citric acid, Vitamin E, Folate, Vitamin E, Inositol, Iodine, Vitamin K2, Vitamin K2, Niacin, Pantothenic Acid, Phosphorus, Vitamin B6, Vitamin A, Riboflavin, Thiamine, Calcium phosphate, Vitamin B12, Vitamin B62024-11-29 10:47:42
SUKU Vitamins Teen Girl Total Multi Wild Cherry -- 60 Pectin GummiesSUKU VitaminsVitamins & Supplementscitric acid, L-5-Methyltetrahydrofolate, agar, Vitamin C, Biotin, Vitamin D3, Choline, citric acid, Vitamin E, Folate, Vitamin E, Inositol, Iodine, Vitamin K2, Vitamin K2, Niacin, Pantothenic Acid, Phosphorus, Vitamin B6, Vitamin A, Riboflavin, Thiamine, Calcium phosphate, Vitamin B12, Vitamin B62024-11-29 10:47:42
SUKU Vitamins The Complete Kids Multi Gummy Vitamin Tropical Bonanza -- 60 GummiesSUKU VitaminsVitamins & Supplementscitric acid, agar, Vitamin C, beta-carotene, Biotin, Choline, citric acid, Vitamin E, Folate, Vitamin E, Inositol, Iodine, Pantothenic Acid, Vitamin B6, Vitamin A, sodium citrate, Vitamin B12, Vitamin B62024-11-29 10:47:42
Swolverine B-Complex -- 30 TabletsSwolverineVitamins & SupplementsPara Aminobenzoic Acid, Biotin, Choline, Folate, Inositol, Calcium carbonate, Niacin, Pantothenic Acid, Vitamin B6, Riboflavin, Thiamin, Vitamin B12, Vitamin B62024-11-29 10:47:42
Terry Naturally Clinical Essentials Multi-Vitamin & Minerals -- 60 TabletsTerry NaturallyVitamins & SupplementsPABA, citric acid, Vitamin C, Benfotiamine, Biotin, Boron, calcium ascorbate, calcium fructoborate, dicalcium phosphate, Vitamin D3, Choline, Chromium, citric acid, Vitamin E, Folate, Vitamin E, glycerol monostearate, glycine, Microcrystalline cellulose, Inositol, Iodine, maltodextrin, Manganese, Molybdenum, Niacin, PABA, Pantothenic Acid, Vitamin B6, Vitamin A, Riboflavin, Selenium, Vanadium, Vitamin B12, Vitamin B62024-11-29 10:47:42
Thompson B 100 Complex Timed-Release -- 60 TabletsThompsonVitamins & SupplementsPABA, Biotin, Cellulose, Choline, Folate, Inositol, Niacin, PABA, Pantothenic Acid, Vitamin B6, Riboflavin, stearic acid, Thiamin, Vitamin B12, Vitamin B62024-11-29 10:47:42
Thompson B 50 Complex -- 60 Vegetarian CapsulesThompsonVitamins & SupplementsPABA, Biotin, Folic Acid, Inositol, Niacin, PABA, Pantothenic Acid, Vitamin B6, Riboflavin, Thiamine, Vitamin B12, Vitamin B62024-11-29 10:47:42
Thompson B Complex plus Rice Bran -- 60 TabletsThompsonVitamins & SupplementsBiotin, Cellulose, Folic Acid, Inositol, Niacin, Pantothenic Acid, Vitamin B6, Riboflavin, Thiamin, Vitamin B12, Vitamin B62024-11-29 10:47:42
Trace Minerals Research Liquid Multi Vitamin-Mineral Tropical Mixed Berry -- 30 fl ozTrace Minerals ResearchVitamins & Supplementscitric acid, Vitamin C, Biotin, Boron, Calcium Citrate, Vitamin D3, Choline, Chromium, citric acid, Vitamin E, Folate, Vitamin E, Inositol, Iodine, Manganese, Vitamin K2, Vitamin K2, Molybdenum, Niacin, Pantothenic Acid, Phosphorus, Vitamin B6, Vitamin A, Selenium, Thiamine, Tricalcium Phosphate, Vitamin B12, Vitamin B6, xylitol2024-11-29 10:47:42
Tropical Oasis Liquid B-Complex -- 16 fl ozTropical OasisVitamins & Supplementscitric acid, Biotin, Choline, citric acid, Folic Acid, Inositol, Niacin, Pantothenic Acid, Vitamin B6, Riboflavin, Thiamin, Vitamin B12, Vitamin B6, xylitol2024-11-29 10:47:42
Tropical Oasis Mega Premium Multi-Vitamin -- 32 fl ozTropical OasisVitamins & SupplementsPABA, Vitamin C, Biotin, Choline, CoQ10, Vitamin E, Folate, Vitamin E, Inositol, Vitamin B3, PABA, Pantothenic Acid, Vitamin B6, Quercetin, Vitamin A, Vitamin B2, Vitamin B1, Vitamin B12, Vitamin B6, xylitol2024-11-29 10:47:42
TruBiotics Daily Probiotic Digestive + Immune Health -- 30 Vegetarian CapsulesTruBioticsVitamins & Supplementsinositol, sodium glutamate, titanium dioxide2024-11-29 10:47:42
TruBiotics Probiotic Digestive + Immune Health -- 30 Vegetarian CapsulesTruBioticsVitamins & Supplementsinositol, sodium glutamate, titanium dioxide2024-11-29 10:47:42
Twinlab Daily One Caps For Women -- 60 CapsulesTwinlabVitamins & Supplements Agnuside, Vitamin C, Biotin, Vitamin D3, Choline, Chromium, Vitamin E, riboflavin-5'-phosphate, Folate, Vitamin E, Inositol, Iodine, Manganese, Vitamin K2, Vitamin K2, Molybdenum, Niacin, Pantothenic Acid, pyridoxal-5'-phosphate, pyridoxine HCI, Vitamin B6, Vitamin A, Vitamin B2, Selenium, Vitamin B1, Vitamin B12, Vitamin B62024-11-29 10:47:42
Twinlab Daily One Caps without Iron -- 180 CapsulesTwinlabVitamins & SupplementsVitamin C, Biotin, Choline, Chromium, Vitamin E, Folate, Vitamin E, Inositol, Iodine, Manganese, Molybdenum, Niacin, Pantothenic Acid, Vitamin B6, Vitamin A, Riboflavin, Selenium, Thiamin, Vitamin B12, Vitamin B62024-11-29 10:47:42
Twinlab Stress B-Complex Caps -- 100 CapsulesTwinlabVitamins & SupplementsPABA, Vitamin C, Biotin, Folic Acid, Inositol, Niacin, PABA, Pantothenic Acid, Vitamin B6, Vitamin B2, Thiamin, Vitamin B12, Vitamin B62024-11-29 10:47:42
Twinlab Stress B-Complex Caps -- 250 CapsulesTwinlabVitamins & SupplementsPABA, Vitamin C, Biotin, Choline, Folate, Inositol, Niacin, PABA, Pantothenic Acid, Vitamin B6, Riboflavin, Thiamin, Vitamin B12, Vitamin B62024-11-29 10:47:42
VegLife Vegan B-Complex -- 100 TabletsVegLifeVitamins & SupplementsPABA, Biotin, Folate, Inositol, Niacin, PABA, Pantothenic Acid, Vitamin B6, Riboflavin, stearic acid, Thiamine, Vitamin B12, Vitamin B62024-11-29 10:47:42
VegLife Vegan One Multiple with Iron -- 60 TabletsVegLifeVitamins & SupplementsPABA, Vitamin C, Biotin, calcium citrate, Choline, Chromium, Vitamin E, Folate, Vitamin E, Inositol, Iodine, Manganese, Molybdenum, Niacin, PABA, Pantothenic Acid, Vitamin B6, Vitamin A, Riboflavin, Selenium, stearic acid, Thiamine, calcium phosphate, Vitamin B12, Vitamin B62024-11-29 10:47:42
VegLife Vegan One™ Multiple Iron-Free -- 60 TabletsVegLifeVitamins & SupplementsPABA, Vitamin C, Biotin, calcium citrate, Choline, Chromium, Vitamin E, Folate, Vitamin E, Inositol, Iodine, Manganese, Molybdenum, Niacin, PABA, Pantothenic Acid, Vitamin B6, Vitamin A, Riboflavin, Selenium, montmorillonite clay, stearic acid, Thiamine, calcium phosphate, Vitamin B12, Vitamin B62024-11-29 10:47:42
Vitacost B-50 Complex -- 100 CapsulesVitacost BrandVitamins & SupplementsBiotin, Choline, riboflavin 5'-phosphate, Folate, Inositol, Niacin, Pantothenic Acid, Vitamin B6, Riboflavin, Thiamin, Vitamin B12, Vitamin B62024-11-29 10:47:42
Vitacost-Synergy Optimized B-100 Complex Enhanced Absorption -- 60 CapsulesVitacost-SynergyVitamins & SupplementsBiotin, Choline, riboflavin 5'-phosphate, Folate, inositol hexanicotinate, Inositol, Niacin, niacinamide, Pantothenic Acid, pyridoxal 5-phosphate, Vitamin B6, Riboflavin, Thiamin, Vitamin B12, Vitamin B62024-11-29 10:47:42
Vitafusion MultiVites Adult Complete Multivitamin Gummy Assorted Fruit -- 70 GummiesVitafusionVitamins & SupplementsVitamin C, Biotin, Boron, Choline, Chromium, Vitamin E, Folic Acid, Vitamin E, Inositol, lactic acid, Lutein, Molybdenum, Niacin, Pantothenic Acid, Vitamin B6, Vitamin A, sucrose, Vitamin B12, Vitamin B62024-11-29 10:47:42
Vitafusion MultiVites™ Multivitamin Gummies Berry Peach and Orange -- 150 GummiesVitafusionVitamins & Supplementscitric acid, Vitamin C, Biotin, Boron, Chromium, citric acid, Vitamin E, Folic Acid, Vitamin E, Inositol, lactic acid, Molybdenum, Niacin, Pantothenic Acid, Vitamin B6, Vitamin A, sucrose, Vitamin B12, Vitamin B62024-11-29 10:47:42
Vitauthority Detox Nourish Orange Pineapple -- 50 ServingsVitauthorityWeight ManagementLipase, Citric acid, Chromium, Citric acid, leaf, Inositol, Vitamin B6, stevia, Vitamin B12, Vitamin B62024-11-29 10:47:42
Viteyes Complete Eye & Total Body Health Multivitamin -- 180 CapsulesViteyesVitamins & SupplementsN-Acetyl Cysteine, Vitamin C, Biotin, Boron, Chromium, Coenzyme Q10, Vitamin E, Folate, Vitamin E, Inositol, Iodine, Lutein, Lycopene, Manganese, Molybdenum, Niacin, Nickel, Pantothenic Acid, Phosphorus, Vitamin B6, Vitamin A, Riboflavin, Selenium, Taurine, Thiamin, Alpha-Lipoic Acid, Vitamin B12, Vitamin B6, Vitamin K, Zeaxanthin2024-11-29 10:47:42
Wholesome Story Myo & D-Chiro Inositol -- 120 Vegetarian CapsulesWholesome StoryVitamins & SupplementsD-Chiro Inositol2024-11-29 10:47:42
Wholesome Story Myo & D-Chiro Inositol -- 360 Vegetarian CapsulesWholesome StoryVitamins & SupplementsD-Chiro Inositol2024-11-29 10:47:42
Wholesome Story Myo & D-Chiro Inositol Powder 30-Day Supply -- 2.17 ozWholesome StoryVitamins & SupplementsD-Chiro Inositol2024-11-29 10:47:42
Wholesome Story Myo & D-Chiro Inositol Powder 90-Day Supply -- 6.5 ozWholesome StoryVitamins & SupplementsD-Chiro Inositol2024-11-29 10:47:42
Wholesome Story Myo & D-Chiro Inositol with MTHF Folate + Vitamin D3 -- 120 Vegetarian CapsulesWholesome StoryVitamins & SupplementsVitamin D3, Folate, D-Chiro Inositol2024-11-29 10:47:42
World Organic Hair-Nu Supplement -- 120 TabletsWorld OrganicVitamins & SupplementsPABA, Vitamin C, Biotin, Di-calcium phosphate, Choline, L-Cysteine, Folate, Inositol, Iodine, PABA, Pantothenic Acid, Vitamin B6, stearic acid, Vitamin B62024-11-29 10:47:42
World Organic Ultra-B Liquid -- 16 fl ozWorld OrganicVitamins & SupplementsPABA, Biotin, Choline, Folate, Inositol, Niacin, PABA, Pantothenic Acid, Vitamin B6, Riboflavin, Thiamin, Vitamin B12, Vitamin B62024-11-29 10:47:42
Zahler B-Complex Bioactive B Complex Formula -- 60 Time Release TabletsZahlerVitamins & SupplementsBenfotiamine, Biotin, Dicalcium phosphate, Choline, Folate, microcrystalline cellulose, Inositol, Niacin, Pantethine, Vitamin B6, Riboflavin, stearic acid, Vitamin B12, Vitamin B62024-11-29 10:47:42
Zahler B-Complex Bioactive B-Complex Formula -- 120 Time Release TabletsZahlerVitamins & SupplementsBenfotiamine, Biotin, Dicalcium phosphate, Choline, Folate, microcrystalline cellulose, Inositol, Niacin, Pantethine, Vitamin B6, Riboflavin, stearic acid, Vitamin B12, Vitamin B62024-11-29 10:47:42
Zahler Inositol + Glycine -- 11.5 ozZahlerVitamins & SupplementsGlycine, Inositol2024-11-29 10:47:42
Zhou Daily Boost -- 30 Vegetarian CapsulesZhouVitamins & SupplementsPABA, Vitamin C, Biotin, cellulose, Vitamin D3, Choline, Chromium, Vitamin E, Folate, Vitamin E, Inositol, Iodine, maltodextrin, Manganese, Molybdenum, Niacin, PABA, Pantothenic Acid, Vitamin B6, Vitamin A, Riboflavin, Selenium, stearic acid, Thiamine, Vitamin B12, Vitamin B6, Vitamin K12024-11-29 10:47:42

Drug Classes (2)

ClassDescription
cyclitolA polyol consisting of a cycloalkane containing at least three hydroxy groups, each attached to a different ring carbon atom.
hexolA polyol that contains 6 hydroxy groups.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Pathways (66)

PathwayProteinsCompounds
Transport of small molecules39295
SLC-mediated transmembrane transport13567
Transport of bile salts and organic acids, metal ions and amine compounds4928
Inositol transporters33
Metabolism14961108
Inositol phosphate metabolism3235
Synthesis of IP2, IP, and Ins in the cytosol517
Metabolism of lipids500463
Phospholipid metabolism12242
Glycerophospholipid biosynthesis7439
Synthesis of PI25
PI Metabolism4911
Glycerophospholipid catabolism77
Galactose Metabolism1234
Inositol Metabolism2226
Inositol Phosphate Metabolism1423
Phosphatidylinositol Phosphate Metabolism2213
Galactosemia1234
Joubert Syndrome2213
D-myo-Inositol (1,4,5)-Trisphosphate Biosynthesis57
3-phosphoinositide biosynthesis08
glycerophosphodiester degradation18
stachyose biosynthesis523
UDP-u03B1-D-glucuronate biosynthesis (from myo-inositol)415
B series fagopyritols biosynthesis28
myo-inositol biosynthesis55
lychnose and isolychnose biosynthesis09
pinitol biosynthesis II016
indole-3-acetate activation II09
1D-myo-inositol hexakisphosphate biosynthesis III (Spirodela polyrrhiza)711
superpathway of indole-3-acetate conjugate biosynthesis828
indole-3-acetate inactivation IX017
superpathway of phospholipid biosynthesis II (plants)1731
ajugose biosynthesis I (galactinol-dependent)25
D-myo-inositol (1,4,5)-trisphosphate degradation56
pinitol biosynthesis I16
galactosylcyclitol biosynthesis17
phosphatidylinositol biosynthesis II (eukaryotes)03
stellariose and mediose biosynthesis08
D-myo-inositol (1,4,5)-trisphosphate biosynthesis27
phytate degradation I316
A series fagopyritols biosynthesis18
Inositol phosphate metabolism ( Inositol phosphate metabolism )4218
Renz2020 - GEM of Human alveolar macrophage with SARS-CoV-20490
16p11.2 proximal deletion syndrome039
L-ascorbate biosynthesis VI (plants, myo-inositol pathway)010
myo-inositol de novo biosynthesis36
1D-myo-inositol hexakisphosphate biosynthesis IV (Dictyostelium)111
1D-myo-inositol hexakisphosphate biosynthesis III (Spirodela polyrrhiza)211
superpathway of inositol phosphate compounds625
3-phosphoinositide biosynthesis2919
ajugose biosynthesis I (galactinol-dependent)15
stellariose and mediose biosynthesis010
stachyose biosynthesis323
phosphatidylinositol biosynthesis II (eukaryotes)210
indole-3-acetate activation II011
phytate degradation I021
streptomycin biosynthesis452
myo-, chiro- and scyllo-inositol degradation921
myo-inositol degradation II511
myo-inositol degradation I921
D-myo-inositol (1,4,5)-trisphosphate degradation147
UDP-u03B1-D-glucuronate biosynthesis (from myo-inositol)515
D-myo-inositol (1,4,5)-trisphosphate biosynthesis1621
superpathway of D-myo-inositol (1,4,5)-trisphosphate metabolism2015
myo-inositol biosynthesis109
galactosylcyclitol biosynthesis19
superpathway of indole-3-acetate conjugate biosynthesis533
phosphatidylinositol phosphate biosynthesis1410
superpathway of phospholipid biosynthesis II (plants)55
superpathway of phospholipid biosynthesis027
ester phospholipid biosynthesis021
myo-, chiro- and scillo-inositol degradation617
PIP metabolism4710
myo-inositol degradation014
UDP-D-glucuronate biosynthesis (from myo-inositol)011
AtMetExpress overview0109
Glycerophospholipid biosynthetic pathway3233
MECP2 and associated Rett syndrome011
Biochemical pathways: part I0466
Stachyose biosynthesis27
UDP-D-GlcA biosynthesis39
IAA conjugation I010
Galactosylcyclitol biosynthesis03
Lipid-independent phytate biosynthesis512
Myo-inositol biosynthesis15

Protein Targets (11)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
TDP1 proteinHomo sapiens (human)Potency16.90030.000811.382244.6684AID686978; AID686979
parathyroid hormone/parathyroid hormone-related peptide receptor precursorHomo sapiens (human)Potency50.11873.548119.542744.6684AID743266
DNA polymerase iota isoform a (long)Homo sapiens (human)Potency5.31550.050127.073689.1251AID588590
gemininHomo sapiens (human)Potency0.23110.004611.374133.4983AID624297
lamin isoform A-delta10Homo sapiens (human)Potency10.00000.891312.067628.1838AID1487
Cellular tumor antigen p53Homo sapiens (human)Potency23.71010.002319.595674.0614AID651631
TAR DNA-binding protein 43Homo sapiens (human)Potency11.22021.778316.208135.4813AID652104
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Chain B, Pulmonary surfactant-associated protein DHomo sapiens (human)IC50 (µMol)5,700.00005,700.00005,700.00005,700.0000AID977608
Chain A, Pulmonary surfactant-associated protein DHomo sapiens (human)IC50 (µMol)5,700.00005,700.00005,700.00005,700.0000AID977608
Amyloid-beta precursor proteinHomo sapiens (human)IC50 (µMol)100.00000.00053.889510.0000AID748709
Sodium/myo-inositol cotransporter 2Homo sapiens (human)IC50 (µMol)104.00000.380052.1900104.0000AID1794826
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (217)

Processvia Protein(s)Taxonomy
negative regulation of cell population proliferationCellular tumor antigen p53Homo sapiens (human)
regulation of cell cycleCellular tumor antigen p53Homo sapiens (human)
regulation of cell cycle G2/M phase transitionCellular tumor antigen p53Homo sapiens (human)
DNA damage responseCellular tumor antigen p53Homo sapiens (human)
ER overload responseCellular tumor antigen p53Homo sapiens (human)
cellular response to glucose starvationCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
regulation of apoptotic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of transcription by RNA polymerase IICellular tumor antigen p53Homo sapiens (human)
positive regulation of miRNA transcriptionCellular tumor antigen p53Homo sapiens (human)
negative regulation of transcription by RNA polymerase IICellular tumor antigen p53Homo sapiens (human)
mitophagyCellular tumor antigen p53Homo sapiens (human)
in utero embryonic developmentCellular tumor antigen p53Homo sapiens (human)
somitogenesisCellular tumor antigen p53Homo sapiens (human)
release of cytochrome c from mitochondriaCellular tumor antigen p53Homo sapiens (human)
hematopoietic progenitor cell differentiationCellular tumor antigen p53Homo sapiens (human)
T cell proliferation involved in immune responseCellular tumor antigen p53Homo sapiens (human)
B cell lineage commitmentCellular tumor antigen p53Homo sapiens (human)
T cell lineage commitmentCellular tumor antigen p53Homo sapiens (human)
response to ischemiaCellular tumor antigen p53Homo sapiens (human)
nucleotide-excision repairCellular tumor antigen p53Homo sapiens (human)
double-strand break repairCellular tumor antigen p53Homo sapiens (human)
regulation of DNA-templated transcriptionCellular tumor antigen p53Homo sapiens (human)
regulation of transcription by RNA polymerase IICellular tumor antigen p53Homo sapiens (human)
protein import into nucleusCellular tumor antigen p53Homo sapiens (human)
autophagyCellular tumor antigen p53Homo sapiens (human)
DNA damage responseCellular tumor antigen p53Homo sapiens (human)
DNA damage response, signal transduction by p53 class mediator resulting in cell cycle arrestCellular tumor antigen p53Homo sapiens (human)
DNA damage response, signal transduction by p53 class mediator resulting in transcription of p21 class mediatorCellular tumor antigen p53Homo sapiens (human)
transforming growth factor beta receptor signaling pathwayCellular tumor antigen p53Homo sapiens (human)
Ras protein signal transductionCellular tumor antigen p53Homo sapiens (human)
gastrulationCellular tumor antigen p53Homo sapiens (human)
neuroblast proliferationCellular tumor antigen p53Homo sapiens (human)
negative regulation of neuroblast proliferationCellular tumor antigen p53Homo sapiens (human)
protein localizationCellular tumor antigen p53Homo sapiens (human)
negative regulation of DNA replicationCellular tumor antigen p53Homo sapiens (human)
negative regulation of cell population proliferationCellular tumor antigen p53Homo sapiens (human)
determination of adult lifespanCellular tumor antigen p53Homo sapiens (human)
mRNA transcriptionCellular tumor antigen p53Homo sapiens (human)
rRNA transcriptionCellular tumor antigen p53Homo sapiens (human)
response to salt stressCellular tumor antigen p53Homo sapiens (human)
response to inorganic substanceCellular tumor antigen p53Homo sapiens (human)
response to X-rayCellular tumor antigen p53Homo sapiens (human)
response to gamma radiationCellular tumor antigen p53Homo sapiens (human)
positive regulation of gene expressionCellular tumor antigen p53Homo sapiens (human)
cardiac muscle cell apoptotic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of cardiac muscle cell apoptotic processCellular tumor antigen p53Homo sapiens (human)
glial cell proliferationCellular tumor antigen p53Homo sapiens (human)
viral processCellular tumor antigen p53Homo sapiens (human)
glucose catabolic process to lactate via pyruvateCellular tumor antigen p53Homo sapiens (human)
cerebellum developmentCellular tumor antigen p53Homo sapiens (human)
negative regulation of cell growthCellular tumor antigen p53Homo sapiens (human)
DNA damage response, signal transduction by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
negative regulation of transforming growth factor beta receptor signaling pathwayCellular tumor antigen p53Homo sapiens (human)
mitotic G1 DNA damage checkpoint signalingCellular tumor antigen p53Homo sapiens (human)
negative regulation of telomere maintenance via telomeraseCellular tumor antigen p53Homo sapiens (human)
T cell differentiation in thymusCellular tumor antigen p53Homo sapiens (human)
tumor necrosis factor-mediated signaling pathwayCellular tumor antigen p53Homo sapiens (human)
regulation of tissue remodelingCellular tumor antigen p53Homo sapiens (human)
cellular response to UVCellular tumor antigen p53Homo sapiens (human)
multicellular organism growthCellular tumor antigen p53Homo sapiens (human)
positive regulation of mitochondrial membrane permeabilityCellular tumor antigen p53Homo sapiens (human)
cellular response to glucose starvationCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
positive regulation of apoptotic processCellular tumor antigen p53Homo sapiens (human)
negative regulation of apoptotic processCellular tumor antigen p53Homo sapiens (human)
entrainment of circadian clock by photoperiodCellular tumor antigen p53Homo sapiens (human)
mitochondrial DNA repairCellular tumor antigen p53Homo sapiens (human)
regulation of DNA damage response, signal transduction by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
positive regulation of neuron apoptotic processCellular tumor antigen p53Homo sapiens (human)
transcription initiation-coupled chromatin remodelingCellular tumor antigen p53Homo sapiens (human)
negative regulation of proteolysisCellular tumor antigen p53Homo sapiens (human)
negative regulation of DNA-templated transcriptionCellular tumor antigen p53Homo sapiens (human)
positive regulation of DNA-templated transcriptionCellular tumor antigen p53Homo sapiens (human)
positive regulation of RNA polymerase II transcription preinitiation complex assemblyCellular tumor antigen p53Homo sapiens (human)
positive regulation of transcription by RNA polymerase IICellular tumor antigen p53Homo sapiens (human)
response to antibioticCellular tumor antigen p53Homo sapiens (human)
fibroblast proliferationCellular tumor antigen p53Homo sapiens (human)
negative regulation of fibroblast proliferationCellular tumor antigen p53Homo sapiens (human)
circadian behaviorCellular tumor antigen p53Homo sapiens (human)
bone marrow developmentCellular tumor antigen p53Homo sapiens (human)
embryonic organ developmentCellular tumor antigen p53Homo sapiens (human)
positive regulation of peptidyl-tyrosine phosphorylationCellular tumor antigen p53Homo sapiens (human)
protein stabilizationCellular tumor antigen p53Homo sapiens (human)
negative regulation of helicase activityCellular tumor antigen p53Homo sapiens (human)
protein tetramerizationCellular tumor antigen p53Homo sapiens (human)
chromosome organizationCellular tumor antigen p53Homo sapiens (human)
neuron apoptotic processCellular tumor antigen p53Homo sapiens (human)
regulation of cell cycleCellular tumor antigen p53Homo sapiens (human)
hematopoietic stem cell differentiationCellular tumor antigen p53Homo sapiens (human)
negative regulation of glial cell proliferationCellular tumor antigen p53Homo sapiens (human)
type II interferon-mediated signaling pathwayCellular tumor antigen p53Homo sapiens (human)
cardiac septum morphogenesisCellular tumor antigen p53Homo sapiens (human)
positive regulation of programmed necrotic cell deathCellular tumor antigen p53Homo sapiens (human)
protein-containing complex assemblyCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to endoplasmic reticulum stressCellular tumor antigen p53Homo sapiens (human)
thymocyte apoptotic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of thymocyte apoptotic processCellular tumor antigen p53Homo sapiens (human)
necroptotic processCellular tumor antigen p53Homo sapiens (human)
cellular response to hypoxiaCellular tumor antigen p53Homo sapiens (human)
cellular response to xenobiotic stimulusCellular tumor antigen p53Homo sapiens (human)
cellular response to ionizing radiationCellular tumor antigen p53Homo sapiens (human)
cellular response to gamma radiationCellular tumor antigen p53Homo sapiens (human)
cellular response to UV-CCellular tumor antigen p53Homo sapiens (human)
stem cell proliferationCellular tumor antigen p53Homo sapiens (human)
signal transduction by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
reactive oxygen species metabolic processCellular tumor antigen p53Homo sapiens (human)
cellular response to actinomycin DCellular tumor antigen p53Homo sapiens (human)
positive regulation of release of cytochrome c from mitochondriaCellular tumor antigen p53Homo sapiens (human)
cellular senescenceCellular tumor antigen p53Homo sapiens (human)
replicative senescenceCellular tumor antigen p53Homo sapiens (human)
oxidative stress-induced premature senescenceCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathwayCellular tumor antigen p53Homo sapiens (human)
oligodendrocyte apoptotic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of execution phase of apoptosisCellular tumor antigen p53Homo sapiens (human)
negative regulation of mitophagyCellular tumor antigen p53Homo sapiens (human)
regulation of mitochondrial membrane permeability involved in apoptotic processCellular tumor antigen p53Homo sapiens (human)
regulation of intrinsic apoptotic signaling pathway by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
positive regulation of miRNA transcriptionCellular tumor antigen p53Homo sapiens (human)
negative regulation of G1 to G0 transitionCellular tumor antigen p53Homo sapiens (human)
negative regulation of miRNA processingCellular tumor antigen p53Homo sapiens (human)
negative regulation of glucose catabolic process to lactate via pyruvateCellular tumor antigen p53Homo sapiens (human)
negative regulation of pentose-phosphate shuntCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to hypoxiaCellular tumor antigen p53Homo sapiens (human)
regulation of fibroblast apoptotic processCellular tumor antigen p53Homo sapiens (human)
negative regulation of reactive oxygen species metabolic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of reactive oxygen species metabolic processCellular tumor antigen p53Homo sapiens (human)
negative regulation of stem cell proliferationCellular tumor antigen p53Homo sapiens (human)
positive regulation of cellular senescenceCellular tumor antigen p53Homo sapiens (human)
positive regulation of intrinsic apoptotic signaling pathwayCellular tumor antigen p53Homo sapiens (human)
regulation of gene expressionAmyloid-beta precursor proteinHomo sapiens (human)
cognitionAmyloid-beta precursor proteinHomo sapiens (human)
G2/M transition of mitotic cell cycleAmyloid-beta precursor proteinHomo sapiens (human)
microglial cell activationAmyloid-beta precursor proteinHomo sapiens (human)
positive regulation of protein phosphorylationAmyloid-beta precursor proteinHomo sapiens (human)
suckling behaviorAmyloid-beta precursor proteinHomo sapiens (human)
astrocyte activation involved in immune responseAmyloid-beta precursor proteinHomo sapiens (human)
regulation of translationAmyloid-beta precursor proteinHomo sapiens (human)
protein phosphorylationAmyloid-beta precursor proteinHomo sapiens (human)
intracellular copper ion homeostasisAmyloid-beta precursor proteinHomo sapiens (human)
endocytosisAmyloid-beta precursor proteinHomo sapiens (human)
response to oxidative stressAmyloid-beta precursor proteinHomo sapiens (human)
cell adhesionAmyloid-beta precursor proteinHomo sapiens (human)
regulation of epidermal growth factor-activated receptor activityAmyloid-beta precursor proteinHomo sapiens (human)
Notch signaling pathwayAmyloid-beta precursor proteinHomo sapiens (human)
axonogenesisAmyloid-beta precursor proteinHomo sapiens (human)
learning or memoryAmyloid-beta precursor proteinHomo sapiens (human)
learningAmyloid-beta precursor proteinHomo sapiens (human)
mating behaviorAmyloid-beta precursor proteinHomo sapiens (human)
locomotory behaviorAmyloid-beta precursor proteinHomo sapiens (human)
axo-dendritic transportAmyloid-beta precursor proteinHomo sapiens (human)
cholesterol metabolic processAmyloid-beta precursor proteinHomo sapiens (human)
negative regulation of cell population proliferationAmyloid-beta precursor proteinHomo sapiens (human)
adult locomotory behaviorAmyloid-beta precursor proteinHomo sapiens (human)
visual learningAmyloid-beta precursor proteinHomo sapiens (human)
regulation of gene expressionAmyloid-beta precursor proteinHomo sapiens (human)
positive regulation of gene expressionAmyloid-beta precursor proteinHomo sapiens (human)
negative regulation of gene expressionAmyloid-beta precursor proteinHomo sapiens (human)
positive regulation of peptidyl-threonine phosphorylationAmyloid-beta precursor proteinHomo sapiens (human)
positive regulation of G2/M transition of mitotic cell cycleAmyloid-beta precursor proteinHomo sapiens (human)
microglia developmentAmyloid-beta precursor proteinHomo sapiens (human)
axon midline choice point recognitionAmyloid-beta precursor proteinHomo sapiens (human)
neuron remodelingAmyloid-beta precursor proteinHomo sapiens (human)
dendrite developmentAmyloid-beta precursor proteinHomo sapiens (human)
regulation of Wnt signaling pathwayAmyloid-beta precursor proteinHomo sapiens (human)
extracellular matrix organizationAmyloid-beta precursor proteinHomo sapiens (human)
forebrain developmentAmyloid-beta precursor proteinHomo sapiens (human)
neuron projection developmentAmyloid-beta precursor proteinHomo sapiens (human)
positive regulation of chemokine productionAmyloid-beta precursor proteinHomo sapiens (human)
positive regulation of interleukin-1 beta productionAmyloid-beta precursor proteinHomo sapiens (human)
positive regulation of interleukin-6 productionAmyloid-beta precursor proteinHomo sapiens (human)
positive regulation of tumor necrosis factor productionAmyloid-beta precursor proteinHomo sapiens (human)
positive regulation of peptidyl-serine phosphorylationAmyloid-beta precursor proteinHomo sapiens (human)
ionotropic glutamate receptor signaling pathwayAmyloid-beta precursor proteinHomo sapiens (human)
regulation of multicellular organism growthAmyloid-beta precursor proteinHomo sapiens (human)
negative regulation of neuron differentiationAmyloid-beta precursor proteinHomo sapiens (human)
positive regulation of glycolytic processAmyloid-beta precursor proteinHomo sapiens (human)
positive regulation of mitotic cell cycleAmyloid-beta precursor proteinHomo sapiens (human)
positive regulation of transcription by RNA polymerase IIAmyloid-beta precursor proteinHomo sapiens (human)
positive regulation of JNK cascadeAmyloid-beta precursor proteinHomo sapiens (human)
astrocyte activationAmyloid-beta precursor proteinHomo sapiens (human)
regulation of long-term neuronal synaptic plasticityAmyloid-beta precursor proteinHomo sapiens (human)
collateral sprouting in absence of injuryAmyloid-beta precursor proteinHomo sapiens (human)
positive regulation of inflammatory responseAmyloid-beta precursor proteinHomo sapiens (human)
regulation of peptidyl-tyrosine phosphorylationAmyloid-beta precursor proteinHomo sapiens (human)
regulation of synapse structure or activityAmyloid-beta precursor proteinHomo sapiens (human)
synapse organizationAmyloid-beta precursor proteinHomo sapiens (human)
positive regulation of calcium-mediated signalingAmyloid-beta precursor proteinHomo sapiens (human)
neuromuscular process controlling balanceAmyloid-beta precursor proteinHomo sapiens (human)
synaptic assembly at neuromuscular junctionAmyloid-beta precursor proteinHomo sapiens (human)
positive regulation of protein metabolic processAmyloid-beta precursor proteinHomo sapiens (human)
neuron apoptotic processAmyloid-beta precursor proteinHomo sapiens (human)
smooth endoplasmic reticulum calcium ion homeostasisAmyloid-beta precursor proteinHomo sapiens (human)
neuron cellular homeostasisAmyloid-beta precursor proteinHomo sapiens (human)
positive regulation of ERK1 and ERK2 cascadeAmyloid-beta precursor proteinHomo sapiens (human)
response to interleukin-1Amyloid-beta precursor proteinHomo sapiens (human)
modulation of excitatory postsynaptic potentialAmyloid-beta precursor proteinHomo sapiens (human)
NMDA selective glutamate receptor signaling pathwayAmyloid-beta precursor proteinHomo sapiens (human)
regulation of spontaneous synaptic transmissionAmyloid-beta precursor proteinHomo sapiens (human)
cytosolic mRNA polyadenylationAmyloid-beta precursor proteinHomo sapiens (human)
negative regulation of long-term synaptic potentiationAmyloid-beta precursor proteinHomo sapiens (human)
positive regulation of long-term synaptic potentiationAmyloid-beta precursor proteinHomo sapiens (human)
positive regulation of non-canonical NF-kappaB signal transductionAmyloid-beta precursor proteinHomo sapiens (human)
cellular response to amyloid-betaAmyloid-beta precursor proteinHomo sapiens (human)
regulation of presynapse assemblyAmyloid-beta precursor proteinHomo sapiens (human)
positive regulation of amyloid fibril formationAmyloid-beta precursor proteinHomo sapiens (human)
amyloid fibril formationAmyloid-beta precursor proteinHomo sapiens (human)
neuron projection maintenanceAmyloid-beta precursor proteinHomo sapiens (human)
positive regulation of T cell migrationAmyloid-beta precursor proteinHomo sapiens (human)
central nervous system developmentAmyloid-beta precursor proteinHomo sapiens (human)
negative regulation of protein phosphorylationTAR DNA-binding protein 43Homo sapiens (human)
mRNA processingTAR DNA-binding protein 43Homo sapiens (human)
RNA splicingTAR DNA-binding protein 43Homo sapiens (human)
negative regulation of gene expressionTAR DNA-binding protein 43Homo sapiens (human)
regulation of protein stabilityTAR DNA-binding protein 43Homo sapiens (human)
positive regulation of insulin secretionTAR DNA-binding protein 43Homo sapiens (human)
response to endoplasmic reticulum stressTAR DNA-binding protein 43Homo sapiens (human)
positive regulation of protein import into nucleusTAR DNA-binding protein 43Homo sapiens (human)
regulation of circadian rhythmTAR DNA-binding protein 43Homo sapiens (human)
regulation of apoptotic processTAR DNA-binding protein 43Homo sapiens (human)
negative regulation by host of viral transcriptionTAR DNA-binding protein 43Homo sapiens (human)
rhythmic processTAR DNA-binding protein 43Homo sapiens (human)
regulation of cell cycleTAR DNA-binding protein 43Homo sapiens (human)
3'-UTR-mediated mRNA destabilizationTAR DNA-binding protein 43Homo sapiens (human)
3'-UTR-mediated mRNA stabilizationTAR DNA-binding protein 43Homo sapiens (human)
nuclear inner membrane organizationTAR DNA-binding protein 43Homo sapiens (human)
amyloid fibril formationTAR DNA-binding protein 43Homo sapiens (human)
regulation of gene expressionTAR DNA-binding protein 43Homo sapiens (human)
sodium ion transportSodium/myo-inositol cotransporter 2Homo sapiens (human)
apoptotic processSodium/myo-inositol cotransporter 2Homo sapiens (human)
polyol transmembrane transportSodium/myo-inositol cotransporter 2Homo sapiens (human)
myo-inositol transportSodium/myo-inositol cotransporter 2Homo sapiens (human)
glucose transmembrane transportSodium/myo-inositol cotransporter 2Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (50)

Processvia Protein(s)Taxonomy
transcription cis-regulatory region bindingCellular tumor antigen p53Homo sapiens (human)
RNA polymerase II cis-regulatory region sequence-specific DNA bindingCellular tumor antigen p53Homo sapiens (human)
DNA-binding transcription factor activity, RNA polymerase II-specificCellular tumor antigen p53Homo sapiens (human)
cis-regulatory region sequence-specific DNA bindingCellular tumor antigen p53Homo sapiens (human)
core promoter sequence-specific DNA bindingCellular tumor antigen p53Homo sapiens (human)
TFIID-class transcription factor complex bindingCellular tumor antigen p53Homo sapiens (human)
DNA-binding transcription repressor activity, RNA polymerase II-specificCellular tumor antigen p53Homo sapiens (human)
DNA-binding transcription activator activity, RNA polymerase II-specificCellular tumor antigen p53Homo sapiens (human)
protease bindingCellular tumor antigen p53Homo sapiens (human)
p53 bindingCellular tumor antigen p53Homo sapiens (human)
DNA bindingCellular tumor antigen p53Homo sapiens (human)
chromatin bindingCellular tumor antigen p53Homo sapiens (human)
DNA-binding transcription factor activityCellular tumor antigen p53Homo sapiens (human)
mRNA 3'-UTR bindingCellular tumor antigen p53Homo sapiens (human)
copper ion bindingCellular tumor antigen p53Homo sapiens (human)
protein bindingCellular tumor antigen p53Homo sapiens (human)
zinc ion bindingCellular tumor antigen p53Homo sapiens (human)
enzyme bindingCellular tumor antigen p53Homo sapiens (human)
receptor tyrosine kinase bindingCellular tumor antigen p53Homo sapiens (human)
ubiquitin protein ligase bindingCellular tumor antigen p53Homo sapiens (human)
histone deacetylase regulator activityCellular tumor antigen p53Homo sapiens (human)
ATP-dependent DNA/DNA annealing activityCellular tumor antigen p53Homo sapiens (human)
identical protein bindingCellular tumor antigen p53Homo sapiens (human)
histone deacetylase bindingCellular tumor antigen p53Homo sapiens (human)
protein heterodimerization activityCellular tumor antigen p53Homo sapiens (human)
protein-folding chaperone bindingCellular tumor antigen p53Homo sapiens (human)
protein phosphatase 2A bindingCellular tumor antigen p53Homo sapiens (human)
RNA polymerase II-specific DNA-binding transcription factor bindingCellular tumor antigen p53Homo sapiens (human)
14-3-3 protein bindingCellular tumor antigen p53Homo sapiens (human)
MDM2/MDM4 family protein bindingCellular tumor antigen p53Homo sapiens (human)
disordered domain specific bindingCellular tumor antigen p53Homo sapiens (human)
general transcription initiation factor bindingCellular tumor antigen p53Homo sapiens (human)
molecular function activator activityCellular tumor antigen p53Homo sapiens (human)
promoter-specific chromatin bindingCellular tumor antigen p53Homo sapiens (human)
RNA polymerase II cis-regulatory region sequence-specific DNA bindingAmyloid-beta precursor proteinHomo sapiens (human)
DNA bindingAmyloid-beta precursor proteinHomo sapiens (human)
serine-type endopeptidase inhibitor activityAmyloid-beta precursor proteinHomo sapiens (human)
signaling receptor bindingAmyloid-beta precursor proteinHomo sapiens (human)
protein bindingAmyloid-beta precursor proteinHomo sapiens (human)
heparin bindingAmyloid-beta precursor proteinHomo sapiens (human)
enzyme bindingAmyloid-beta precursor proteinHomo sapiens (human)
identical protein bindingAmyloid-beta precursor proteinHomo sapiens (human)
transition metal ion bindingAmyloid-beta precursor proteinHomo sapiens (human)
receptor ligand activityAmyloid-beta precursor proteinHomo sapiens (human)
PTB domain bindingAmyloid-beta precursor proteinHomo sapiens (human)
protein serine/threonine kinase bindingAmyloid-beta precursor proteinHomo sapiens (human)
signaling receptor activator activityAmyloid-beta precursor proteinHomo sapiens (human)
RNA polymerase II cis-regulatory region sequence-specific DNA bindingTAR DNA-binding protein 43Homo sapiens (human)
DNA bindingTAR DNA-binding protein 43Homo sapiens (human)
double-stranded DNA bindingTAR DNA-binding protein 43Homo sapiens (human)
RNA bindingTAR DNA-binding protein 43Homo sapiens (human)
mRNA 3'-UTR bindingTAR DNA-binding protein 43Homo sapiens (human)
protein bindingTAR DNA-binding protein 43Homo sapiens (human)
lipid bindingTAR DNA-binding protein 43Homo sapiens (human)
identical protein bindingTAR DNA-binding protein 43Homo sapiens (human)
pre-mRNA intronic bindingTAR DNA-binding protein 43Homo sapiens (human)
molecular condensate scaffold activityTAR DNA-binding protein 43Homo sapiens (human)
myo-inositol transmembrane transporter activitySodium/myo-inositol cotransporter 2Homo sapiens (human)
protein bindingSodium/myo-inositol cotransporter 2Homo sapiens (human)
polyol transmembrane transporter activitySodium/myo-inositol cotransporter 2Homo sapiens (human)
glucose:sodium symporter activitySodium/myo-inositol cotransporter 2Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (63)

Processvia Protein(s)Taxonomy
nuclear bodyCellular tumor antigen p53Homo sapiens (human)
nucleusCellular tumor antigen p53Homo sapiens (human)
nucleoplasmCellular tumor antigen p53Homo sapiens (human)
replication forkCellular tumor antigen p53Homo sapiens (human)
nucleolusCellular tumor antigen p53Homo sapiens (human)
cytoplasmCellular tumor antigen p53Homo sapiens (human)
mitochondrionCellular tumor antigen p53Homo sapiens (human)
mitochondrial matrixCellular tumor antigen p53Homo sapiens (human)
endoplasmic reticulumCellular tumor antigen p53Homo sapiens (human)
centrosomeCellular tumor antigen p53Homo sapiens (human)
cytosolCellular tumor antigen p53Homo sapiens (human)
nuclear matrixCellular tumor antigen p53Homo sapiens (human)
PML bodyCellular tumor antigen p53Homo sapiens (human)
transcription repressor complexCellular tumor antigen p53Homo sapiens (human)
site of double-strand breakCellular tumor antigen p53Homo sapiens (human)
germ cell nucleusCellular tumor antigen p53Homo sapiens (human)
chromatinCellular tumor antigen p53Homo sapiens (human)
transcription regulator complexCellular tumor antigen p53Homo sapiens (human)
protein-containing complexCellular tumor antigen p53Homo sapiens (human)
extracellular spaceAmyloid-beta precursor proteinHomo sapiens (human)
dendriteAmyloid-beta precursor proteinHomo sapiens (human)
extracellular regionAmyloid-beta precursor proteinHomo sapiens (human)
extracellular spaceAmyloid-beta precursor proteinHomo sapiens (human)
nuclear envelope lumenAmyloid-beta precursor proteinHomo sapiens (human)
cytoplasmAmyloid-beta precursor proteinHomo sapiens (human)
mitochondrial inner membraneAmyloid-beta precursor proteinHomo sapiens (human)
endosomeAmyloid-beta precursor proteinHomo sapiens (human)
early endosomeAmyloid-beta precursor proteinHomo sapiens (human)
endoplasmic reticulumAmyloid-beta precursor proteinHomo sapiens (human)
endoplasmic reticulum lumenAmyloid-beta precursor proteinHomo sapiens (human)
smooth endoplasmic reticulumAmyloid-beta precursor proteinHomo sapiens (human)
Golgi apparatusAmyloid-beta precursor proteinHomo sapiens (human)
Golgi lumenAmyloid-beta precursor proteinHomo sapiens (human)
Golgi-associated vesicleAmyloid-beta precursor proteinHomo sapiens (human)
cytosolAmyloid-beta precursor proteinHomo sapiens (human)
plasma membraneAmyloid-beta precursor proteinHomo sapiens (human)
clathrin-coated pitAmyloid-beta precursor proteinHomo sapiens (human)
cell-cell junctionAmyloid-beta precursor proteinHomo sapiens (human)
synaptic vesicleAmyloid-beta precursor proteinHomo sapiens (human)
cell surfaceAmyloid-beta precursor proteinHomo sapiens (human)
membraneAmyloid-beta precursor proteinHomo sapiens (human)
COPII-coated ER to Golgi transport vesicleAmyloid-beta precursor proteinHomo sapiens (human)
axonAmyloid-beta precursor proteinHomo sapiens (human)
growth coneAmyloid-beta precursor proteinHomo sapiens (human)
platelet alpha granule lumenAmyloid-beta precursor proteinHomo sapiens (human)
neuromuscular junctionAmyloid-beta precursor proteinHomo sapiens (human)
endosome lumenAmyloid-beta precursor proteinHomo sapiens (human)
trans-Golgi network membraneAmyloid-beta precursor proteinHomo sapiens (human)
ciliary rootletAmyloid-beta precursor proteinHomo sapiens (human)
dendritic spineAmyloid-beta precursor proteinHomo sapiens (human)
dendritic shaftAmyloid-beta precursor proteinHomo sapiens (human)
perikaryonAmyloid-beta precursor proteinHomo sapiens (human)
membrane raftAmyloid-beta precursor proteinHomo sapiens (human)
apical part of cellAmyloid-beta precursor proteinHomo sapiens (human)
synapseAmyloid-beta precursor proteinHomo sapiens (human)
perinuclear region of cytoplasmAmyloid-beta precursor proteinHomo sapiens (human)
presynaptic active zoneAmyloid-beta precursor proteinHomo sapiens (human)
spindle midzoneAmyloid-beta precursor proteinHomo sapiens (human)
recycling endosomeAmyloid-beta precursor proteinHomo sapiens (human)
extracellular exosomeAmyloid-beta precursor proteinHomo sapiens (human)
receptor complexAmyloid-beta precursor proteinHomo sapiens (human)
early endosomeAmyloid-beta precursor proteinHomo sapiens (human)
membrane raftAmyloid-beta precursor proteinHomo sapiens (human)
cell surfaceAmyloid-beta precursor proteinHomo sapiens (human)
Golgi apparatusAmyloid-beta precursor proteinHomo sapiens (human)
plasma membraneAmyloid-beta precursor proteinHomo sapiens (human)
intracellular non-membrane-bounded organelleTAR DNA-binding protein 43Homo sapiens (human)
nucleusTAR DNA-binding protein 43Homo sapiens (human)
nucleoplasmTAR DNA-binding protein 43Homo sapiens (human)
perichromatin fibrilsTAR DNA-binding protein 43Homo sapiens (human)
mitochondrionTAR DNA-binding protein 43Homo sapiens (human)
cytoplasmic stress granuleTAR DNA-binding protein 43Homo sapiens (human)
nuclear speckTAR DNA-binding protein 43Homo sapiens (human)
interchromatin granuleTAR DNA-binding protein 43Homo sapiens (human)
nucleoplasmTAR DNA-binding protein 43Homo sapiens (human)
chromatinTAR DNA-binding protein 43Homo sapiens (human)
plasma membraneSodium/myo-inositol cotransporter 2Homo sapiens (human)
apical plasma membraneSodium/myo-inositol cotransporter 2Homo sapiens (human)
plasma membraneSodium/myo-inositol cotransporter 2Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (85)

Assay IDTitleYearJournalArticle
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID504810Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID504812Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID158606Inhibition of Phosphoinositide specific phospholipase C (PI-PLC) from Bacillus cereus on the internal face of the cell membrane.1996Journal of medicinal chemistry, Oct-25, Volume: 39, Issue:22
Synthesis, structure-activity relationships, and the effect of polyethylene glycol on inhibitors of phosphatidylinositol-specific phospholipase C from Bacillus cereus.
AID361504Effect on amyloid beta 42 aggregation assessed as inhibition of fiber formation at 3 mM2008Bioorganic & medicinal chemistry, Aug-01, Volume: 16, Issue:15
Synthesis of scyllo-inositol derivatives and their effects on amyloid beta peptide aggregation.
AID748709Inhibition of amyloid beta (1 to 42) aggregation (unknown origin) at 4:1 compound to protein concentration after 48 hrs by thioflavin T fluorescence assay2013Journal of medicinal chemistry, Jun-13, Volume: 56, Issue:11
Progress and developments in tau aggregation inhibitors for Alzheimer disease.
AID1198840Inhibition of amyloid beta(42) aggregation (unknown origin) assessed as A11-positive oligomer formation at 100 uM after 0.5 to 70 hrs by kinetic study2015European journal of medicinal chemistry, May-05, Volume: 95New mimetic peptides inhibitors of Αβ aggregation. Molecular guidance for rational drug design.
AID1347083qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347086qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347082qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID647239Inhibition of rat intestinal alpha-glucosidase sucrase using sucrose as substrate at 10 mg/mL preincubated for 10 mins prior substrate addition measured after 40 mins by spectrophotometry2012Bioorganic & medicinal chemistry letters, Feb-15, Volume: 22, Issue:4
Concise synthesis of (+)-conduritol F and inositol analogues from naturally available (+)-proto-quercitol and their glucosidase inhibitory activity.
AID647237Inhibition of rat intestinal alpha-glucosidase maltase using maltose as substrate at 10 mg/mL preincubated for 10 mins prior substrate addition measured after 40 mins by spectrophotometry2012Bioorganic & medicinal chemistry letters, Feb-15, Volume: 22, Issue:4
Concise synthesis of (+)-conduritol F and inositol analogues from naturally available (+)-proto-quercitol and their glucosidase inhibitory activity.
AID647234Inhibition of Baker's yeast Alpha-glucosidase-1 using p-nitrophenyl-alpha-D-glucopyranoside as substrate preincubated for 10 mins prior substrate addition measured after 20 mins by spectrophotometry2012Bioorganic & medicinal chemistry letters, Feb-15, Volume: 22, Issue:4
Concise synthesis of (+)-conduritol F and inositol analogues from naturally available (+)-proto-quercitol and their glucosidase inhibitory activity.
AID504749qHTS profiling for inhibitors of Plasmodium falciparum proliferation2011Science (New York, N.Y.), Aug-05, Volume: 333, Issue:6043
Chemical genomic profiling for antimalarial therapies, response signatures, and molecular targets.
AID1347108qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh41 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347102qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh18 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347407qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Pharmaceutical Collection2020ACS chemical biology, 07-17, Volume: 15, Issue:7
High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1296008Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening2020SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1
Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening.
AID1347095qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB-EBc1 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347100qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for LAN-5 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347094qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-37 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347107qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh30 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347096qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for U-2 OS cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347154Primary screen GU AMC qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347105qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for MG 63 (6-TG R) cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347103qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for OHS-50 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347424RapidFire Mass Spectrometry qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1)2019The Journal of biological chemistry, 11-15, Volume: 294, Issue:46
Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens.
AID1347106qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for control Hh wild type fibroblast cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347089qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for TC32 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347093qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-MC cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347091qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SJ-GBM2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347097qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Saos-2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347099qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB1643 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347090qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for DAOY cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1508630Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay2021Cell reports, 04-27, Volume: 35, Issue:4
A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1347101qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-12 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347092qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for A673 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347425Rhodamine-PBP qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1)2019The Journal of biological chemistry, 11-15, Volume: 294, Issue:46
Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens.
AID1347104qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for RD cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347098qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-SH cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1811Experimentally measured binding affinity data derived from PDB2007Biochemistry, May-01, Volume: 46, Issue:17
Critical role of Arg/Lys343 in the species-dependent recognition of phosphatidylinositol by pulmonary surfactant protein D.
AID977608Experimentally measured binding affinity data (IC50) for protein-ligand complexes derived from PDB2007Biochemistry, May-01, Volume: 46, Issue:17
Critical role of Arg/Lys343 in the species-dependent recognition of phosphatidylinositol by pulmonary surfactant protein D.
AID1224817Assays to identify small molecules inhibitory for eIF4E expression2015Chemistry & biology, Jul-23, Volume: 22, Issue:7
Internal Ribosome Entry Site-Based Bicistronic In Situ Reporter Assays for Discovery of Transcription-Targeted Lead Compounds.
AID1346987P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1346986P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID30433Compound was tested for inhibition of Human acrosin by polyols1981Journal of medicinal chemistry, Nov, Volume: 24, Issue:11
Inhibition of human acrosin by monosaccharides and related compounds: structure-activity relationships.
AID27145Oxidation catalyzed by inositol dehydrogenase at pH 9.13.2002Journal of medicinal chemistry, Mar-14, Volume: 45, Issue:6
Stereochemistry at phosphorus of the reaction catalyzed by myo-inositol monophosphatase.
AID588211Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in humans2010Chemical research in toxicology, Jan, Volume: 23, Issue:1
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID588220Literature-mined public compounds from Kruhlak et al phospholipidosis modelling dataset2008Toxicology mechanisms and methods, , Volume: 18, Issue:2-3
Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.
AID625295Drug Induced Liver Injury Prediction System (DILIps) validation dataset; compound DILI positive/negative as observed in Pfizer data2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID588213Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in non-rodents2010Chemical research in toxicology, Jan, Volume: 23, Issue:1
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID44234Concentration required to inhibit beta-mannosidase; IA means inactive2004Bioorganic & medicinal chemistry letters, Mar-08, Volume: 14, Issue:5
New oligomers of conduritol-F and muco-inositol. Synthesis and biological evaluation as glycosidase inhibitors.
AID40280Concentration required to inhibit beta-galactosidase; IA means inactive2004Bioorganic & medicinal chemistry letters, Mar-08, Volume: 14, Issue:5
New oligomers of conduritol-F and muco-inositol. Synthesis and biological evaluation as glycosidase inhibitors.
AID40448Concentration required to inhibit beta-glucosidase; IA means inactive2004Bioorganic & medicinal chemistry letters, Mar-08, Volume: 14, Issue:5
New oligomers of conduritol-F and muco-inositol. Synthesis and biological evaluation as glycosidase inhibitors.
AID687625Activity of Saccharomyces cerevisiae alpha-glucosidase assessed as production of p-nitrophenol using p-nitrophenyl-alpha-D-glucopyranoside as substrate at 50 mM after 3 mins by spectrophotometer2011Bioorganic & medicinal chemistry, May-15, Volume: 19, Issue:10
Cellular zwitterionic metabolite analogs simultaneously enhance reaction rate, thermostability, salt tolerance, and substrate specificity of α-glucosidase.
AID500279Ratio of Kcat to Km for Neisseria meningitidis lgtC2006Nature chemical biology, Dec, Volume: 2, Issue:12
Using substrate engineering to harness enzymatic promiscuity and expand biological catalysis.
AID687626Activity of commercial yeast alpha-glucosidase assessed as production of p-nitrophenol using p-nitrophenyl-alpha-D-glucopyranoside as substrate at 50 mM after 3 mins by spectrophotometer2011Bioorganic & medicinal chemistry, May-15, Volume: 19, Issue:10
Cellular zwitterionic metabolite analogs simultaneously enhance reaction rate, thermostability, salt tolerance, and substrate specificity of α-glucosidase.
AID37433Concentration required to inhibit alpha-glucosidase; IA means inactive2004Bioorganic & medicinal chemistry letters, Mar-08, Volume: 14, Issue:5
New oligomers of conduritol-F and muco-inositol. Synthesis and biological evaluation as glycosidase inhibitors.
AID228549Michaelis-Menten constant was determined1993Journal of medicinal chemistry, Nov-12, Volume: 36, Issue:23
Synthesis and evaluation of 3-modified 1D-myo-inositols as inhibitors and substrates of phosphatidylinositol synthase and inhibitors of myo-inositol uptake by cells.
AID588209Literature-mined public compounds from Greene et al multi-species hepatotoxicity modelling dataset2010Chemical research in toxicology, Jul-19, Volume: 23, Issue:7
Developing structure-activity relationships for the prediction of hepatotoxicity.
AID158605Compound was tested for the inhibition of Phosphoinositide specific phospholipase C (PI-PLC) in the presence of buffer at concentration of 40.0 mM1996Journal of medicinal chemistry, Oct-25, Volume: 39, Issue:22
Synthesis, structure-activity relationships, and the effect of polyethylene glycol on inhibitors of phosphatidylinositol-specific phospholipase C from Bacillus cereus.
AID27144Oxidation catalyzed by inositol dehydrogenase at pH 9.13.2002Journal of medicinal chemistry, Mar-14, Volume: 45, Issue:6
Stereochemistry at phosphorus of the reaction catalyzed by myo-inositol monophosphatase.
AID588212Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in rodents2010Chemical research in toxicology, Jan, Volume: 23, Issue:1
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID155658Tested as substrate of phosphatidylinositol synthase in mouse brain by measuring percent CMP formation compared with myo-inositol tested at 5 mM1993Journal of medicinal chemistry, Nov-12, Volume: 36, Issue:23
Synthesis and evaluation of 3-modified 1D-myo-inositols as inhibitors and substrates of phosphatidylinositol synthase and inhibitors of myo-inositol uptake by cells.
AID27334Oxidation catalyzed by inositol dehydrogenase at pH 9.13.2002Journal of medicinal chemistry, Mar-14, Volume: 45, Issue:6
Stereochemistry at phosphorus of the reaction catalyzed by myo-inositol monophosphatase.
AID625294Drug Induced Liver Injury Prediction System (DILIps) validation dataset; compound DILI positive/negative as observed in O'Brien data2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID37134Concentration required to inhibit alpha-galactocosidase; IA means inactive2004Bioorganic & medicinal chemistry letters, Mar-08, Volume: 14, Issue:5
New oligomers of conduritol-F and muco-inositol. Synthesis and biological evaluation as glycosidase inhibitors.
AID158604Compound was tested for the inhibition of Phosphatidylinositol-Specific Phospholipase C (PI-PLC) in the presence of PEG-600 at concentration of 40.0 mM1996Journal of medicinal chemistry, Oct-25, Volume: 39, Issue:22
Synthesis, structure-activity relationships, and the effect of polyethylene glycol on inhibitors of phosphatidylinositol-specific phospholipase C from Bacillus cereus.
AID687624Activity of Bacillus stearothermophilus alpha-glucosidase assessed as production of p-nitrophenol using p-nitrophenyl-alpha-D-glucopyranoside as substrate at 50 mM after 3 mins by spectrophotometer2011Bioorganic & medicinal chemistry, May-15, Volume: 19, Issue:10
Cellular zwitterionic metabolite analogs simultaneously enhance reaction rate, thermostability, salt tolerance, and substrate specificity of α-glucosidase.
AID35261Concentration required to inhibit alpha-mannosidase; IA means inactive2004Bioorganic & medicinal chemistry letters, Mar-08, Volume: 14, Issue:5
New oligomers of conduritol-F and muco-inositol. Synthesis and biological evaluation as glycosidase inhibitors.
AID588210Human drug-induced liver injury (DILI) modelling dataset from Ekins et al2010Drug metabolism and disposition: the biological fate of chemicals, Dec, Volume: 38, Issue:12
A predictive ligand-based Bayesian model for human drug-induced liver injury.
AID1327042Induction of 2-deoxy-D-[2,6-3H]glucose uptake in differentiated mouse 3T3L1 cells at 200 uM after 60 mins by liquid scintillation counting relative to basal uptake2016European journal of medicinal chemistry, Oct-21, Volume: 122Synthesis and biological activities of d-chiro-inositol analogues with insulin-like actions.
AID1327043Induction of 2-deoxy-D-[2,6-3H]glucose uptake in differentiated mouse 3T3L1 cells at 200 uM after 60 mins by liquid scintillation counting relative to insulin2016European journal of medicinal chemistry, Oct-21, Volume: 122Synthesis and biological activities of d-chiro-inositol analogues with insulin-like actions.
AID1159607Screen for inhibitors of RMI FANCM (MM2) intereaction2016Journal of biomolecular screening, Jul, Volume: 21, Issue:6
A High-Throughput Screening Strategy to Identify Protein-Protein Interaction Inhibitors That Block the Fanconi Anemia DNA Repair Pathway.
AID977611Experimentally measured binding affinity data (Kd) for protein-ligand complexes derived from PDB2013Journal of bacteriology, May, Volume: 195, Issue:10
myo-inositol and D-ribose ligand discrimination in an ABC periplasmic binding protein.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (7,960)

TimeframeStudies, This Drug (%)All Drugs %
pre-19902870 (36.06)18.7374
1990's1521 (19.11)18.2507
2000's1381 (17.35)29.6817
2010's1546 (19.42)24.3611
2020's642 (8.07)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 67.56

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be very strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index67.56 (24.57)
Research Supply Index9.07 (2.92)
Research Growth Index4.54 (4.65)
Search Engine Demand Index244.29 (26.88)
Search Engine Supply Index3.96 (0.95)

This Compound (67.56)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials400 (4.84%)5.53%
Reviews610 (7.38%)6.00%
Case Studies112 (1.35%)4.05%
Observational18 (0.22%)0.25%
Other7,128 (86.21%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Clinical Trials (104)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
A Prospective, Randomized, Double-Blind, Placebo-Controlled, Phase 2 Safety and Efficacy Study of Oral ELND005 as an Adjunctive Maintenance Treatment in Patients With Bipolar I Disorder [NCT01674010]Phase 2309 participants (Actual)Interventional2012-08-31Terminated(stopped due to Business Decision)
A Prospective, Randomized, Double Blind, Study on the Clinical Efficacy Myo-inositol Versus D-chiro-inositol in Women Undergoing in Vitro Fertilization Embryo Transfer. [NCT01338844]Phase 40 participants InterventionalCompleted
A Single Group Study to Evaluate the Effects of a Myo-Inositol and D-Chiro Inositol Supplement on Symptoms Associated With Polycystic Ovary Syndrome and Hormone Imbalance [NCT06158932]40 participants (Actual)Interventional2023-09-08Active, not recruiting
A Phase IB/IIA, Single-centered Study of the Effects of OXY111A in Primary and Secondary Hepato-Pancreato-Biliary Neoplasia [NCT02528526]Phase 1/Phase 269 participants (Anticipated)Interventional2014-02-28Recruiting
An Open-label, Randomized and Crossover Study to Assess the Effect of Co-administration of Vildagliptin and Voglibose on the Steady-state Pharmacokinetics / Pharmacodynamics in Japanese Patients With Type 2 Diabetes [NCT01309698]Phase 424 participants (Actual)Interventional2011-02-28Completed
Myo-inositol and Melatonin in Menopausal Transition. A Prospective, Randomized Trial [NCT01115127]Phase 2/Phase 390 participants (Actual)Interventional2010-03-31Completed
Randomized, Controlled, Open-label Study to Evaluate the Efficacy and Safety of a Combination Containing Myo-inositol, D-chiro-inositol, Alpha-lactalbumin, Zinc and Extract of Gymnema Sylvestre in Subjects With Type 2 Mellitus Diabetes. [NCT04745780]75 participants (Actual)Interventional2021-02-10Completed
[NCT02418130]Phase 4166 participants (Actual)Interventional2014-10-31Completed
The Effect of In-vitro Myoinositol Supplementation of Human Sperm on the Outcome of Cryopreservation [NCT03153436]Phase 1/Phase 241 participants (Actual)Interventional2016-08-28Completed
Phase II Randomized, Double-Masked, Placebo-Controlled, Safety, Pharmacokinetic, and Dose-Ranging Study of Multiple Doses of Inositol in Premature Infants [NCT01030575]Phase 2125 participants (Actual)Interventional2010-01-31Completed
Novel Strategies in Weight Loss in Women With Polycystic Ovary Syndrome: do Changes in the Gut Microbiome Play a Role? [NCT03642600]Phase 421 participants (Actual)Interventional2019-02-28Completed
Effect of Myoinositol Treatment of Spermatozoa on in Vitro Fertilization Outcome: a Prospective, Randomized Sibling-oocyte Study [NCT02050672]249 participants (Actual)Interventional2013-05-31Completed
D-chiro Inositol in Prevention of Gestational Diabetes Mellitus in High Risk Pregnant Women in China [NCT04801485]291 participants (Actual)Interventional2021-01-01Completed
Improved Effects of Myo-inositol in Association With Alpha-lactalbumin in PCOS Women [NCT03422289]37 participants (Actual)Interventional2016-11-02Completed
Effect of Myo-Inositol- Based Co-treatment on Oocyte Quality in Women With Polycystic Ovarian Syndrome Undergoing Assisted Reproductive Technology [NCT03177122]Phase 4100 participants (Anticipated)Interventional2017-03-01Recruiting
Use of Myoinositol Plus L-tyrosine, Selenium and Chromium in PCOS Women [NCT03673995]186 participants (Actual)Interventional2017-05-02Completed
Glycemic Impact of Myo-inositol in High Risk and Gestational Diabetic Pregnancies: a Pilot Study [NCT02149992]40 participants (Anticipated)Interventional2014-11-30Recruiting
Sitagliptin (MK0431) Phase III Double-blind Comparative Study - Type 2 Diabetes Mellitus - [NCT00411554]Phase 3319 participants (Actual)Interventional2007-01-31Completed
Effects of Combined Resveratrol and Myo-inositol on Altered Metabolic, Endocrine Parameters and Perceived Stress in Patients With Polycystic Ovarian Syndrome [NCT04867252]Phase 288 participants (Actual)Interventional2021-05-03Completed
Different Effects of Inositol Stereoisomers on Insulin Sensitivity in Women With Gestational Diabetes [NCT02097069]80 participants (Anticipated)Interventional2014-04-30Not yet recruiting
Involvement of Reticulum Endoplasmic Stress in the Physiopathology of Polycystic Ovary Syndrome: Possible Therapeutic Implications of Insulin Sensitizers. [NCT02302326]50 participants (Anticipated)Interventional2013-01-31Completed
Improved Maternal and Fetal Outcomes Associated With Inositol Dietary Supplementation in Women With Early Gestational Diabetes Mellitus [NCT01342874]30 participants (Actual)Observational2010-08-31Completed
Pretreatment With Myo-inositol in Hyperandrogenic PCOS Patients Undergoing ART: a Randomized Controlled Trial [NCT03767569]Phase 3134 participants (Anticipated)Interventional2018-09-01Recruiting
Myoinositol Supplementation, Insulin Resistance and Fetal Sonographic Parameters in Gestational Diabetes, Diet Treated: a Prospective, Randomized, Placebo-controlled Study [NCT03763669]120 participants (Actual)Interventional2018-11-14Completed
[NCT01560065]Phase 40 participants InterventionalCompleted
A Phase 2/3, Double-blind, Randomized, Placebo-controlled, Parallel-group, Multicenter Study to Determine the Efficacy and Safety of SYR-322 When Used in Combination With α-glucosidase Inhibitor in Subjects With Type 2 Diabetes in Japan [NCT01263483]Phase 2/Phase 3230 participants (Actual)Interventional2007-01-31Completed
The Effect of Inositol Treatment in Women With PCOS of Different Phenotype [NCT05678114]120 participants (Actual)Interventional2022-12-21Completed
A Double-Blind, Placebo-Controlled Study of Inositol in Trichotillomania [NCT01875445]Phase 238 participants (Actual)Interventional2013-05-31Completed
Myo-inositol for the Management of Poor Ovarian Responders: A Prospective Randomized Controlled Trial [NCT04273256]Phase 2/Phase 3226 participants (Anticipated)Interventional2020-02-11Recruiting
Inositol for Comorbid Anxiety in Children and Adolescents With Bipolar Disorder [NCT02811133]Phase 1/Phase 20 participants (Actual)Interventional2023-08-31Withdrawn(stopped due to Funding terminated)
Inositol Hexaphosphate: A Novel Treatment Strategy for Bipolar Disorder? [NCT02081287]Phase 18 participants (Actual)Interventional2014-05-31Completed
Altered Myo-inositol/D-chiro-inositol Ratio in Follicular Fluid of Women Undergoing in Vitro Fertilization Has Detrimental Effects on Oocyte and Embryo Quality [NCT03055442]34 participants (Actual)Observational2016-10-31Completed
The Action of Inositols and Alpha-lactalbumin on Glucose Metabolism, Arterial Stiffness and Vascular Damage in Patients With Metabolic Syndrome at Risk of Cardiac Fibrosis [NCT05689710]30 participants (Anticipated)Interventional2022-12-23Recruiting
Effects of Vitamin D, Epigallocatechin Gallate, Vitamin B6, and D-Chiro-inositol Combination on Uterine Fibroids: a Randomized Controlled Trial [NCT05409872]108 participants (Anticipated)Interventional2022-09-15Recruiting
[NCT01046500]Phase 2100 participants (Anticipated)Interventional2013-01-31Recruiting
Myo-inositol May Prevent Gestational Diabetes in Obese Women [NCT01047982]220 participants (Actual)Interventional2010-03-31Completed
Phase IIb Randomized Comparative Study of the Efficacy and Safety of Myo-inositol Versus Placebo in Smokers With Bronchial Dysplasia [NCT00783705]Phase 285 participants (Actual)Interventional2008-11-30Completed
Myo-inositol Versus Clomiphene Citrate as First Line Treatment for Ovulation Induction in PCOS [NCT04306692]Phase 412 participants (Actual)Interventional2020-07-02Terminated(stopped due to clomiphene citrate is no longer being considered as standard treatment for polycystic ovary syndrome)
Myoinositol for the Treatment of Ovarian and Psychiatric Disorder in PCOS Patients. [NCT01246310]24 participants (Actual)Interventional2010-11-30Terminated(stopped due to The number of patients enrolled was insufficient to match the calculated sample size and to carry out statistical analyses)
Effects of Combined Therapy With Myo-inositol and Alpha-Lipoic Acid on Clinical, Endocrine and Metabolic Features in Women Affected by Polycystic Ovary Syndrome [NCT02651636]40 participants (Actual)Interventional2014-06-30Completed
A Double-blind Phase III Study to Evaluate the Efficacy of BI 1356 5 mg and 10 mg vs. Placebo for 12 Weeks and vs. Voglibose 0.6 mg for 26 Weeks in Patients With Type 2 Diabetes Mellitus and Insufficient Glycaemic Control, Followed by an Extension Study t [NCT00654381]Phase 3561 participants (Actual)Interventional2008-04-30Completed
Effect of Myo-inositol Administration on Insulin Sensitivity in Gestational Diabetes Patients by Continuous Glucose Monitoring System (CGMS) [NCT00734448]30 participants (Anticipated)Interventional2013-11-30Recruiting
Improving Oocyte Retrieval Using a Combined Therapy of Recombinant Follicle Stimulating Hormone (rFSH) and Inositol and Melatonin [NCT01267604]Phase 40 participants (Actual)Interventional2010-12-31Withdrawn
"Influence of Espresso on Adsorption of Orally Administrated Myo-inositol in Humans" [NCT01244399]12 participants (Actual)Observational2010-11-30Completed
Value of Oral Phytate (InsP6) in the Prevention of Progression of the Cardiovascular Calcifications [NCT01000233]Phase 2/Phase 3250 participants (Anticipated)Interventional2009-08-31Recruiting
A Comparative Study of Myo Inositol and Metformin in Improving Biochemical and Clinical Profile of Patients With Polycystic Ovarian Syndrome; a Randomized Clinical Trial [NCT04204044]Early Phase 1126 participants (Anticipated)Interventional2020-11-01Not yet recruiting
A Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging, Safety and Efficacy Study of Oral ELND005 (AZD-103) in Alzheimer's Disease [NCT00568776]Phase 2353 participants (Actual)Interventional2007-12-31Completed
The Effects of Myo-inositol Plus Alpha-lactalbumin in Ovulation Induction of PCOS Myo-inositol-resistant Patients [NCT03667443]0 participants (Actual)Interventional2022-04-11Withdrawn(stopped due to Due to COVID-19 restrictions, enrollment was unsuccessful)
Nutritional Supplement Based on Myo-inositol-D-chiro-inositol: Effectiveness on the Reproductive System Functionality in Long-term Survivors of Lymphoma [NCT05410314]90 participants (Actual)Observational2020-02-07Completed
Inositol Supplementation to Treat Polycystic Ovary Syndrome: A Double Blind Dose Ranging RCT (INSUPP-PCOS) [NCT03864068]Phase 2128 participants (Anticipated)Interventional2020-01-24Recruiting
Use of Inositols Within IVF Protocols to Reduce Gonadotropin Administration [NCT04576546]30 participants (Anticipated)Interventional2020-11-02Recruiting
Effect of Non-surgical Periodontal Therapy Along With Myo-inositol on High Sensitivity C-reactive Protein and Insulin Resistance in Polycystic Ovary Syndrome Women Having Chronic Periodontitis: A Randomized Controlled Trial [NCT02633462]Phase 256 participants (Anticipated)Interventional2015-05-31Active, not recruiting
A Pilot Study of D-Chiro-Inositol Plus Folic Acid in Overweight Patients With Type 1 Diabetes [NCT02730949]Phase 326 participants (Actual)Interventional2014-03-31Completed
Graceful Lifestyle Changes Intervention Study for Women With PCOS and Infertility [NCT02630485]240 participants (Anticipated)Interventional2015-12-31Not yet recruiting
Myo-Inositol Chemoprevention in Colitis-Associated Dysplasia [NCT01111292]Phase 1/Phase 25 participants (Actual)Interventional2010-10-31Terminated(stopped due to The study was closed prematurely due to poor accrual.)
D-chiro-inositol, a Putative Aromatase Inhibitor, Increases Androgen and Reduces Estrogen Levels in Serum of Male Volunteers. A Pilot Study. [NCT04615767]10 participants (Actual)Interventional2020-10-28Completed
Effects of a Supplementation With Zinc and Myo-inositol in Paediatric Obesity [NCT03283813]Phase 460 participants (Anticipated)Interventional2018-02-05Recruiting
An Open-Label Clinical Trial Conducted Via Telepsychiatry of Complementary and Alternative Treatments (Omega-3 Fatty Acids and Inositol vs. N-acetylcysteine) for the Management of Emotional Dysregulation in Youth With Non-verbal Learning Disability (NVLD) [NCT03757585]Phase 460 participants (Anticipated)Interventional2019-05-20Recruiting
A Long-Term Follow-Up Study of Oral ELND005 (AZD-103) in Subjects With Alzheimer's Disease [NCT00934050]Phase 2103 participants (Actual)Interventional2009-06-30Completed
"A Comparative Clinical Evaluation of the Efficacy of Topical Adapalene, Benzoyl Peroxide Gel, Oral Lactobacillus Rhamnosus, D-chiro-inositol, Inulin Capsule, and Their Fixed Combination in Mild to Moderate Acne Vulgaris Patients." [NCT05855629]59 participants (Actual)Interventional2022-02-18Active, not recruiting
The Effects of Acetyl L--Carnitine and Myo/Chiro-Inositol on Improving Ovulation, Pregnancy Rate, Ovarian Function and Perceived Stress Response in Patients With PCOS [NCT05767515]120 participants (Anticipated)Interventional2023-04-15Not yet recruiting
Prevention of Neural Tube Defects by Inositol in Conjunction With Folic Acid (PONTI Study) [NCT00452829]Phase 1100 participants (Actual)Interventional2009-09-30Completed
An Open-Label Clinical Trial Conducted Via Telepsychiatry of Complementary and Alternative Treatments (Omega-3 Fatty Acids and Inositol vs. N-acetylcysteine) for the Management of Emotional Dysregulation in Youth [NCT03911414]Phase 460 participants (Anticipated)Interventional2019-06-18Recruiting
Effects of Myo-inositol, Alpha-Lactalbumin and Folic Acid Treatment in PCOS Women of Mexico and Italy [NCT04645745]36 participants (Actual)Interventional2019-06-15Completed
D-chiroinositol Administration for Testosterone Level Improvement in Hypogonadal Males [NCT04708249]10 participants (Actual)Interventional2021-01-18Completed
Single-Dose Intravenous Inositol Pharmacokinetics in Preterm Infants [NCT00349726]Phase 274 participants (Actual)Interventional2006-06-30Completed
A Long-term, Open-label Extension Study to Investigate the Long-term Safety of SYR-322 When Used in Combination With α-glucosidase Inhibitor in Subjects With Type 2 Diabetes in Japan [NCT01263509]Phase 2/Phase 3179 participants (Actual)Interventional2007-06-30Completed
[NCT01511835]Phase 40 participants InterventionalRecruiting
[NCT01514942]Phase 40 participants InterventionalCompleted
[NCT01540747]Phase 40 participants InterventionalCompleted
A Prospective, Randomized, Double-Blind, Placebo-Controlled, Phase 2 Efficacy and Safety Study of Oral ELND005 for Treatment of Agitation and Aggression in Patients With Moderate to Severe Alzheimer's Disease [NCT01735630]Phase 2350 participants (Actual)Interventional2012-11-30Completed
Combination Therapy With Myo-inositol and Folic Acid Versus Myo-inositol Alone: Effects of Six Months Treatment on Clinical, Endocrine and Metabolic Features in Obese Women With Polycystic Ovary Syndrome [NCT01555190]50 participants (Actual)Interventional2012-01-31Completed
[NCT01511822]Phase 40 participants InterventionalCompleted
Systematic Treatment Enhancement Program for Bipolar Disorder (STEP-BD) [NCT00012558]5,000 participants Interventional1998-09-30Completed
Project 1A) To Determine Whether the Transplacental Gradients for 6 Polyols and Mannose Are Altered in IUGR Pregnancies Compared to Normal Pregnancies. Project 1B) To Determine the Relative Contributions of Transplacental Transport vs. Production by the C [NCT02397291]24 participants (Actual)Interventional2001-01-31Terminated
A Phase I Study Of The Safety Of Myo-Inositol As A Chemopreventive Agent [NCT00061997]Phase 10 participants Interventional2003-05-31Completed
Myo-inositol Versus Metformin: Effects of Six Months Treatment on Clinical, Endocrine and Metabolic Features in Obese Women With Polycystic Ovary Syndrome [NCT01791647]40 participants (Actual)Interventional2011-06-30Completed
Effects of Myo-inositol on the Menstrual Cycle, Hyperandrogenism, Chronic Inflammatory Process and Carbohydrate Metabolism in Women With Polycystic Ovary Syndrome [NCT04892186]60 participants (Anticipated)Interventional2021-05-26Recruiting
Myo-Inositol as an Adjuvant to Letrozole for Infertility in PolyCystic Ovary Syndrome (MALI-PCOS): a Randomized Pilot Trial [NCT04407754]168 participants (Anticipated)Interventional2020-12-19Recruiting
[NCT01626443]Phase 446 participants (Actual)Interventional2014-01-31Completed
Reduction of Insulin Therapy Under Myo-inositol for the Treatment of Gestational Diabetes Mellitus: a Randomized Multicenter and Prospective Trial. MYO-GDM Study [NCT03875755]1,080 participants (Anticipated)Interventional2020-03-04Recruiting
Effects of Different Doses of Pinitol on Carbohydrate Metabolism Parameters in Healthy Subjects: a Randomized Cross-over Placebo-controlled Study [NCT01738763]30 participants (Actual)Interventional2011-07-31Completed
A Randomized, Double-blind, Placebo-controlled Study on the Influence of Pinitol on Carbohydrate, Lipid and Inflammatory Parameters, Endothelial Function and Oxidative Stress in Diabetic, Impaired and Normal Fasting Glucose Subjects [NCT01754792]120 participants (Actual)Interventional2012-01-31Completed
Adverse Obstetric Outcomes in Gestational Diabetes Mellitus and Inositol Stereoisomears [NCT01762826]120 participants (Actual)Observational2012-09-30Enrolling by invitation
Effects of Inositols on Insulin Resistance in Children With Obesity (ONIRICO Trial) [NCT05701813]56 participants (Anticipated)Interventional2023-02-01Not yet recruiting
Effects of Oral Inositol Supplementation on Spontaneous Reproductive Outcomes in Infertile Polycystic Ovarian Syndrome Women. [NCT03598374]80 participants (Anticipated)Interventional2022-01-01Not yet recruiting
Effects of Oral Inositol Supplementation on Obstetrics Outcomes in Polycystic Ovary Syndrome Women After Spontaneous Conception [NCT03585738]80 participants (Anticipated)Interventional2022-01-01Not yet recruiting
Salivary Cystatin SN Binds to Phytic Acid and is a Predictor of Non-heme Iron Bioavailability With Phytic Acid Supplementation [NCT03030703]7 participants (Actual)Interventional2016-11-11Completed
Evaluation of the Effects of D-chiro-inositol in Female Healthy Volunteer [NCT05448378]10 participants (Actual)Interventional2022-06-04Completed
Effects of Nitrosigine on Flow-Mediated Dilation Among Young Adults [NCT04278053]24 participants (Actual)Interventional2018-10-15Completed
Effect of Treatment With Myo-inositol on Human Semen Parameters in Patients Undergoing IVF Cycles [NCT01828710]62 participants (Actual)Interventional2012-08-31Completed
MYPP-trial: Myo-inositol Supplementation to Prevent Pregnancy Complications in Women With Polycystic Ovary Syndrome: a Multicentre Double-blind Randomised Controlled Trial [NCT05524259]464 participants (Anticipated)Interventional2019-06-21Recruiting
[NCT01574261]Early Phase 170 participants (Anticipated)Interventional2012-03-31Recruiting
A Randomized Controlled Trial of Inositol and Omega-3 Fatty Acids in Pediatric Mania [NCT01396486]Phase 469 participants (Actual)Interventional2012-02-03Completed
The Use of Vitamin D in Combination With Epigallocatechin Gallate, D-chiro-inositol and Vitamin B6 in the Treatment of Women With Uterine Fibroid [NCT05448365]Phase 360 participants (Anticipated)Interventional2022-07-01Recruiting
Evaluation Concerning the Influence of Myo-inositol Therapy on the Dynamics of Embryo Development in Patients Suffering From PCOS Undergoing ICSI Treatment [NCT02385396]Phase 2217 participants (Actual)InterventionalCompleted
Comparison of the Effect of a Combination of Myoinositol:D-chiro-inositol With Low Proportion of DCI (40:1) Versus a Combination With a Higher Proportion of DCI (3.6:1) in the Oocyte Quality and Pregnancy Rates in Women With PCOS [NCT03201601]Phase 2/Phase 360 participants (Actual)Interventional2016-02-29Completed
The Effect of Myo-inositol, Somatropin, and DHEA on Poor Ovarian Responders Undergoing ICSI : an Open Label Randomized Clinical Trial. [NCT05900661]Phase 2/Phase 3300 participants (Anticipated)Interventional2023-07-30Not yet recruiting
A 36-Week Safety Extension Study of Oral ELND005 for Treatment of Agitation and Aggression in Patients With Moderate to Severe Alzheimer's Disease [NCT01766336]Phase 2296 participants (Actual)Interventional2013-01-31Terminated
Combined Natural Molecules Improve Markers of Metabolic Syndrome and Climacteric in Menopausal Women [NCT06057896]200 participants (Actual)Observational2022-09-30Completed
Effects of Inositol Alone or Associated With Alpha-lipoic Acid in Polycystic Ovary Syndrome Treatment [NCT04881851]90 participants (Anticipated)Interventional2015-05-07Recruiting
INS-3: A Phase 3, Randomized, Double-Masked, Placebo-Controlled Study of the Efficacy and Safety of Myo-Inositol 5% Injection to Increase Survival Without Severe Retinopathy of Prematurity (Reduce-ROP) in Extremely Premature Infants [NCT01954082]Phase 3638 participants (Actual)Interventional2014-04-17Terminated(stopped due to Study terminated due to safety concerns; participant follow up will continue until March 2018)
Interest of Myo-inositol Supplementation in Women With Polycystic Ovarian Syndrome During Induction of Ovulation With Clomiphene Citrate [NCT03059173]Phase 3276 participants (Anticipated)Interventional2022-03-31Not yet recruiting
Effect of Myoinositol on Serum Asprosin Levels in Pregnant Women [NCT05943158]40 participants (Actual)Interventional2021-06-01Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

TrialOutcome
NCT00411554 (3) [back to overview]Change From Baseline in 2 Hour Postprandial Glucose at Week 12
NCT00411554 (3) [back to overview]Change From Baseline in Fasting Plasma Glucose at Week 12
NCT00411554 (3) [back to overview]Change From Baseline in HbA1c at Week 12
NCT00568776 (7) [back to overview]Additional Analysis of Primary Outcome Measure: Change From Baseline to Week 78 in Neuropsychological Test Battery (NTB) Z-score (Per Protocol Set; PPS)
NCT00568776 (7) [back to overview]Change in Neuropsychiatric Inventory (NPI) Score From Baseline to Week 78 (Full Analysis Set; FAS)
NCT00568776 (7) [back to overview]Change in Clinical Dementia Rating - Sum of Boxes (CDR-SB) Score From Baseline to Week 78 (Full Analysis Set; FAS)
NCT00568776 (7) [back to overview]Change in Alzheimer's Disease Assessment Scale - Cognitive Subscale (ADAS-Cog) Score From Baseline to Week 78 (Full Analysis Set; FAS)
NCT00568776 (7) [back to overview]Change From Baseline to Week 78 in Neuropsychological Test Battery (NTB) Z-score (Full Analysis Set; FAS)
NCT00568776 (7) [back to overview]Change From Baseline to Week 78 in Alzheimer's Disease Cooperative Study - Activities of Daily Living (ADCS-ADL) Score (Full Analysis Set; FAS)
NCT00568776 (7) [back to overview]Additional Analysis of Primary Outcome Measure: Change From Baseline to Week 78 in Alzheimer's Disease Cooperative Study - Activities of Daily Living (ADCS-ADL) Score (Per Protocol Set; PPS)
NCT00654381 (9) [back to overview]Relative Efficacy Response of HbA1c at Week 12
NCT00654381 (9) [back to overview]Examination of Long-term Safety of Linagliptin (52-week Treatment)
NCT00654381 (9) [back to overview]Change From Baseline in HbA1c at Week 26
NCT00654381 (9) [back to overview]Change From Baseline in Fasting Plasma Glucose (FPG) at Week 26
NCT00654381 (9) [back to overview]Change From Baseline in Fasting Plasma Glucose (FPG) at Week 52
NCT00654381 (9) [back to overview]Change From Baseline in Fasting Plasma Glucose (FPG) at Week 12
NCT00654381 (9) [back to overview]Change From Baseline in HbA1c at Week 12
NCT00654381 (9) [back to overview]Relative Efficacy Response of HbA1c at Week 52
NCT00654381 (9) [back to overview]Relative Efficacy Response of HbA1c at Week 26
NCT00783705 (19) [back to overview]Change in Inflammatory Biomarkers Levels (IL-6) in Bronchoalveolar Lavage Samples as Assessed by Enzyme-linked Immunoassay (ELISA)
NCT00783705 (19) [back to overview]Change in Inflammatory Biomarkers Levels (IL-6) in Plasma Samples as Assessed by ELISA
NCT00783705 (19) [back to overview]Change in Inflammatory Biomarkers Levels (MPO) in Plasma Samples as Assessed by ELISA
NCT00783705 (19) [back to overview]Change in Inflammatory Biomarkers Levels (Nitrotyrosine) in Plasma Samples as Assessed by ELISA
NCT00783705 (19) [back to overview]Change in Inflammatory Biomarkers Levels (SFTPD) in Bronchoalveolar Lavage Samples as Assessed by Enzyme-linked Immunoassay (ELISA)
NCT00783705 (19) [back to overview]Change in Inflammatory Biomarkers Levels (SFTPD) in Plasma Samples as Assessed by ELISA
NCT00783705 (19) [back to overview]Change in Inflammatory Biomarkers Levels (Total Glutathione) in Bronchoalveolar Lavage Samples as Assessed by Enzyme-linked Immunoassay (ELISA)
NCT00783705 (19) [back to overview]Mean Percent Change in Ki-67 Expression Level in the Bronchial Biopsies With Dysplasia
NCT00783705 (19) [back to overview]Percent Change in the Number of Bronchial Dysplastic Lesions Before and After Treatment
NCT00783705 (19) [back to overview]Percentage of Participants With Response Determined by Change in the Histologic Grade of Bronchial Dysplasia as Measured by Mucosal Biopsy Samples on Lesion-specific Analysis.
NCT00783705 (19) [back to overview]Percentage of Participants With Response Determined by Change in the Histologic Grade of Bronchial Dysplasia as Measured by Mucosal Biopsy Samples on Participant-specific Analysis.
NCT00783705 (19) [back to overview]Change in Inflammatory Biomarkers Levels (MPO) in Bronchoalveolar Lavage Samples as Assessed by Enzyme-linked Immunoassay (ELISA)
NCT00783705 (19) [back to overview]Change in Inflammatory Biomarkers Levels (CC-16) in Bronchoalveolar Lavage Samples as Assessed by Enzyme-linked Immunoassay (ELISA)
NCT00783705 (19) [back to overview]Change in Inflammatory Biomarkers Levels (CC-16) in Plasma Samples as Assessed by ELISA
NCT00783705 (19) [back to overview]Change in Inflammatory Biomarkers Levels (CC18) in Bronchoalveolar Lavage Samples as Assessed by Enzyme-linked Immunoassay (ELISA)
NCT00783705 (19) [back to overview]Change in Inflammatory Biomarkers Levels (CC18) in Plasma Samples as Assessed by ELISA
NCT00783705 (19) [back to overview]Change in Inflammatory Biomarkers Levels (CCL-2) in Bronchoalveolar Lavage Samples as Assessed by Enzyme-linked Immunoassay (ELISA)
NCT00783705 (19) [back to overview]Change in Inflammatory Biomarkers Levels (CCL-2) in Plasma Samples as Assessed by ELISA
NCT00783705 (19) [back to overview]Change in Inflammatory Biomarkers Levels (CRP) in Plasma Samples as Assessed by ELISA
NCT00934050 (1) [back to overview]Treatment Emergent Adverse Events (TEAEs)
NCT01030575 (21) [back to overview]Population Pharmacokinetics: V - Volume
NCT01030575 (21) [back to overview]Number of Participants With Any Ophthalmologic Diagnosis
NCT01030575 (21) [back to overview]Number of Participants With Any Ophthalmologic Medical Treatment
NCT01030575 (21) [back to overview]Number of Participants With Any Ophthalmologic Surgical Treatment
NCT01030575 (21) [back to overview]Number of Participants With Any Ophthalmologic Treatment
NCT01030575 (21) [back to overview]Number of Participants With Any Retinopathy of Prematurity (ROP)
NCT01030575 (21) [back to overview]Number of Participants With Any Retinopathy of Prematurity Through 18-22 Month Corrected Age or Death
NCT01030575 (21) [back to overview]Number of Participants With Composite Motor Score Less Than 70
NCT01030575 (21) [back to overview]Number of Participants With Gross Motor Function Greater Than or Equal to 2
NCT01030575 (21) [back to overview]Population Pharmacokinetics: R - Endogenous Infusion Rate
NCT01030575 (21) [back to overview]Population Pharmacokinetics: k - Elimination Rate (Cl/V)
NCT01030575 (21) [back to overview]Population Pharmacokinetics: E - Concentration Due to Endogenous Infusion (R/Cl)
NCT01030575 (21) [back to overview]Population Pharmacokinetics: Cl - Clearance
NCT01030575 (21) [back to overview]Number of Participants With Severe Vision Loss
NCT01030575 (21) [back to overview]Number of Participants With Severe Hearing Impairment
NCT01030575 (21) [back to overview]Number of Participants With Composite Cognitive Score Less Than 70
NCT01030575 (21) [back to overview]Number of Participants With Moderate or Severe Neurodevelopmental Impairment at 18-22 Month Corrected Age or Death
NCT01030575 (21) [back to overview]Number of Participants With Moderate or Severe Neurodevelopmental Impairment at 18-22 Month Corrected Age
NCT01030575 (21) [back to overview]Number of Participants With Moderate or Severe Cerebral Palsy
NCT01030575 (21) [back to overview]SD of Residual Error (mg/l)
NCT01030575 (21) [back to overview]Population Pharmacokinetics: t1/2 - Half-Life (0.693/k)
NCT01111292 (1) [back to overview]The Effect of Myo-inositol (Inositol) on P-β-catenin Staining in Areas of Low Grade Dysplasia in Subjects With Known Colitis-induced Low Grade Dysplasia.
NCT01263483 (17) [back to overview]Change From Baseline in Blood Glucose Measured by Meal Tolerance Testing (2-hr Postprandial Value).
NCT01263483 (17) [back to overview]Change From Baseline in Blood Glucose Measured by Meal Tolerance Testing (AUC (0-2)).
NCT01263483 (17) [back to overview]Change From Baseline in C-peptide Measured by Meal Tolerance Testing (AUC(0-2).
NCT01263483 (17) [back to overview]Change From Baseline in Fasting C-peptide (Week 12).
NCT01263483 (17) [back to overview]Change From Baseline in Fasting C-peptide (Week 2).
NCT01263483 (17) [back to overview]Change From Baseline in Fasting C-peptide (Week 4).
NCT01263483 (17) [back to overview]Change From Baseline in Fasting C-peptide (Week 8).
NCT01263483 (17) [back to overview]Change From Baseline in Fasting Plasma Glucose (Week 12).
NCT01263483 (17) [back to overview]Change From Baseline in Fasting Plasma Glucose (Week 2).
NCT01263483 (17) [back to overview]Change From Baseline in Fasting Plasma Glucose (Week 4).
NCT01263483 (17) [back to overview]Change From Baseline in Fasting Plasma Glucose (Week 8).
NCT01263483 (17) [back to overview]Change From Baseline in Glucagon Measured by Meal Tolerance Testing (AUC (0-2)).
NCT01263483 (17) [back to overview]Change From Baseline in Glycosylated Hemoglobin (Week 12).
NCT01263483 (17) [back to overview]Change From Baseline in Glycosylated Hemoglobin (Week 2).
NCT01263483 (17) [back to overview]Change From Baseline in Glycosylated Hemoglobin (Week 4).
NCT01263483 (17) [back to overview]Change From Baseline in Glycosylated Hemoglobin (Week 8).
NCT01263483 (17) [back to overview]Change From Baseline in Insulin Measured by Meal Tolerance Testing (AUC(0-2).
NCT01263509 (60) [back to overview]Change From Baseline in Blood Glucose Measured by Meal Tolerance Testing (AUC (0-2)) (Week 52).
NCT01263509 (60) [back to overview]Change From Baseline in Insulin Measured by Meal Tolerance Testing (AUC(0-2)) (Week 24).
NCT01263509 (60) [back to overview]Change From Baseline in Insulin Measured by Meal Tolerance Testing (AUC(0-2)) (Week 52).
NCT01263509 (60) [back to overview]Change From Baseline in Blood Glucose Measured by Meal Tolerance Testing (2-hr Postprandial Value) (Final Visit).
NCT01263509 (60) [back to overview]Change From Baseline in Blood Glucose Measured by Meal Tolerance Testing (2-hr Postprandial Value) (Week 12).
NCT01263509 (60) [back to overview]Change From Baseline in Blood Glucose Measured by Meal Tolerance Testing (2-hr Postprandial Value) (Week 24).
NCT01263509 (60) [back to overview]Change From Baseline in Blood Glucose Measured by Meal Tolerance Testing (2-hr Postprandial Value) (Week 52).
NCT01263509 (60) [back to overview]Change From Baseline in Blood Glucose Measured by Meal Tolerance Testing (AUC (0-2)) (Final Visit).
NCT01263509 (60) [back to overview]Change From Baseline in Blood Glucose Measured by Meal Tolerance Testing (AUC (0-2)) (Week 12).
NCT01263509 (60) [back to overview]Change From Baseline in Blood Glucose Measured by Meal Tolerance Testing (AUC (0-2)) (Week 24).
NCT01263509 (60) [back to overview]Change From Baseline in Fasting C-peptide (Week 28).
NCT01263509 (60) [back to overview]Change From Baseline in C-peptide Measured by Meal Tolerance Testing (AUC(0-2)) (Final Visit).
NCT01263509 (60) [back to overview]Change From Baseline in C-peptide Measured by Meal Tolerance Testing (AUC(0-2)) (Week 12).
NCT01263509 (60) [back to overview]Change From Baseline in C-peptide Measured by Meal Tolerance Testing (AUC(0-2)) (Week 24).
NCT01263509 (60) [back to overview]Change From Baseline in C-peptide Measured by Meal Tolerance Testing (AUC(0-2)) (Week 52).
NCT01263509 (60) [back to overview]Change From Baseline in Fasting C-peptide (Final Visit).
NCT01263509 (60) [back to overview]Change From Baseline in Fasting C-peptide (Week 12).
NCT01263509 (60) [back to overview]Change From Baseline in Fasting C-peptide (Week 16).
NCT01263509 (60) [back to overview]Change From Baseline in Fasting C-peptide (Week 20).
NCT01263509 (60) [back to overview]Change From Baseline in Fasting C-peptide (Week 24).
NCT01263509 (60) [back to overview]Number of Participants With Adverse Events.
NCT01263509 (60) [back to overview]Change From Baseline in Fasting C-peptide (Week 32).
NCT01263509 (60) [back to overview]Change From Baseline in Fasting C-peptide (Week 36).
NCT01263509 (60) [back to overview]Change From Baseline in Fasting C-peptide (Week 40).
NCT01263509 (60) [back to overview]Change From Baseline in Fasting C-peptide (Week 44).
NCT01263509 (60) [back to overview]Change From Baseline in Fasting C-peptide (Week 48).
NCT01263509 (60) [back to overview]Change From Baseline in Fasting C-peptide (Week 52).
NCT01263509 (60) [back to overview]Change From Baseline in Fasting C-peptide (Week 8).
NCT01263509 (60) [back to overview]Change From Baseline in Fasting Plasma Glucose (Final Visit).
NCT01263509 (60) [back to overview]Change From Baseline in Fasting Plasma Glucose (Week 12).
NCT01263509 (60) [back to overview]Change From Baseline in Fasting Plasma Glucose (Week 16).
NCT01263509 (60) [back to overview]Change From Baseline in Fasting Plasma Glucose (Week 20).
NCT01263509 (60) [back to overview]Change From Baseline in Fasting Plasma Glucose (Week 24).
NCT01263509 (60) [back to overview]Change From Baseline in Fasting Plasma Glucose (Week 28).
NCT01263509 (60) [back to overview]Change From Baseline in Fasting Plasma Glucose (Week 32).
NCT01263509 (60) [back to overview]Change From Baseline in Fasting Plasma Glucose (Week 36).
NCT01263509 (60) [back to overview]Change From Baseline in Fasting Plasma Glucose (Week 40).
NCT01263509 (60) [back to overview]Change From Baseline in Fasting Plasma Glucose (Week 44).
NCT01263509 (60) [back to overview]Change From Baseline in Fasting Plasma Glucose (Week 48).
NCT01263509 (60) [back to overview]Change From Baseline in Fasting Plasma Glucose (Week 52).
NCT01263509 (60) [back to overview]Change From Baseline in Fasting Plasma Glucose (Week 8).
NCT01263509 (60) [back to overview]Change From Baseline in Glucagon Measured by Meal Tolerance Testing (AUC (0-2)) (Final Visit).
NCT01263509 (60) [back to overview]Change From Baseline in Glucagon Measured by Meal Tolerance Testing (AUC (0-2)) (Week 12).
NCT01263509 (60) [back to overview]Change From Baseline in Glucagon Measured by Meal Tolerance Testing (AUC (0-2)) (Week 24).
NCT01263509 (60) [back to overview]Change From Baseline in Glucagon Measured by Meal Tolerance Testing (AUC (0-2)) (Week 52).
NCT01263509 (60) [back to overview]Change From Baseline in Glycosylated Hemoglobin (Final Visit).
NCT01263509 (60) [back to overview]Change From Baseline in Glycosylated Hemoglobin (Week 12).
NCT01263509 (60) [back to overview]Change From Baseline in Glycosylated Hemoglobin (Week 16).
NCT01263509 (60) [back to overview]Change From Baseline in Glycosylated Hemoglobin (Week 20).
NCT01263509 (60) [back to overview]Change From Baseline in Glycosylated Hemoglobin (Week 24).
NCT01263509 (60) [back to overview]Change From Baseline in Glycosylated Hemoglobin (Week 28).
NCT01263509 (60) [back to overview]Change From Baseline in Glycosylated Hemoglobin (Week 32).
NCT01263509 (60) [back to overview]Change From Baseline in Glycosylated Hemoglobin (Week 36).
NCT01263509 (60) [back to overview]Change From Baseline in Glycosylated Hemoglobin (Week 40).
NCT01263509 (60) [back to overview]Change From Baseline in Glycosylated Hemoglobin (Week 44).
NCT01263509 (60) [back to overview]Change From Baseline in Glycosylated Hemoglobin (Week 48).
NCT01263509 (60) [back to overview]Change From Baseline in Glycosylated Hemoglobin (Week 52).
NCT01263509 (60) [back to overview]Change From Baseline in Glycosylated Hemoglobin (Week 8).
NCT01263509 (60) [back to overview]Change From Baseline in Insulin Measured by Meal Tolerance Testing (AUC(0-2)) (Final Visit).
NCT01263509 (60) [back to overview]Change From Baseline in Insulin Measured by Meal Tolerance Testing (AUC(0-2)) (Week 12).
NCT01396486 (2) [back to overview]Improvement in Depression Symptoms by Children's Depression Rating Scale (CDRS)
NCT01396486 (2) [back to overview]Improvement in Mania Symptoms by Change in Young Mania Rating Scale (YMRS)
NCT01674010 (1) [back to overview]Treatment Emergent Adverse Events
NCT01735630 (5) [back to overview]Change From Baseline in ADCS-ADL Scores
NCT01735630 (5) [back to overview]Change From Baseline in MMSE Scores
NCT01735630 (5) [back to overview]Change From Baseline in Modified-ADCS-CGIC Agitation Scores
NCT01735630 (5) [back to overview]Change From Baseline in NPI Total Scores
NCT01735630 (5) [back to overview]Change From Baseline in NPI-C Combined Agitation and Aggression Subscores (NPI-C A+A).
NCT01766336 (1) [back to overview]Number of Participants Experiencing Treatment Emergent Adverse Events
NCT01875445 (2) [back to overview]The Massachusetts General Hospital (MGH) Hairpulling Scale
NCT01875445 (2) [back to overview]The National Institute of Mental Health Trichotillomania Symptom Severity Scale (NIMH-TSS)
NCT01954082 (7) [back to overview]Number of Participants With Unfavorable Outcome, Defined as Severe Retinopathy of Prematurity (ROP) or Death Prior to Reaching Acute/Final ROP Status
NCT01954082 (7) [back to overview]Number of Participants With All Cause Death Before Retinopathy of Prematurity (ROP) Endpoint
NCT01954082 (7) [back to overview]Number of Participants With Any Retinopathy of Prematurity (ROP)
NCT01954082 (7) [back to overview]Number of Participants With Bronchopulmonary Dysplasia (BPD)
NCT01954082 (7) [back to overview]Number of Participants With Bronchopulmonary Dysplasia (BPD) or Death From BPD
NCT01954082 (7) [back to overview]Number of Participants With Severe Intraventricular Hemorrhage (IVH)
NCT01954082 (7) [back to overview]Number of Participants With Type 2 or More Severe Retinopathy of Prematurity (ROP)
NCT02397291 (4) [back to overview]Fetal Enrichment of Mannose
NCT02397291 (4) [back to overview]Fetal Enrichment of Myoinositol
NCT02397291 (4) [back to overview]Maternal Enrichment of Mannose
NCT02397291 (4) [back to overview]Maternal Enrichment of Myoinositol

Change From Baseline in 2 Hour Postprandial Glucose at Week 12

Change from baseline at Week 12 is defined as 2-hour postprandial glucose Week 12 minus 2-hour postprandial glucose Week 0. (NCT00411554)
Timeframe: Baseline and Week 12

Interventionmg/dL (Least Squares Mean)
Sitagliptin 50 mg QD-51.0
Voglibose 0.2 mg TID-32.2

[back to top]

Change From Baseline in Fasting Plasma Glucose at Week 12

Change from baseline at Week 12 is defined as fasting plasma glucose at Week 12 minus fasting plasma glucose at Week 0. (NCT00411554)
Timeframe: Baseline and Week 12

Interventionmg/dL (Least Squares Mean)
Sitagliptin 50 mg QD-19.6
Voglibose 0.2 mg TID-8.9

[back to top]

Change From Baseline in HbA1c at Week 12

HbA1c is measured as a percent. Thus, this change from baseline reflects the Week 12 HbA1c percent minus the Week 0 HbA1c percent. (NCT00411554)
Timeframe: Baseline and Week 12

InterventionPercent (Least Squares Mean)
Sitagliptin 50 mg QD-0.70
Voglibose 0.2 mg TID-0.30

[back to top]

Additional Analysis of Primary Outcome Measure: Change From Baseline to Week 78 in Neuropsychological Test Battery (NTB) Z-score (Per Protocol Set; PPS)

The NTB assessment is comprised of 9 instruments that measure cognition and executive function. Three of these tests measure immediate memory, next three measure delayed memory, and remaining three assess executive function. The total score is a weighted mean of the nine tests, referred to as the Z-score. Typically, scores range from -3 and 3, with lower scores suggesting greater cognitive impairment. (NCT00568776)
Timeframe: Baseline and 78 weeks

InterventionScores on a Scale (Mean)
Placebo BID-0.369
ELND005 250 mg BID-0.222

[back to top]

Change in Neuropsychiatric Inventory (NPI) Score From Baseline to Week 78 (Full Analysis Set; FAS)

The NPI is used to obtain information on the presence of severity of neuropsychological symptoms, and was specifically designed for use in Alzheimer's disease subjects. The scale consists of 12 items with each item having outcomes from 0 to 12; hence the total score ranges from 0 to 144. Higher scores suggest greater psychiatric impairment. (NCT00568776)
Timeframe: Baseline and 78 weeks

InterventionScores on a Scale (Mean)
Placebo BID-6.132
ELND005 250 mg BID-5.116

[back to top]

Change in Clinical Dementia Rating - Sum of Boxes (CDR-SB) Score From Baseline to Week 78 (Full Analysis Set; FAS)

The CDR-SB consists of 6 items; 3 measuring cognitive ability and 3 measuring functional ability. The score for each of the six items range from 0 to 3; hence the total score is between 0 and 18. Higher scores suggest greater cognitive impairment. (NCT00568776)
Timeframe: Baseline and 78 weeks

InterventionScores on a Scale (Mean)
Placebo BID-2.742
ELND005 250 mg BID-2.452

[back to top]

Change in Alzheimer's Disease Assessment Scale - Cognitive Subscale (ADAS-Cog) Score From Baseline to Week 78 (Full Analysis Set; FAS)

The ADAS-Cog primarily measures cognitive ability. The version used in this study was comprised of 12 items with scores ranging from 0 to 75. Higher scores suggest greater cognitive impairment. (NCT00568776)
Timeframe: Baseline and 78 weeks

InterventionScores on a Scale (Mean)
Placebo BID-8.239
ELND005 250 mg BID-10.796

[back to top]

Change From Baseline to Week 78 in Neuropsychological Test Battery (NTB) Z-score (Full Analysis Set; FAS)

The NTB assessment is comprised of 9 instruments that measure cognition and executive function. Three of these tests measure immediate memory, next three measure delayed memory, and remaining three assess executive function. The total score is a weighted mean of the nine tests, referred to as the Z-score. Typically, scores range from -3 and 3, with lower scores suggesting greater cognitive impairment. (NCT00568776)
Timeframe: Baseline and 78 weeks

InterventionScores on a Scale (Mean)
Placebo BID-0.383
ELND005 250 mg BID-0.350

[back to top]

Change From Baseline to Week 78 in Alzheimer's Disease Cooperative Study - Activities of Daily Living (ADCS-ADL) Score (Full Analysis Set; FAS)

The ADCS-ADL is a 23-item scale that measures a subject's functional abilities as assessed by the subject's caregiver. This scale ranges from 0 to 78, with lower scores suggesting greater functional impairment. (NCT00568776)
Timeframe: Baseline and 78 weeks

InterventionScores on a Scale (Mean)
Placebo BID-9.467
ELND005 250 mg BID-10.861

[back to top]

Additional Analysis of Primary Outcome Measure: Change From Baseline to Week 78 in Alzheimer's Disease Cooperative Study - Activities of Daily Living (ADCS-ADL) Score (Per Protocol Set; PPS)

The ADCS-ADL is a 23-item scale that measures a subject's functional abilities as assessed by the subject's caregiver. This scale ranges from 0 to 78, with lower scores suggesting greater functional impairment. (NCT00568776)
Timeframe: Baseline and 78 weeks

InterventionScores on a Scale (Mean)
Placebo BID-9.635
ELND005 250 mg BID-8.987

[back to top]

Relative Efficacy Response of HbA1c at Week 12

HbA1c value decreased below 7.0%, below 6.5% and reduction from baseline ≥0.5% at Week 12 (NCT00654381)
Timeframe: 12 weeks

,,
InterventionParticipants (Number)
HbA1c <7.0%HbA1c <6.5%HbA1c reduction from baseline ≥0.5%
Linagliptin 10 mg561894
Linagliptin 5mg421591
Placebo807

[back to top]

Examination of Long-term Safety of Linagliptin (52-week Treatment)

The incidence of AEs (Preferred Terms) with a frequency of 5% or more in the patients with type 2 diabetes mellitus who received linagliptin (5 mg or 10 mg) once daily for 52 weeks (NCT00654381)
Timeframe: 52 weeks

,
Interventionparticipants (Number)
NasopharyngitisBack painConstipation
Linagliptin 10 mg812119
Linagliptin 5mg841512

[back to top]

Change From Baseline in HbA1c at Week 26

Change from the baseline measurement, where the baseline measurement was obtained at randomization (0 week) before receiving study medication (NCT00654381)
Timeframe: 26 weeks

InterventionPercent (Least Squares Mean)
Linagliptin 5mg-0.13
Linagliptin 10 mg-0.19
Voglibose0.19

[back to top]

Change From Baseline in Fasting Plasma Glucose (FPG) at Week 26

Change from the baseline measurement, where the baseline measurement was obtained at randomization (0 week) before receiving study medication (NCT00654381)
Timeframe: 26 weeks

Interventionmg/dL (Least Squares Mean)
Linagliptin 5mg-5.0
Linagliptin 10 mg-7.8
Voglibose2.0

[back to top]

Change From Baseline in Fasting Plasma Glucose (FPG) at Week 52

Change from the baseline measurement, where the baseline measurement was obtained at randomization (0 week) before receiving study medication (NCT00654381)
Timeframe: 52 weeks

Interventionmg/dL (Least Squares Mean)
Linagliptin 5mg-3.2
Linagliptin 10 mg-5.9

[back to top]

Change From Baseline in Fasting Plasma Glucose (FPG) at Week 12

Change from the baseline measurement, where the baseline measurement was obtained at randomization (0 week) before receiving study medication (NCT00654381)
Timeframe: 12 weeks

Interventionmg/dL (Least Squares Mean)
Placebo7.4
Linagliptin 5mg-12.3
Linagliptin 10 mg-13.0

[back to top]

Change From Baseline in HbA1c at Week 12

Change from the baseline measurement, where the baseline measurement was obtained at randomization (0 week) before receiving study medication (NCT00654381)
Timeframe: 12 weeks

InterventionPercent (Least Squares Mean)
Placebo0.63
Linagliptin 5mg-0.24
Linagliptin 10 mg-0.25

[back to top]

Relative Efficacy Response of HbA1c at Week 52

HbA1c value decreased below 7.0%, below 6.5% and reduction from baseline ≥0.5% at Week 52 (NCT00654381)
Timeframe: 52 weeks

,
InterventionParticipants (Number)
HbA1c <7.0%HbA1c <6.5%HbA1c reduction from baseline ≥0.5%
Linagliptin 10mg291062
Linagliptin 5mg38662

[back to top]

Relative Efficacy Response of HbA1c at Week 26

HbA1c value decreased below 7.0%, below 6.5% and reduction from baseline ≥0.5% at Week 26 (NCT00654381)
Timeframe: 26 weeks

,,
InterventionParticipants (Number)
HbA1c <7.0%HbA1c <6.5%HbA1c reduction from baseline ≥0.5%
Linagliptin 10 mg542184
Linagliptin 5mg481591
Voglibose36761

[back to top]

Change in Inflammatory Biomarkers Levels (IL-6) in Bronchoalveolar Lavage Samples as Assessed by Enzyme-linked Immunoassay (ELISA)

The biomarkers that were examined were: 1) pro-inflammatory proteins: C-reactive protein (CRP, R&D Systems), interleukin-6 (IL-6, R&D Systems), and CCL-2 (R&D Systems); 2) oxidant/antioxidants: myeloperoxidase (MPO, R&D Systems), nitrotyrosine (Hycult Biotech) and glutathione (Millipore-Calbiochem); and 3) pneumoproteins: Clara cell protein-16 (CC-16, Biovendor), surfactant protein-D (SFTPD, R&D Systems) and CC18 (R&D Systems). (NCT00783705)
Timeframe: From baseline up to 6 months

Interventionpg/mL (Median)
Arm A (Myo-inositol)-0.68
Arm B (Placebo)-0.27

[back to top]

Change in Inflammatory Biomarkers Levels (IL-6) in Plasma Samples as Assessed by ELISA

The biomarkers that were examined were: 1) pro-inflammatory proteins: C-reactive protein (CRP, R&D Systems), interleukin-6 (IL-6, R&D Systems), and CCL-2 (R&D Systems); 2) oxidant/antioxidants: myeloperoxidase (MPO, R&D Systems), nitrotyrosine (Hycult Biotech) and glutathione (Millipore-Calbiochem); and 3) pneumoproteins: Clara cell protein-16 (CC-16, Biovendor), surfactant protein-D (SFTPD, R&D Systems) and CC18 (R&D Systems). (NCT00783705)
Timeframe: From baseline up to 6 months

Interventionpg/mL (Median)
Arm A (Myo-inositol)0.06
Arm B (Placebo)0.01

[back to top]

Change in Inflammatory Biomarkers Levels (MPO) in Plasma Samples as Assessed by ELISA

The biomarkers that were examined were: 1) pro-inflammatory proteins: C-reactive protein (CRP, R&D Systems), interleukin-6 (IL-6, R&D Systems), and CCL-2 (R&D Systems); 2) oxidant/antioxidants: myeloperoxidase (MPO, R&D Systems), nitrotyrosine (Hycult Biotech) and glutathione (Millipore-Calbiochem); and 3) pneumoproteins: Clara cell protein-16 (CC-16, Biovendor), surfactant protein-D (SFTPD, R&D Systems) and CC18 (R&D Systems). (NCT00783705)
Timeframe: From baseline up to 6 months

Interventionng/mL (Median)
Arm A (Myo-inositol)0.20
Arm B (Placebo)0.09

[back to top]

Change in Inflammatory Biomarkers Levels (Nitrotyrosine) in Plasma Samples as Assessed by ELISA

The biomarkers that were examined were: 1) pro-inflammatory proteins: C-reactive protein (CRP, R&D Systems), interleukin-6 (IL-6, R&D Systems), and CCL-2 (R&D Systems); 2) oxidant/antioxidants: myeloperoxidase (MPO, R&D Systems), nitrotyrosine (Hycult Biotech) and glutathione (Millipore-Calbiochem); and 3) pneumoproteins: Clara cell protein-16 (CC-16, Biovendor), surfactant protein-D (SFTPD, R&D Systems) and CC18 (R&D Systems). (NCT00783705)
Timeframe: From baseline up to 6 months

Interventionmmol/L (Median)
Arm A (Myo-inositol)0.77
Arm B (Placebo)0.88

[back to top]

Change in Inflammatory Biomarkers Levels (SFTPD) in Bronchoalveolar Lavage Samples as Assessed by Enzyme-linked Immunoassay (ELISA)

The biomarkers that were examined were: 1) pro-inflammatory proteins: C-reactive protein (CRP, R&D Systems), interleukin-6 (IL-6, R&D Systems), and CCL-2 (R&D Systems); 2) oxidant/antioxidants: myeloperoxidase (MPO, R&D Systems), nitrotyrosine (Hycult Biotech) and glutathione (Millipore-Calbiochem); and 3) pneumoproteins: Clara cell protein-16 (CC-16, Biovendor), surfactant protein-D (SFTPD, R&D Systems) and CC18 (R&D Systems). (NCT00783705)
Timeframe: From baseline up to 6 months

Interventionng/mL (Median)
Arm A (Myo-inositol)-12.39
Arm B (Placebo)7.21

[back to top]

Change in Inflammatory Biomarkers Levels (SFTPD) in Plasma Samples as Assessed by ELISA

The biomarkers that were examined were: 1) pro-inflammatory proteins: C-reactive protein (CRP, R&D Systems), interleukin-6 (IL-6, R&D Systems), and CCL-2 (R&D Systems); 2) oxidant/antioxidants: myeloperoxidase (MPO, R&D Systems), nitrotyrosine (Hycult Biotech) and glutathione (Millipore-Calbiochem); and 3) pneumoproteins: Clara cell protein-16 (CC-16, Biovendor), surfactant protein-D (SFTPD, R&D Systems) and CC18 (R&D Systems). (NCT00783705)
Timeframe: From baseline up to 6 months

Interventionng/mL (Median)
Arm A (Myo-inositol)-0.28
Arm B (Placebo)-0.22

[back to top]

Change in Inflammatory Biomarkers Levels (Total Glutathione) in Bronchoalveolar Lavage Samples as Assessed by Enzyme-linked Immunoassay (ELISA)

The biomarkers that were examined were: 1) pro-inflammatory proteins: C-reactive protein (CRP, R&D Systems), interleukin-6 (IL-6, R&D Systems), and CCL-2 (R&D Systems); 2) oxidant/antioxidants: myeloperoxidase (MPO, R&D Systems), nitrotyrosine (Hycult Biotech) and glutathione (Millipore-Calbiochem); and 3) pneumoproteins: Clara cell protein-16 (CC-16, Biovendor), surfactant protein-D (SFTPD, R&D Systems) and CC18 (R&D Systems). (NCT00783705)
Timeframe: From baseline up to 6 months

Interventionumol/L (Median)
Arm A (Myo-inositol)-0.25
Arm B (Placebo)-0.56

[back to top]

Mean Percent Change in Ki-67 Expression Level in the Bronchial Biopsies With Dysplasia

(NCT00783705)
Timeframe: From baseline up to 6 months

Interventionpercentage of Ki67 expression level (Mean)
Arm A (Myo-inositol)-22.8
Arm B (Placebo)-6.2

[back to top]

Percent Change in the Number of Bronchial Dysplastic Lesions Before and After Treatment

The change in the number of bronchial dysplastic lesions is defined as disappearance or appearance of lesions. (NCT00783705)
Timeframe: From baseline up to 6 months

Interventionpercentage change in number of lesions (Mean)
Arm A (Myo-inositol)-53.5
Arm B (Placebo)-50.0

[back to top]

Percentage of Participants With Response Determined by Change in the Histologic Grade of Bronchial Dysplasia as Measured by Mucosal Biopsy Samples on Lesion-specific Analysis.

"The definitions of responses are:~Complete response: the regression of a dysplastic lesion (DL) of any grade to one classified as being hyperplastic/normal; Progressive disease: appearance of lesions that were classified as mild dysplasia or worse; Stable disease: lesions that are not classified as complete response or progressive disease" (NCT00783705)
Timeframe: From baseline up to 6 months

,
Interventionpercentage of participants (Number)
Complete responseStable diseaseProgressive disease
Arm A (Myo-inositol)10.215.912.5
Arm B (Placebo)7.422.610.3

[back to top]

Percentage of Participants With Response Determined by Change in the Histologic Grade of Bronchial Dysplasia as Measured by Mucosal Biopsy Samples on Participant-specific Analysis.

"The definitions of responses are:~Complete response: regression of all dysplastic lesion (DL) found at baseline to lesions that were no worse than hyperplasia and no new DL that were mild dysplasia or worse; Partial response: regression of some but not all of the DL with no new lesions that are mild dysplasia or worse; Progressive disease: progression of one or more sites by two or more grades or new DL that were mild dysplasia or worse; Stable disease: no complete response, partial response or progression." (NCT00783705)
Timeframe: From baseline up to 6 months

,
Interventionpercentage of participants (Number)
Complete responsePartial responseStable diseaseProgressive disease
Arm A (Myo-inositol)26.310.515.847.4
Arm B (Placebo)13.916.736.133.3

[back to top]

Change in Inflammatory Biomarkers Levels (MPO) in Bronchoalveolar Lavage Samples as Assessed by Enzyme-linked Immunoassay (ELISA)

The biomarkers that were examined were: 1) pro-inflammatory proteins: C-reactive protein (CRP, R&D Systems), interleukin-6 (IL-6, R&D Systems), and CCL-2 (R&D Systems); 2) oxidant/antioxidants: myeloperoxidase (MPO, R&D Systems), nitrotyrosine (Hycult Biotech) and glutathione (Millipore-Calbiochem); and 3) pneumoproteins: Clara cell protein-16 (CC-16, Biovendor), surfactant protein-D (SFTPD, R&D Systems) and CC18 (R&D Systems). (NCT00783705)
Timeframe: From baseline up to 6 months

Interventionng/mL (Median)
Arm A (Myo-inositol)-3.46
Arm B (Placebo)-1.15

[back to top]

Change in Inflammatory Biomarkers Levels (CC-16) in Bronchoalveolar Lavage Samples as Assessed by Enzyme-linked Immunoassay (ELISA)

The biomarkers that were examined were: 1) pro-inflammatory proteins: C-reactive protein (CRP, R&D Systems), interleukin-6 (IL-6, R&D Systems), and CCL-2 (R&D Systems); 2) oxidant/antioxidants: myeloperoxidase (MPO, R&D Systems), nitrotyrosine (Hycult Biotech) and glutathione (Millipore-Calbiochem); and 3) pneumoproteins: Clara cell protein-16 (CC-16, Biovendor), surfactant protein-D (SFTPD, R&D Systems) and CC18 (R&D Systems). (NCT00783705)
Timeframe: From baseline up to 6 months

Interventionng/mL (Median)
Arm A (Myo-inositol)-66.96
Arm B (Placebo)-54.32

[back to top]

Change in Inflammatory Biomarkers Levels (CC-16) in Plasma Samples as Assessed by ELISA

The biomarkers that were examined were: 1) pro-inflammatory proteins: C-reactive protein (CRP, R&D Systems), interleukin-6 (IL-6, R&D Systems), and CCL-2 (R&D Systems); 2) oxidant/antioxidants: myeloperoxidase (MPO, R&D Systems), nitrotyrosine (Hycult Biotech) and glutathione (Millipore-Calbiochem); and 3) pneumoproteins: Clara cell protein-16 (CC-16, Biovendor), surfactant protein-D (SFTPD, R&D Systems) and CC18 (R&D Systems). (NCT00783705)
Timeframe: From baseline up to 6 months

Interventionng/mL (Median)
Arm A (Myo-inositol)-0.08
Arm B (Placebo)-0.58

[back to top]

Change in Inflammatory Biomarkers Levels (CC18) in Bronchoalveolar Lavage Samples as Assessed by Enzyme-linked Immunoassay (ELISA)

The biomarkers that were examined were: 1) pro-inflammatory proteins: C-reactive protein (CRP, R&D Systems), interleukin-6 (IL-6, R&D Systems), and CCL-2 (R&D Systems); 2) oxidant/antioxidants: myeloperoxidase (MPO, R&D Systems), nitrotyrosine (Hycult Biotech) and glutathione (Millipore-Calbiochem); and 3) pneumoproteins: Clara cell protein-16 (CC-16, Biovendor), surfactant protein-D (SFTPD, R&D Systems) and CC18 (R&D Systems). (NCT00783705)
Timeframe: From baseline up to 6 months

Interventionng/mL (Median)
Arm A (Myo-inositol)-121.47
Arm B (Placebo)10.70

[back to top]

Change in Inflammatory Biomarkers Levels (CC18) in Plasma Samples as Assessed by ELISA

The biomarkers that were examined were: 1) pro-inflammatory proteins: C-reactive protein (CRP, R&D Systems), interleukin-6 (IL-6, R&D Systems), and CCL-2 (R&D Systems); 2) oxidant/antioxidants: myeloperoxidase (MPO, R&D Systems), nitrotyrosine (Hycult Biotech) and glutathione (Millipore-Calbiochem); and 3) pneumoproteins: Clara cell protein-16 (CC-16, Biovendor), surfactant protein-D (SFTPD, R&D Systems) and CC18 (R&D Systems). (NCT00783705)
Timeframe: From baseline up to 6 months

Interventionng/mL (Median)
Arm A (Myo-inositol)1.50
Arm B (Placebo)-0.16

[back to top]

Change in Inflammatory Biomarkers Levels (CCL-2) in Bronchoalveolar Lavage Samples as Assessed by Enzyme-linked Immunoassay (ELISA)

The biomarkers that were examined were: 1) pro-inflammatory proteins: C-reactive protein (CRP, R&D Systems), interleukin-6 (IL-6, R&D Systems), and CCL-2 (R&D Systems); 2) oxidant/antioxidants: myeloperoxidase (MPO, R&D Systems), nitrotyrosine (Hycult Biotech) and glutathione (Millipore-Calbiochem); and 3) pneumoproteins: Clara cell protein-16 (CC-16, Biovendor), surfactant protein-D (SFTPD, R&D Systems) and CC18 (R&D Systems). (NCT00783705)
Timeframe: From baseline up to 6 months

Interventionpg/mL (Median)
Arm A (Myo-inositol)-9.25
Arm B (Placebo)9.41

[back to top]

Change in Inflammatory Biomarkers Levels (CCL-2) in Plasma Samples as Assessed by ELISA

The biomarkers that were examined were: 1) pro-inflammatory proteins: C-reactive protein (CRP, R&D Systems), interleukin-6 (IL-6, R&D Systems), and CCL-2 (R&D Systems); 2) oxidant/antioxidants: myeloperoxidase (MPO, R&D Systems), nitrotyrosine (Hycult Biotech) and glutathione (Millipore-Calbiochem); and 3) pneumoproteins: Clara cell protein-16 (CC-16, Biovendor), surfactant protein-D (SFTPD, R&D Systems) and CC18 (R&D Systems). (NCT00783705)
Timeframe: From baseline up to 6 months

Interventionpg/mL (Median)
Arm A (Myo-inositol)2.19
Arm B (Placebo)9.08

[back to top]

Change in Inflammatory Biomarkers Levels (CRP) in Plasma Samples as Assessed by ELISA

The biomarkers that were examined were: 1) pro-inflammatory proteins: C-reactive protein (CRP, R&D Systems), interleukin-6 (IL-6, R&D Systems), and CCL-2 (R&D Systems); 2) oxidant/antioxidants: myeloperoxidase (MPO, R&D Systems), nitrotyrosine (Hycult Biotech) and glutathione (Millipore-Calbiochem); and 3) pneumoproteins: Clara cell protein-16 (CC-16, Biovendor), surfactant protein-D (SFTPD, R&D Systems) and CC18 (R&D Systems). (NCT00783705)
Timeframe: From baseline up to 6 months

Interventionng/mL (Median)
Arm A (Myo-inositol)161.18
Arm B (Placebo)-74.11

[back to top]

Treatment Emergent Adverse Events (TEAEs)

Safety and Tolerability was assessed by the incidence of Treatment Emergent Adverse Events (TEAEs) (NCT00934050)
Timeframe: 12 months

Interventionparticipants (Number)
Placebo/ELND005 250mg BID21
250 mg/ELND005 250 mg BID23

[back to top]

Population Pharmacokinetics: V - Volume

(NCT01030575)
Timeframe: 8-10 blood samples per infant were drawn over 10 weeks for infant safety with the full study duration represented across all infants. Samples were drawn at baseline & on days 1, 2, 4, 6, 8, 10, 12, 14, 16, 20, 24, 28, 35, 42, 56, and 70.

Interventionl/kg (Mean)
PK Population0.6572

[back to top]

Number of Participants With Any Ophthalmologic Diagnosis

Any ophthalmologic diagnosis at 18-22 month corrected age (NCT01030575)
Timeframe: 18-22 month corrected age

InterventionParticipants (Count of Participants)
Inositol Low Volume9
Inositol Mid-level Volume6
Inositol High Volume10
Placebo5

[back to top]

Number of Participants With Any Ophthalmologic Medical Treatment

Any ophthalmologic medical treatment at 18-22 month corrected age (NCT01030575)
Timeframe: 18-22 month corrected age

InterventionParticipants (Count of Participants)
Inositol Low Volume2
Inositol Mid-level Volume1
Inositol High Volume1
Placebo2

[back to top]

Number of Participants With Any Ophthalmologic Surgical Treatment

Any ophthalmologic surgical treatment at 18-22 month corrected age (NCT01030575)
Timeframe: 18-22 month corrected age

InterventionParticipants (Count of Participants)
Inositol Low Volume3
Inositol Mid-level Volume4
Inositol High Volume0
Placebo4

[back to top]

Number of Participants With Any Ophthalmologic Treatment

Any ophthalmologic treatment at 18-22 month corrected age (NCT01030575)
Timeframe: 18-22 month corrected age

InterventionParticipants (Count of Participants)
Inositol Low Volume4
Inositol Mid-level Volume4
Inositol High Volume2
Placebo5

[back to top]

Number of Participants With Any Retinopathy of Prematurity (ROP)

Any ROP is defined as ROP of any severity that is observed at 18-22 month corrected age (NCT01030575)
Timeframe: 18-22 month corrected age

InterventionParticipants (Count of Participants)
Inositol Low Volume11
Inositol Mid-level Volume11
Inositol High Volume14
Placebo12

[back to top]

Number of Participants With Any Retinopathy of Prematurity Through 18-22 Month Corrected Age or Death

Number of participants with any Retinopathy of Prematurity (ROP) through 18-22 month corrected age or death (NCT01030575)
Timeframe: 18-22 month corrected age

InterventionParticipants (Count of Participants)
Inositol Low Volume13
Inositol Mid-level Volume17
Inositol High Volume15
Placebo18

[back to top]

Number of Participants With Composite Motor Score Less Than 70

This is measured as a scored of less than 70 on the Bayley Scale of Infant and Toddler Development (BSID)-III composite motor score. Higher scores indicate better performance. (NCT01030575)
Timeframe: 18-22 months corrected age

InterventionParticipants (Count of Participants)
Inositol Low Volume1
Inositol Mid-level Volume1
Inositol High Volume2
Placebo6

[back to top]

Number of Participants With Gross Motor Function Greater Than or Equal to 2

A Gross Motor Function Classification System (GMFCS) level of at least II (on a scale from level I to V, with I indicating normal gross motor function and higher levels indicating greater impairment). Level II is defined as Infants maintain floor sitting but may need to use their hands for support to maintain balance. Infants creep on their stomach or crawl on hands and knees with reciprocal leg movement. Infants may pull to stand and take steps holding on to furniture.) (NCT01030575)
Timeframe: 18 -22 months corrected age

InterventionParticipants (Count of Participants)
Inositol Low Volume0
Inositol Mid-level Volume2
Inositol High Volume3
Placebo4

[back to top]

Population Pharmacokinetics: R - Endogenous Infusion Rate

(NCT01030575)
Timeframe: 8-10 blood samples per infant were drawn over 10 weeks for infant safety with the full study duration represented across all infants. Samples were drawn at baseline & on days 1, 2, 4, 6, 8, 10, 12, 14, 16, 20, 24, 28, 35, 42, 56, and 70.

Intervention(mg/kg)/h (Mean)
PK Population2.369

[back to top]

Population Pharmacokinetics: k - Elimination Rate (Cl/V)

(NCT01030575)
Timeframe: 8-10 blood samples per infant were drawn over 10 weeks for infant safety with the full study duration represented across all infants. Samples were drawn at baseline & on days 1, 2, 4, 6, 8, 10, 12, 14, 16, 20, 24, 28, 35, 42, 56, and 70.

Interventionliter/hour (Mean)
PK Population0.0878

[back to top]

Population Pharmacokinetics: E - Concentration Due to Endogenous Infusion (R/Cl)

(NCT01030575)
Timeframe: 8-10 blood samples per infant were drawn over 10 weeks for infant safety with the full study duration represented across all infants. Samples were drawn at baseline & on days 1, 2, 4, 6, 8, 10, 12, 14, 16, 20, 24, 28, 35, 42, 56, and 70.

Interventionmiligrams/liter (Mean)
PK Population41.06

[back to top]

Population Pharmacokinetics: Cl - Clearance

(NCT01030575)
Timeframe: 8-10 blood samples per infant were drawn over 10 weeks for infant safety with the full study duration represented across all infants. Samples were drawn at baseline & on days 1, 2, 4, 6, 8, 10, 12, 14, 16, 20, 24, 28, 35, 42, 56, and 70.

Intervention(l/kg)/h (Mean)
PK Population0.0577

[back to top]

Number of Participants With Severe Vision Loss

"Vision loss as diagnosed by an ophthalmologist as legally blind, and subdivided into ophthalmic origin, or not ophthalmic origin (i.e., cortical blindness is non-ophthalmic in origin and indicates that there is no retinal detachment or other abnormal fundus or ocular finding, except optic atrophy. Such cases will be considered central [neurologic] in origin.)" (NCT01030575)
Timeframe: 18-22 Months Corrected Age

InterventionParticipants (Count of Participants)
Inositol Low Volume0
Inositol Mid-level Volume0
Inositol High Volume0
Placebo0

[back to top]

Number of Participants With Severe Hearing Impairment

Defined as permanent hearing loss that does not permit child to understand directions of the examiner and communicate despite amplification with cochlear implant or hearing aid. (NCT01030575)
Timeframe: 18-22 months corrected age.

InterventionParticipants (Count of Participants)
Inositol Low Volume0
Inositol Mid-level Volume0
Inositol High Volume0
Placebo0

[back to top]

Number of Participants With Composite Cognitive Score Less Than 70

This is measured as a score of less than 70 on the Bayley Scale of Infant and Toddler Development (BSID)-III composite cognitive score (NCT01030575)
Timeframe: 18-22 months corrected age.

InterventionParticipants (Count of Participants)
Inositol Low Volume0
Inositol Mid-level Volume1
Inositol High Volume1
Placebo2

[back to top]

Number of Participants With Moderate or Severe Neurodevelopmental Impairment at 18-22 Month Corrected Age or Death

Moderate or Severe NDI defined as occurrence of any of the following: GMFCS level II or higher (severe is level 4 or 5), Bayley III cognitive composite score < 85 (severe is <70), Bayley III motor composite score < 85 (severe is <70), unilateral blind or bilateral blind, permanent hearing loss that does not permit child to understand directions of the examiner and communicate despite amplification with cochlear implant or hearing aid (NCT01030575)
Timeframe: 8-22 months corrected age.

InterventionParticipants (Count of Participants)
Inositol Low Volume10
Inositol Mid-level Volume15
Inositol High Volume13
Placebo20

[back to top]

Number of Participants With Moderate or Severe Neurodevelopmental Impairment at 18-22 Month Corrected Age

A composite outcome that measures the occurrence of neurodevelopmental impairment between birth and 18-22 months corrected age. (NCT01030575)
Timeframe: 18-22 month corrected age

InterventionParticipants (Count of Participants)
Inositol Low Volume8
Inositol Mid-level Volume9
Inositol High Volume11
Placebo13

[back to top]

Number of Participants With Moderate or Severe Cerebral Palsy

Cerebral palsy by severity category (absent/mild/moderate/severe). (NCT01030575)
Timeframe: 18-22 months corrected age.

InterventionParticipants (Count of Participants)
Inositol Low Volume0
Inositol Mid-level Volume1
Inositol High Volume1
Placebo2

[back to top]

SD of Residual Error (mg/l)

(NCT01030575)
Timeframe: 8-10 blood samples per infant were drawn over 10 weeks for infant safety with the full study duration represented across all infants. Samples were drawn at baseline & on days 1, 2, 4, 6, 8, 10, 12, 14, 16, 20, 24, 28, 35, 42, 56, and 70.

Interventionmg/l (Mean)
PK Population24.77

[back to top]

Population Pharmacokinetics: t1/2 - Half-Life (0.693/k)

(NCT01030575)
Timeframe: 8-10 blood samples per infant were drawn over 10 weeks for infant safety with the full study duration represented across all infants. Samples were drawn at baseline & on days 1, 2, 4, 6, 8, 10, 12, 14, 16, 20, 24, 28, 35, 42, 56, and 70.

Interventionhour (Mean)
PK Population7.90

[back to top]

The Effect of Myo-inositol (Inositol) on P-β-catenin Staining in Areas of Low Grade Dysplasia in Subjects With Known Colitis-induced Low Grade Dysplasia.

The primary objective of this study will be to evaluate the effect of myo-inositol (inositol), administered for three months, on P-β-catenin staining in areas of low grade dysplasia or in areas of prior low grade dysplasia in subjects with known colitis-induced low grade dysplasia at baseline. (NCT01111292)
Timeframe: Baseline to 90 days

,
InterventionColonic Biopsies (Mean)
Baseline Cells/100 IECPost Intervention Cells/100 IECBaseline Crypts w/2 cellsPost Intervention Crypts w/ 2 cellsBaseline Crypts w/3 cellsPost Intervention Crypts w/ 3 CellsBaseline Crypts w/4 cellsPost Intervention Crypts w/4 cellsBaseline Crypts w/>5 cellsPost Intervention Crypts w/>5 cellsBaseline # HF Fields of ViewPost Intervention # HF Fields
Arm I (Inositol)2.53.677.758.6722.6721.672.2502.52
Arm II (Placebo)002.50.50000000

[back to top]

Change From Baseline in Blood Glucose Measured by Meal Tolerance Testing (2-hr Postprandial Value).

The change between the value of blood glucose collected at week 12 or final visit and blood glucose collected at baseline. Meal tolerance test measures blood glucose, insulin, C-peptide and glucagon through blood samples drawn before a meal and at 2 hours after the start of the meal. (NCT01263483)
Timeframe: Baseline and Week 12.

Interventionmg/dL (Mean)
Voglibose 0.2 mg TID72.4
Alogliptin 12.5 mg QD40.9
Alogliptin 25 mg QD and Voglibose 0.2 mg TID38.7

[back to top]

Change From Baseline in Blood Glucose Measured by Meal Tolerance Testing (AUC (0-2)).

The change between the value of blood glucose collected at week 12 or final visit and blood glucose collected at baseline. Meal tolerance test measures blood glucose, insulin, C-peptide and glucagon through blood samples drawn before a meal and at 2 hours after the start of the meal. (NCT01263483)
Timeframe: Baseline and Week 12.

Interventionmg·hr/dL (Mean)
Voglibose 0.2 mg TID-4.3
Alogliptin 12.5 mg QD-74.7
Alogliptin 25 mg QD and Voglibose 0.2 mg TID-76.8

[back to top]

Change From Baseline in C-peptide Measured by Meal Tolerance Testing (AUC(0-2).

The change between the value of C-peptide collected at week 12 or final visit and C-peptide collected at baseline as measured by the meal tolerance test. Meal tolerance test measures blood glucose, insulin, C-peptide and glucagon through blood samples drawn before a meal and at 2 hours after the start of the meal. (NCT01263483)
Timeframe: Baseline and Week 12.

Interventionng·hr/mL (Mean)
Voglibose 0.2 mg TID0.14
Alogliptin 12.5 mg QD0.69
Alogliptin 25 mg QD and Voglibose 0.2 mg TID0.57

[back to top]

Change From Baseline in Fasting C-peptide (Week 12).

The change between the value of fasting C-peptide collected at week 12 or final visit and fasting C-peptide collected at baseline. (NCT01263483)
Timeframe: Baseline and Week 12.

Interventionng/mL (Mean)
Voglibose 0.2 mg TID0.02
Alogliptin 12.5 mg QD0.06
Alogliptin 25 mg QD and Voglibose 0.2 mg TID0.10

[back to top]

Change From Baseline in Fasting C-peptide (Week 2).

The change between the value of fasting C-peptide collected at week 2 and fasting C-peptide collected at baseline. (NCT01263483)
Timeframe: Baseline and Week 2.

Interventionng/mL (Mean)
Voglibose 0.2 mg TID0.03
Alogliptin 12.5 mg QD-0.07
Alogliptin 25 mg QD and Voglibose 0.2 mg TID-0.01

[back to top]

Change From Baseline in Fasting C-peptide (Week 4).

The change between the value of fasting C-peptide collected at week 4 and fasting C-peptide collected at baseline. (NCT01263483)
Timeframe: Baseline and Week 4.

Interventionng/mL (Mean)
Voglibose 0.2 mg TID0.05
Alogliptin 12.5 mg QD0.06
Alogliptin 25 mg QD and Voglibose 0.2 mg TID0.01

[back to top]

Change From Baseline in Fasting C-peptide (Week 8).

The change between the value of fasting C-peptide collected at week 8 and fasting C-peptide collected at baseline. (NCT01263483)
Timeframe: Baseline and Week 8.

Interventionng/mL (Mean)
Voglibose 0.2 mg TID0.07
Alogliptin 12.5 mg QD0.03
Alogliptin 25 mg QD and Voglibose 0.2 mg TID-0.01

[back to top]

Change From Baseline in Fasting Plasma Glucose (Week 12).

The change between the value of fasting plasma glucose collected at week 12 or final visit and fasting plasma glucose collected at baseline. (NCT01263483)
Timeframe: Baseline and Week 12.

Interventionmg/dL (Mean)
Voglibose 0.2 mg TID-5.6
Alogliptin 12.5 mg QD-19.1
Alogliptin 25 mg QD and Voglibose 0.2 mg TID-18.5

[back to top]

Change From Baseline in Fasting Plasma Glucose (Week 2).

The change between the value of fasting plasma glucose collected at week 2 and fasting plasma glucose collected at baseline. (NCT01263483)
Timeframe: Baseline and Week 2

Interventionmg/dL (Mean)
Voglibose 0.2 mg TID-3.5
Alogliptin 12.5 mg QD-15.5
Alogliptin 25 mg QD and Voglibose 0.2 mg TID-18.8

[back to top]

Change From Baseline in Fasting Plasma Glucose (Week 4).

The change between the value of fasting plasma glucose collected at week 4 and fasting plasma glucose collected at baseline. (NCT01263483)
Timeframe: Baseline and Week 4.

Interventionmg/dL (Mean)
Voglibose 0.2 mg TID-0.6
Alogliptin 12.5 mg QD-16.2
Alogliptin 25 mg QD and Voglibose 0.2 mg TID-22.6

[back to top]

Change From Baseline in Fasting Plasma Glucose (Week 8).

The change between the value of fasting plasma glucose collected at week 8 and fasting plasma glucose collected at baseline. (NCT01263483)
Timeframe: Baseline and Week 8.

Interventionmg/dL (Mean)
Voglibose 0.2 mg TID-2.5
Alogliptin 12.5 mg QD-20.8
Alogliptin 25 mg QD and Voglibose 0.2 mg TID-21.9

[back to top]

Change From Baseline in Glucagon Measured by Meal Tolerance Testing (AUC (0-2)).

The change between the value of glucagons collected at week 12 or final visit and glucagons collected at baseline. Meal tolerance test measures blood glucose, insulin, C-peptide and glucagon through blood samples drawn before a meal and at 2 hours after the start of the meal. (NCT01263483)
Timeframe: Baseline and Week 12

Interventionpg·hr/mL (Mean)
Voglibose 0.2 mg TID-0.4
Alogliptin 12.5 mg QD-19.2
Alogliptin 25 mg QD and Voglibose 0.2 mg TID-20.5

[back to top]

Change From Baseline in Glycosylated Hemoglobin (Week 12).

The change in the value of glycosylated hemoglobin (the concentration of glucose bound to hemoglobin as a percent of the absolute maximum that can be bound) collected at week 12 or final visit and glycosylated hemoglobin collected at baseline. (NCT01263483)
Timeframe: Baseline and Week 12.

Interventionpercentage of Glycosylated Hemoglobin (Mean)
Voglibose 0.2 mg TID0.04
Alogliptin 12.5 mg QD-0.96
Alogliptin 25 mg QD and Voglibose 0.2 mg TID-0.91

[back to top]

Change From Baseline in Glycosylated Hemoglobin (Week 2).

The change in the value of glycosylated hemoglobin (the concentration of glucose bound to hemoglobin as a percent of the absolute maximum that can be bound) collected at week 2 and glycosylated hemoglobin collected at baseline. (NCT01263483)
Timeframe: Baseline and Week 2.

Interventionpercentage of Glycosylated Hemoglobin (Mean)
Voglibose 0.2 mg TID-0.01
Alogliptin 12.5 mg QD-0.19
Alogliptin 25 mg QD and Voglibose 0.2 mg TID-0.21

[back to top]

Change From Baseline in Glycosylated Hemoglobin (Week 4).

The change in the value of glycosylated hemoglobin (the concentration of glucose bound to hemoglobin as a percent of the absolute maximum that can be bound) collected at week 4 and glycosylated hemoglobin collected at baseline. (NCT01263483)
Timeframe: Baseline and Week 4.

Interventionpercentage of Glycosylated Hemoglobin (Mean)
Voglibose 0.2 mg TID-0.02
Alogliptin 12.5 mg QD-0.44
Alogliptin 25 mg QD and Voglibose 0.2 mg TID-0.43

[back to top]

Change From Baseline in Glycosylated Hemoglobin (Week 8).

The change in the value of glycosylated hemoglobin (the concentration of glucose bound to hemoglobin as a percent of the absolute maximum that can be bound) collected at week 8 and glycosylated hemoglobin collected at baseline. (NCT01263483)
Timeframe: Baseline and Week 8.

Interventionpercentage of Glycosylated Hemoglobin (Mean)
Voglibose 0.2 mg TID-0.01
Alogliptin 12.5 mg QD-0.74
Alogliptin 25 mg QD and Voglibose 0.2 mg TID-0.75

[back to top]

Change From Baseline in Insulin Measured by Meal Tolerance Testing (AUC(0-2).

The change between the value of insulin collected at week 12 or final visit and insulin collected at baseline as measured by the meal tolerance test. Meal tolerance test measures blood glucose, insulin, C-peptide and glucagon through blood samples drawn before a meal and at 2 hours after the start of the meal. (NCT01263483)
Timeframe: Baseline and Week 12

InterventionμU·hr/mL (Mean)
Voglibose 0.2 mg TID-2.47
Alogliptin 12.5 mg QD4.62
Alogliptin 25 mg QD and Voglibose 0.2 mg TID1.50

[back to top]

Change From Baseline in Blood Glucose Measured by Meal Tolerance Testing (AUC (0-2)) (Week 52).

The change between the value of blood glucose collected at week 52 and blood glucose collected at baseline. Meal tolerance test measures blood glucose, insulin, C-peptide and glucagon through blood samples drawn before a meal and 2 hours after the start of the meal. (NCT01263509)
Timeframe: Baseline and Week 52.

Interventionmg•hr/dL (Mean)
Alogliptin 12.5 mg QD and Voglibose 0.2 mg TID-83.5
Alogliptin 25 mg QD and Voglibose 0.2 mg TID-83.4

[back to top]

Change From Baseline in Insulin Measured by Meal Tolerance Testing (AUC(0-2)) (Week 24).

The change between the value of insulin collected at week 24 and insulin collected at baseline as measured by the meal tolerance test. Meal tolerance test measures blood glucose, insulin, C-peptide and glucagon through blood samples drawn before a meal and 2 hours after the start of the meal. (NCT01263509)
Timeframe: Baseline and Week 24.

InterventionμU•hr/mL (Mean)
Alogliptin 12.5 mg QD and Voglibose 0.2 mg TID4.42
Alogliptin 25 mg QD and Voglibose 0.2 mg TID2.26

[back to top]

Change From Baseline in Insulin Measured by Meal Tolerance Testing (AUC(0-2)) (Week 52).

The change between the value of insulin collected at week 52 and insulin collected at baseline as measured by the meal tolerance test. Meal tolerance test measures blood glucose, insulin, C-peptide and glucagon through blood samples drawn before a meal and 2 hours after the start of the meal. (NCT01263509)
Timeframe: Baseline and Week 52.

InterventionμU•hr/mL (Mean)
Alogliptin 12.5 mg QD and Voglibose 0.2 mg TID-1.28
Alogliptin 25 mg QD and Voglibose 0.2 mg TID0.18

[back to top]

Change From Baseline in Blood Glucose Measured by Meal Tolerance Testing (2-hr Postprandial Value) (Final Visit).

The change between the value of blood glucose collected at week 52 or final visit and blood glucose collected at baseline. Meal tolerance test measures blood glucose, insulin, C-peptide and glucagon through blood samples drawn before a meal and 2 hours after the start of the meal. (NCT01263509)
Timeframe: Baseline and Final Visit (up to Week 52).

Interventionmg/dL (Mean)
Alogliptin 12.5 mg QD and Voglibose 0.2 mg TID39.6
Alogliptin 25 mg QD and Voglibose 0.2 mg TID39.4

[back to top]

Change From Baseline in Blood Glucose Measured by Meal Tolerance Testing (2-hr Postprandial Value) (Week 12).

The change between the value of blood glucose collected at week 12 and blood glucose collected at baseline. Meal tolerance test measures blood glucose, insulin, C-peptide and glucagon through blood samples drawn before a meal and 2 hours after the start of the meal. (NCT01263509)
Timeframe: Baseline and Week 12.

Interventionmg/dL (Mean)
Alogliptin 12.5 mg QD and Voglibose 0.2 mg TID41.2
Alogliptin 25 mg QD and Voglibose 0.2 mg TID37.6

[back to top]

Change From Baseline in Blood Glucose Measured by Meal Tolerance Testing (2-hr Postprandial Value) (Week 24).

The change between the value of blood glucose collected at week 24 and blood glucose collected at baseline. Meal tolerance test measures blood glucose, insulin, C-peptide and glucagon through blood samples drawn before a meal and 2 hours after the start of the meal. (NCT01263509)
Timeframe: Baseline and Week 24.

Interventionmg/dL (Mean)
Alogliptin 12.5 mg QD and Voglibose 0.2 mg TID38.0
Alogliptin 25 mg QD and Voglibose 0.2 mg TID37.1

[back to top]

Change From Baseline in Blood Glucose Measured by Meal Tolerance Testing (2-hr Postprandial Value) (Week 52).

The change between the value of blood glucose collected at week 52 and blood glucose collected at baseline. Meal tolerance test measures blood glucose, insulin, C-peptide and glucagon through blood samples drawn before a meal and 2 hours after the start of the meal. (NCT01263509)
Timeframe: Baseline and Week 52.

Interventionmg/dL (Mean)
Alogliptin 12.5 mg QD and Voglibose 0.2 mg TID39.0
Alogliptin 25 mg QD and Voglibose 0.2 mg TID40.8

[back to top]

Change From Baseline in Blood Glucose Measured by Meal Tolerance Testing (AUC (0-2)) (Final Visit).

The change between the value of blood glucose collected at week 52 or final visit and blood glucose collected at baseline. Meal tolerance test measures blood glucose, insulin, C-peptide and glucagon through blood samples drawn before a meal and 2 hours after the start of the meal. (NCT01263509)
Timeframe: Baseline and Final Visit (up to Week 52).

Interventionmg•hr/dL (Mean)
Alogliptin 12.5 mg QD and Voglibose 0.2 mg TID-77.5
Alogliptin 25 mg QD and Voglibose 0.2 mg TID-82.2

[back to top]

Change From Baseline in Blood Glucose Measured by Meal Tolerance Testing (AUC (0-2)) (Week 12).

The change between the value of blood glucose collected at week 12 and blood glucose collected at baseline. Meal tolerance test measures blood glucose, insulin, C-peptide and glucagon through blood samples drawn before a meal and 2 hours after the start of the meal. (NCT01263509)
Timeframe: Baseline and Week 12.

Interventionmg•hr/dL (Mean)
Alogliptin 12.5 mg QD and Voglibose 0.2 mg TID-73.2
Alogliptin 25 mg QD and Voglibose 0.2 mg TID-76.8

[back to top]

Change From Baseline in Blood Glucose Measured by Meal Tolerance Testing (AUC (0-2)) (Week 24).

The change between the value of blood glucose collected at week 24 and blood glucose collected at baseline. Meal tolerance test measures blood glucose, insulin, C-peptide and glucagon through blood samples drawn before a meal and 2 hours after the start of the meal. (NCT01263509)
Timeframe: Baseline and Week 24.

Interventionmg•hr/dL (Mean)
Alogliptin 12.5 mg QD and Voglibose 0.2 mg TID-69.0
Alogliptin 25 mg QD and Voglibose 0.2 mg TID-70.4

[back to top]

Change From Baseline in Fasting C-peptide (Week 28).

The change between the value of fasting C-peptide collected at week 28 and fasting C-peptide collected at baseline. (NCT01263509)
Timeframe: Baseline and Week 28.

Interventionng/mL (Mean)
Alogliptin 12.5 mg QD and Voglibose 0.2 mg TID0.18
Alogliptin 25 mg QD and Voglibose 0.2 mg TID0.25

[back to top]

Change From Baseline in C-peptide Measured by Meal Tolerance Testing (AUC(0-2)) (Final Visit).

The change between the value of C-peptide collected at week 52 or final visit and C-peptide collected at baseline as measured by the meal tolerance test. Meal tolerance test measures blood glucose, insulin, C-peptide and glucagon through blood samples drawn before a meal and 2 hours after the start of the meal. (NCT01263509)
Timeframe: Baseline and Final Visit (up to Week 52).

Interventionng•hr/mL (Mean)
Alogliptin 12.5 mg QD and Voglibose 0.2 mg TID1.05
Alogliptin 25 mg QD and Voglibose 0.2 mg TID0.80

[back to top]

Change From Baseline in C-peptide Measured by Meal Tolerance Testing (AUC(0-2)) (Week 12).

The change between the value of C-peptide collected at week 12 and C-peptide collected at baseline as measured by the meal tolerance test. Meal tolerance test measures blood glucose, insulin, C-peptide and glucagon through blood samples drawn before a meal and 2 hours after the start of the meal. (NCT01263509)
Timeframe: Baseline and Week 12.

Interventionng•hr/mL (Mean)
Alogliptin 12.5 mg QD and Voglibose 0.2 mg TID0.71
Alogliptin 25 mg QD and Voglibose 0.2 mg TID0.71

[back to top]

Change From Baseline in C-peptide Measured by Meal Tolerance Testing (AUC(0-2)) (Week 24).

The change between the value of C-peptide collected at week 24 and C-peptide collected at baseline as measured by the meal tolerance test. Meal tolerance test measures blood glucose, insulin, C-peptide and glucagon through blood samples drawn before a meal and 2 hours after the start of the meal. (NCT01263509)
Timeframe: Baseline and Week 24.

Interventionng•hr/mL (Mean)
Alogliptin 12.5 mg QD and Voglibose 0.2 mg TID1.38
Alogliptin 25 mg QD and Voglibose 0.2 mg TID1.12

[back to top]

Change From Baseline in C-peptide Measured by Meal Tolerance Testing (AUC(0-2)) (Week 52).

The change between the value of C-peptide collected at week 52 and C-peptide collected at baseline as measured by the meal tolerance test. Meal tolerance test measures blood glucose, insulin, C-peptide and glucagon through blood samples drawn before a meal and 2 hours after the start of the meal. (NCT01263509)
Timeframe: Baseline and Week 52.

Interventionng•hr/mL (Mean)
Alogliptin 12.5 mg QD and Voglibose 0.2 mg TID0.96
Alogliptin 25 mg QD and Voglibose 0.2 mg TID2.18

[back to top]

Change From Baseline in Fasting C-peptide (Final Visit).

The change between the value of fasting C-peptide collected at week 52 or final visit and fasting C-peptide collected at baseline. (NCT01263509)
Timeframe: Baseline and Final Visit (up to Week 52).

Interventionng/mL (Mean)
Alogliptin 12.5 mg QD and Voglibose 0.2 mg TID0.31
Alogliptin 25 mg QD and Voglibose 0.2 mg TID0.29

[back to top]

Change From Baseline in Fasting C-peptide (Week 12).

The change between the value of fasting C-peptide collected at week 12 and fasting C-peptide collected at baseline. (NCT01263509)
Timeframe: Baseline and Week 12.

Interventionng/mL (Mean)
Alogliptin 12.5 mg QD and Voglibose 0.2 mg TID0.10
Alogliptin 25 mg QD and Voglibose 0.2 mg TID0.13

[back to top]

Change From Baseline in Fasting C-peptide (Week 16).

The change between the value of fasting C-peptide collected at week 16 and fasting C-peptide collected at baseline. (NCT01263509)
Timeframe: Baseline and Week 16.

Interventionng/mL (Mean)
Alogliptin 12.5 mg QD and Voglibose 0.2 mg TID0.24
Alogliptin 25 mg QD and Voglibose 0.2 mg TID0.21

[back to top]

Change From Baseline in Fasting C-peptide (Week 20).

The change between the value of fasting C-peptide collected at week 20 and fasting C-peptide collected at baseline. (NCT01263509)
Timeframe: Baseline and Week 20.

Interventionng/mL (Mean)
Alogliptin 12.5 mg QD and Voglibose 0.2 mg TID0.24
Alogliptin 25 mg QD and Voglibose 0.2 mg TID0.15

[back to top]

Change From Baseline in Fasting C-peptide (Week 24).

The change between the value of fasting C-peptide collected at week 24 and fasting C-peptide collected at baseline. (NCT01263509)
Timeframe: Baseline and Week 24.

Interventionng/mL (Mean)
Alogliptin 12.5 mg QD and Voglibose 0.2 mg TID0.19
Alogliptin 25 mg QD and Voglibose 0.2 mg TID0.14

[back to top]

Number of Participants With Adverse Events.

A treatment-emergent adverse event (TEAE) is defined as an adverse event with an onset that occurs after receiving study drug and within 30 days after receiving the last dose of study drug. A TEAE may also be a pre-treatment adverse event or a concurrent medical condition diagnosed prior to the date of first dose of study drug, which increases in intensity after the start of dosing. Adverse events data with onset occurring more than 30 days after last dose of study drug (AE start date - last dose date >30) will be listed, but not included in the summary tables below. (NCT01263509)
Timeframe: 52 Weeks.

,
Interventionparticipants (Number)
Serious Adverse EventSerious Adverse Event Related to Study DrugOther Adverse Events (Incidence ≥3%)
Alogliptin 12.5 mg QD and Voglibose 0.2 mg TID6085
Alogliptin 25 mg QD and Voglibose 0.2 mg TID7173

[back to top]

Change From Baseline in Fasting C-peptide (Week 32).

The change between the value of fasting C-peptide collected at week 32 and fasting C-peptide collected at baseline. (NCT01263509)
Timeframe: Baseline and Week 32.

Interventionng/mL (Mean)
Alogliptin 12.5 mg QD and Voglibose 0.2 mg TID0.47
Alogliptin 25 mg QD and Voglibose 0.2 mg TID0.31

[back to top]

Change From Baseline in Fasting C-peptide (Week 36).

The change between the value of fasting C-peptide collected at week 36 and fasting C-peptide collected at baseline. (NCT01263509)
Timeframe: Baseline and Week 36.

Interventionng/mL (Mean)
Alogliptin 12.5 mg QD and Voglibose 0.2 mg TID0.33
Alogliptin 25 mg QD and Voglibose 0.2 mg TID0.38

[back to top]

Change From Baseline in Fasting C-peptide (Week 40).

The change between the value of fasting C-peptide collected at week 40 and fasting C-peptide collected at baseline. (NCT01263509)
Timeframe: Baseline and Week 40.

Interventionng/mL (Mean)
Alogliptin 12.5 mg QD and Voglibose 0.2 mg TID0.30
Alogliptin 25 mg QD and Voglibose 0.2 mg TID0.37

[back to top]

Change From Baseline in Fasting C-peptide (Week 44).

The change between the value of fasting C-peptide collected at week 44 and fasting C-peptide collected at baseline. (NCT01263509)
Timeframe: Baseline and Week 44.

Interventionng/mL (Mean)
Alogliptin 12.5 mg QD and Voglibose 0.2 mg TID0.08
Alogliptin 25 mg QD and Voglibose 0.2 mg TID0.25

[back to top]

Change From Baseline in Fasting C-peptide (Week 48).

The change between the value of fasting C-peptide collected at week 48 and fasting C-peptide collected at baseline. (NCT01263509)
Timeframe: Baseline and Week 48.

Interventionng/mL (Mean)
Alogliptin 12.5 mg QD and Voglibose 0.2 mg TID0.45
Alogliptin 25 mg QD and Voglibose 0.2 mg TID0.38

[back to top]

Change From Baseline in Fasting C-peptide (Week 52).

The change between the value of fasting C-peptide collected at week 52 and fasting C-peptide collected at baseline. (NCT01263509)
Timeframe: Baseline and Week 52.

Interventionng/mL (Mean)
Alogliptin 12.5 mg QD and Voglibose 0.2 mg TID0.80
Alogliptin 25 mg QD and Voglibose 0.2 mg TID0.40

[back to top]

Change From Baseline in Fasting C-peptide (Week 8).

The change between the value of fasting C-peptide collected at week 8 and fasting C-peptide collected at baseline. (NCT01263509)
Timeframe: Baseline and Week 8.

Interventionng/mL (Mean)
Alogliptin 12.5 mg QD and Voglibose 0.2 mg TID0.05
Alogliptin 25 mg QD and Voglibose 0.2 mg TID0.11

[back to top]

Change From Baseline in Fasting Plasma Glucose (Final Visit).

The change between the value of fasting plasma glucose collected at week 52 or final visit and fasting plasma glucose collected at baseline. (NCT01263509)
Timeframe: Baseline and Final Visit (up to Week 52).

Interventionmg/dL (Mean)
Alogliptin 12.5 mg QD and Voglibose 0.2 mg TID-17.5
Alogliptin 25 mg QD and Voglibose 0.2 mg TID-23.3

[back to top]

Change From Baseline in Fasting Plasma Glucose (Week 12).

The change between the value of fasting plasma glucose collected at week 12 and fasting plasma glucose collected at baseline. (NCT01263509)
Timeframe: Baseline and Week 12.

Interventionmg/dL (Mean)
Alogliptin 12.5 mg QD and Voglibose 0.2 mg TID-17.1
Alogliptin 25 mg QD and Voglibose 0.2 mg TID-18.8

[back to top]

Change From Baseline in Fasting Plasma Glucose (Week 16).

The change between the value of fasting plasma glucose collected at week 16 and fasting plasma glucose collected at baseline. (NCT01263509)
Timeframe: Baseline and Week 16.

Interventionmg/dL (Mean)
Alogliptin 12.5 mg QD and Voglibose 0.2 mg TID-16.0
Alogliptin 25 mg QD and Voglibose 0.2 mg TID-15.3

[back to top]

Change From Baseline in Fasting Plasma Glucose (Week 20).

The change between the value of fasting plasma glucose collected at week 20 and fasting plasma glucose collected at baseline. (NCT01263509)
Timeframe: Baseline and Week 20.

Interventionmg/dL (Mean)
Alogliptin 12.5 mg QD and Voglibose 0.2 mg TID-15.6
Alogliptin 25 mg QD and Voglibose 0.2 mg TID-15.0

[back to top]

Change From Baseline in Fasting Plasma Glucose (Week 24).

The change between the value of fasting plasma glucose collected at week 24 and fasting plasma glucose collected at baseline. (NCT01263509)
Timeframe: Baseline and Week 24.

Interventionmg/dL (Mean)
Alogliptin 12.5 mg QD and Voglibose 0.2 mg TID-13.8
Alogliptin 25 mg QD and Voglibose 0.2 mg TID-15.6

[back to top]

Change From Baseline in Fasting Plasma Glucose (Week 28).

The change between the value of fasting plasma glucose collected at week 28 and fasting plasma glucose collected at baseline. (NCT01263509)
Timeframe: Baseline and Week 28.

Interventionmg/dL (Mean)
Alogliptin 12.5 mg QD and Voglibose 0.2 mg TID-14.5
Alogliptin 25 mg QD and Voglibose 0.2 mg TID-21.9

[back to top]

Change From Baseline in Fasting Plasma Glucose (Week 32).

The change between the value of fasting plasma glucose collected at week 32 and fasting plasma glucose collected at baseline. (NCT01263509)
Timeframe: Baseline and Week 32.

Interventionmg/dL (Mean)
Alogliptin 12.5 mg QD and Voglibose 0.2 mg TID-17.7
Alogliptin 25 mg QD and Voglibose 0.2 mg TID-20.1

[back to top]

Change From Baseline in Fasting Plasma Glucose (Week 36).

The change between the value of fasting plasma glucose collected at week 36 and fasting plasma glucose collected at baseline. (NCT01263509)
Timeframe: Baseline and Week 36.

Interventionmg/dL (Mean)
Alogliptin 12.5 mg QD and Voglibose 0.2 mg TID-17.3
Alogliptin 25 mg QD and Voglibose 0.2 mg TID-22.6

[back to top]

Change From Baseline in Fasting Plasma Glucose (Week 40).

The change between the value of fasting plasma glucose collected at week 40 and fasting plasma glucose collected at baseline. (NCT01263509)
Timeframe: Baseline and Week 40.

Interventionmg/dL (Mean)
Alogliptin 12.5 mg QD and Voglibose 0.2 mg TID-19.7
Alogliptin 25 mg QD and Voglibose 0.2 mg TID-22.8

[back to top]

Change From Baseline in Fasting Plasma Glucose (Week 44).

The change between the value of fasting plasma glucose collected at week 44 and fasting plasma glucose collected at baseline. (NCT01263509)
Timeframe: Baseline and Week 44.

Interventionmg/dL (Mean)
Alogliptin 12.5 mg QD and Voglibose 0.2 mg TID-21.5
Alogliptin 25 mg QD and Voglibose 0.2 mg TID-24.4

[back to top]

Change From Baseline in Fasting Plasma Glucose (Week 48).

The change between the value of fasting plasma glucose collected at week 48 and fasting plasma glucose collected at baseline. (NCT01263509)
Timeframe: Baseline and Week 48.

Interventionmg/dL (Mean)
Alogliptin 12.5 mg QD and Voglibose 0.2 mg TID-20.5
Alogliptin 25 mg QD and Voglibose 0.2 mg TID-23.1

[back to top]

Change From Baseline in Fasting Plasma Glucose (Week 52).

The change between the value of fasting plasma glucose collected at week 52 and fasting plasma glucose collected at baseline. (NCT01263509)
Timeframe: Baseline and Week 52.

Interventionmg/dL (Mean)
Alogliptin 12.5 mg QD and Voglibose 0.2 mg TID-20.7
Alogliptin 25 mg QD and Voglibose 0.2 mg TID-24.0

[back to top]

Change From Baseline in Fasting Plasma Glucose (Week 8).

The change between the value of fasting plasma glucose collected at week 8 and fasting plasma glucose collected at baseline. (NCT01263509)
Timeframe: Baseline and Week 8.

Interventionmg/dL (Mean)
Alogliptin 12.5 mg QD and Voglibose 0.2 mg TID-18.2
Alogliptin 25 mg QD and Voglibose 0.2 mg TID-20.4

[back to top]

Change From Baseline in Glucagon Measured by Meal Tolerance Testing (AUC (0-2)) (Final Visit).

The change between the value of glucagons collected at week 52 or final visit and glucagons collected at baseline. Meal tolerance test measures blood glucose, insulin, C-peptide and glucagon through blood samples drawn before a meal and 2 hours after the start of the meal. (NCT01263509)
Timeframe: Baseline and Final Visit (up to Week 52).

Interventionpg•hr/mL (Mean)
Alogliptin 12.5 mg QD and Voglibose 0.2 mg TID-11.7
Alogliptin 25 mg QD and Voglibose 0.2 mg TID-20.9

[back to top]

Change From Baseline in Glucagon Measured by Meal Tolerance Testing (AUC (0-2)) (Week 12).

The change between the value of glucagons collected at week 12 and glucagons collected at baseline. Meal tolerance test measures blood glucose, insulin, C-peptide and glucagon through blood samples drawn before a meal and 2 hours after the start of the meal. (NCT01263509)
Timeframe: Baseline and Week 12.

Interventionpg•hr/mL (Mean)
Alogliptin 12.5 mg QD and Voglibose 0.2 mg TID-14.3
Alogliptin 25 mg QD and Voglibose 0.2 mg TID-20.0

[back to top]

Change From Baseline in Glucagon Measured by Meal Tolerance Testing (AUC (0-2)) (Week 24).

The change between the value of glucagons collected at week 24 and glucagons collected at baseline. Meal tolerance test measures blood glucose, insulin, C-peptide and glucagon through blood samples drawn before a meal and 2 hours after the start of the meal. (NCT01263509)
Timeframe: Baseline and Week 24.

Interventionpg•hr/mL (Mean)
Alogliptin 12.5 mg QD and Voglibose 0.2 mg TID-4.6
Alogliptin 25 mg QD and Voglibose 0.2 mg TID-6.8

[back to top]

Change From Baseline in Glucagon Measured by Meal Tolerance Testing (AUC (0-2)) (Week 52).

The change between the value of glucagons collected at week 52 and glucagons collected at baseline. Meal tolerance test measures blood glucose, insulin, C-peptide and glucagon through blood samples drawn before a meal and 2 hours after the start of the meal. (NCT01263509)
Timeframe: Baseline and Week 52.

Interventionpg•hr/mL (Mean)
Alogliptin 12.5 mg QD and Voglibose 0.2 mg TID-12.0
Alogliptin 25 mg QD and Voglibose 0.2 mg TID-22.2

[back to top]

Change From Baseline in Glycosylated Hemoglobin (Final Visit).

The change in the value of glycosylated hemoglobin (the concentration of glucose bound to hemoglobin as a percent of the absolute maximum that can be bound) collected at week 52 or final visit and glycosylated hemoglobin collected at baseline. (NCT01263509)
Timeframe: Baseline and Final Visit (up to Week 52).

Interventionpercentage of Glycosylated Hemoglobin (Mean)
Alogliptin 12.5 mg QD and Voglibose 0.2 mg TID-0.81
Alogliptin 25 mg QD and Voglibose 0.2 mg TID-0.89

[back to top]

Change From Baseline in Glycosylated Hemoglobin (Week 12).

The change in the value of glycosylated hemoglobin (the concentration of glucose bound to hemoglobin as a percent of the absolute maximum that can be bound) collected at week 12 and glycosylated hemoglobin collected at baseline. (NCT01263509)
Timeframe: Baseline and Week 12.

Interventionpercentage of Glycosylated Hemoglobin (Mean)
Alogliptin 12.5 mg QD and Voglibose 0.2 mg TID-0.89
Alogliptin 25 mg QD and Voglibose 0.2 mg TID-0.96

[back to top]

Change From Baseline in Glycosylated Hemoglobin (Week 16).

The change in the value of glycosylated hemoglobin (the concentration of glucose bound to hemoglobin as a percent of the absolute maximum that can be bound) collected at week 16 and glycosylated hemoglobin collected at baseline. (NCT01263509)
Timeframe: Baseline and Week 16.

Interventionpercentage of Glycosylated Hemoglobin (Mean)
Alogliptin 12.5 mg QD and Voglibose 0.2 mg TID-0.91
Alogliptin 25 mg QD and Voglibose 0.2 mg TID-0.96

[back to top]

Change From Baseline in Glycosylated Hemoglobin (Week 20).

The change in the value of glycosylated hemoglobin (the concentration of glucose bound to hemoglobin as a percent of the absolute maximum that can be bound) collected at week 20 and glycosylated hemoglobin collected at baseline. (NCT01263509)
Timeframe: Baseline and Week 20.

Interventionpercentage of Glycosylated Hemoglobin (Mean)
Alogliptin 12.5 mg QD and Voglibose 0.2 mg TID-0.90
Alogliptin 25 mg QD and Voglibose 0.2 mg TID-0.89

[back to top]

Change From Baseline in Glycosylated Hemoglobin (Week 24).

The change in the value of glycosylated hemoglobin (the concentration of glucose bound to hemoglobin as a percent of the absolute maximum that can be bound) collected at week 24 and glycosylated hemoglobin collected at baseline. (NCT01263509)
Timeframe: Baseline and Week 24.

Interventionpercentage of Glycosylated Hemoglobin (Mean)
Alogliptin 12.5 mg QD and Voglibose 0.2 mg TID-0.83
Alogliptin 25 mg QD and Voglibose 0.2 mg TID-0.88

[back to top]

Change From Baseline in Glycosylated Hemoglobin (Week 28).

The change in the value of glycosylated hemoglobin (the concentration of glucose bound to hemoglobin as a percent of the absolute maximum that can be bound) collected at week 28 and glycosylated hemoglobin collected at baseline. (NCT01263509)
Timeframe: Baseline and Week 28.

Interventionpercentage of Glycosylated Hemoglobin (Mean)
Alogliptin 12.5 mg QD and Voglibose 0.2 mg TID-0.81
Alogliptin 25 mg QD and Voglibose 0.2 mg TID-0.89

[back to top]

Change From Baseline in Glycosylated Hemoglobin (Week 32).

The change in the value of glycosylated hemoglobin (the concentration of glucose bound to hemoglobin as a percent of the absolute maximum that can be bound) collected at week 32 and glycosylated hemoglobin collected at baseline. (NCT01263509)
Timeframe: Baseline and Week 32.

Interventionpercentage of Glycosylated Hemoglobin (Mean)
Alogliptin 12.5 mg QD and Voglibose 0.2 mg TID-0.80
Alogliptin 25 mg QD and Voglibose 0.2 mg TID-0.85

[back to top]

Change From Baseline in Glycosylated Hemoglobin (Week 36).

The change in the value of glycosylated hemoglobin (the concentration of glucose bound to hemoglobin as a percent of the absolute maximum that can be bound) collected at week 36 and glycosylated hemoglobin collected at baseline. (NCT01263509)
Timeframe: Baseline and Week 36.

Interventionpercentage of Glycosylated Hemoglobin (Mean)
Alogliptin 12.5 mg QD and Voglibose 0.2 mg TID-0.82
Alogliptin 25 mg QD and Voglibose 0.2 mg TID-0.90

[back to top]

Change From Baseline in Glycosylated Hemoglobin (Week 40).

The change in the value of glycosylated hemoglobin (the concentration of glucose bound to hemoglobin as a percent of the absolute maximum that can be bound) collected at week 40 and glycosylated hemoglobin collected at baseline. (NCT01263509)
Timeframe: Baseline and Week 40.

Interventionpercentage of Glycosylated Hemoglobin (Mean)
Alogliptin 12.5 mg QD and Voglibose 0.2 mg TID-0.78
Alogliptin 25 mg QD and Voglibose 0.2 mg TID-0.92

[back to top]

Change From Baseline in Glycosylated Hemoglobin (Week 44).

The change in the value of glycosylated hemoglobin (the concentration of glucose bound to hemoglobin as a percent of the absolute maximum that can be bound) collected at week 44 and glycosylated hemoglobin collected at baseline. (NCT01263509)
Timeframe: Baseline and Week 44.

Interventionpercentage of Glycosylated Hemoglobin (Mean)
Alogliptin 12.5 mg QD and Voglibose 0.2 mg TID-0.88
Alogliptin 25 mg QD and Voglibose 0.2 mg TID-0.94

[back to top]

Change From Baseline in Glycosylated Hemoglobin (Week 48).

The change in the value of glycosylated hemoglobin (the concentration of glucose bound to hemoglobin as a percent of the absolute maximum that can be bound) collected at week 48 and glycosylated hemoglobin collected at baseline. (NCT01263509)
Timeframe: Baseline and Week 48.

Interventionpercentage of Glycosylated Hemoglobin (Mean)
Alogliptin 12.5 mg QD and Voglibose 0.2 mg TID-0.92
Alogliptin 25 mg QD and Voglibose 0.2 mg TID-0.94

[back to top]

Change From Baseline in Glycosylated Hemoglobin (Week 52).

The change in the value of glycosylated hemoglobin (the concentration of glucose bound to hemoglobin as a percent of the absolute maximum that can be bound) collected at week 52 and glycosylated hemoglobin collected at baseline. (NCT01263509)
Timeframe: Baseline and Week 52.

Interventionpercentage of Glycosylated Hemoglobin (Mean)
Alogliptin 12.5 mg QD and Voglibose 0.2 mg TID-0.95
Alogliptin 25 mg QD and Voglibose 0.2 mg TID-0.95

[back to top]

Change From Baseline in Glycosylated Hemoglobin (Week 8).

The change in the value of glycosylated hemoglobin (the concentration of glucose bound to hemoglobin as a percent of the absolute maximum that can be bound) collected at week 8 and glycosylated hemoglobin collected at baseline. (NCT01263509)
Timeframe: Baseline and Week 8.

Interventionpercentage of Glycosylated Hemoglobin (Mean)
Alogliptin 12.5 mg QD and Voglibose 0.2 mg TID-0.69
Alogliptin 25 mg QD and Voglibose 0.2 mg TID-0.79

[back to top]

Change From Baseline in Insulin Measured by Meal Tolerance Testing (AUC(0-2)) (Final Visit).

The change between the value of insulin collected at week 52 or final visit and insulin collected at baseline as measured by the meal tolerance test. Meal tolerance test measures blood glucose, insulin, C-peptide and glucagon through blood samples drawn before a meal and 2 hours after the start of the meal. (NCT01263509)
Timeframe: Baseline and Final Visit (up to Week 52).

InterventionμU•hr/mL (Mean)
Alogliptin 12.5 mg QD and Voglibose 0.2 mg TID-0.61
Alogliptin 25 mg QD and Voglibose 0.2 mg TID0.01

[back to top]

Change From Baseline in Insulin Measured by Meal Tolerance Testing (AUC(0-2)) (Week 12).

The change between the value of insulin collected at week 12 and insulin collected at baseline as measured by the meal tolerance test. Meal tolerance test measures blood glucose, insulin, C-peptide and glucagon through blood samples drawn before a meal and 2 hours after the start of the meal. (NCT01263509)
Timeframe: Baseline and Week 12.

InterventionμU•hr/mL (Mean)
Alogliptin 12.5 mg QD and Voglibose 0.2 mg TID3.05
Alogliptin 25 mg QD and Voglibose 0.2 mg TID2.95

[back to top]

Improvement in Depression Symptoms by Children's Depression Rating Scale (CDRS)

The Children's Depression Rating Scale (CDRS) is a clinician-rated instrument with 17 items scored on a 1 to 5 or 1 to 7 scale. A rating of 1 indicates normal, thus the minimum score is 17. The maximum score is 113. Scores of 20-30 suggest borderline depression. Scores of 40-60 indicate moderate depression. (NCT01396486)
Timeframe: Baseline to endpoint (12 weeks or last observation carried forward if dropped prior to week 12)

Interventionunits on a scale (Mean)
Omega-3/Placebo-4.9
Placebo/Inositol-5.6
Omega-3/Inositol-10.8

[back to top]

Improvement in Mania Symptoms by Change in Young Mania Rating Scale (YMRS)

The Young Mania Rating Scale (YMRS) consists of 7 items rated on a scale from 0 (symptoms not present) to 4 (symptoms extremely severe) and 4 items rated on a scale from 0 (symptom not present) to 8 (symptom extremely severe).The YMRS score ranges from 0-60. Questions are asked about the last week. A higher score signifies more severe manic symptoms. (NCT01396486)
Timeframe: Baseline to endpoint (12 weeks or last observation carried forward if dropped prior to week 12)

Interventionunits on a scale (Mean)
Omega-3/Placebo-4.8
Placebo/Inositol-6.4
Omega-3/Inositol-10.2

[back to top]

Treatment Emergent Adverse Events

The study was terminated early so no efficacy analysis was done, safety data are reported. (NCT01674010)
Timeframe: up to 48 weeks

Interventionparticipants (Number)
Open Treatment Phase 1 ELND005 500 mg BID153
Phase 2 Placebo45
Phase 2 ELND005 500 mg BID45

[back to top]

Change From Baseline in ADCS-ADL Scores

The Alzheimer's Disease Cooperative Study-Activities of Daily Living (ADCS-ADL) (Galasko et al 1997) is a functional assessment that measures instrumental and basic activities of daily living. The total score for the 23-item ADCS-ADL ranges from 0 to 78 points, with lower scores indicating greater impairment in function. (NCT01735630)
Timeframe: Week 12

Interventionunits on a scale (Mean)
ELND005-1.458
Placebo-2.229

[back to top]

Change From Baseline in MMSE Scores

The Mini-Mental State Exam (MMSE) (Folstein et al 1975) is a brief cognitive test assessing general cognitive function that has been employed in numerous clinical trials of products approved for the treatment of AD. The score can range from 0 to 30, with lower scores indicating greater impairment in function. (NCT01735630)
Timeframe: Week 12

Interventionunits on a scale (Mean)
ELND005-0.3
Placebo-0.4

[back to top]

Change From Baseline in Modified-ADCS-CGIC Agitation Scores

The Alzheimer's Disease Cooperative Study-Clinical Global Impression of Change (ADCS-CGIC) is a widely used scale for the global assessment of change in AD trials.It is a 7-point Likert scale that ranges from marked improvement scored as 1 to marked worsening scored as 7, with no change scored as 4. The range is from 1 to 7. Higher scores indicate worsening agitation. (NCT01735630)
Timeframe: Week 12

Interventionunits on a scale (Mean)
ELND0053.6
Placebo3.4

[back to top]

Change From Baseline in NPI Total Scores

The NPI (Cummings et al 1994) is a behavioral measure that assesses psychopathology in dementia subjects. It evaluates 12 neuropsychiatric disturbances common in dementia: delusions, hallucinations, agitation/aggression, dysphoria, anxiety, apathy, irritability, euphoria, disinhibition, aberrant motor behavior, nighttime behavior disturbances, and appetite and eating abnormalities. Higher scores on the NPI are associated with greater frequency and severity of symptoms. The scale range is 0-144. (NCT01735630)
Timeframe: Week 12

Interventionunits on a scale (Mean)
ELND005-14.38
Placebo-15.12

[back to top]

Change From Baseline in NPI-C Combined Agitation and Aggression Subscores (NPI-C A+A).

The NPI-C (de Medeiros et al 2010) is a validated and reliable behavioral measure that assesses psychopathology in dementia subjects. It evaluates 14 neuropsychiatric disturbances common in dementia.Higher scores on the NPI-C are associated with a greater clinical severity of symptoms. The NPI-C Agitation and Aggression score ranges from 0-63. The analysis of the NPI-C A+A score was performed on the mITT population. (NCT01735630)
Timeframe: Week 12

Interventionunits on a scale (Mean)
ELND005-4.3
Placebo-4.2

[back to top]

Number of Participants Experiencing Treatment Emergent Adverse Events

To evaluate the safety and tolerability of ELND005 treatment with up to 36 weeks exposure, in Moderate to Severe AD patients with agitation and aggression. (NCT01766336)
Timeframe: 36 weeks

Interventionparticipants (Number)
ELND005/ELND005105
Placebo/ELND00591

[back to top]

The Massachusetts General Hospital (MGH) Hairpulling Scale

The entire study for an individual subject will last 10 weeks. Every 2 weeks the subject will take the MGH Hairpulling Scale for the duration of the 10 weeks, baseline and final visits will be use for general final outcome assessment. The scale itself asses severity of hair pulling. (NCT01875445)
Timeframe: Once every two weeks for the 10 weeks of the study

Interventionunits on a scale (Mean)
Placebo14.5
Inositol13.2

[back to top]

The National Institute of Mental Health Trichotillomania Symptom Severity Scale (NIMH-TSS)

The entire study for an individual subject will last 10 weeks. Every 2 weeks the subject will take the NIMH-TSS for the duration of the 10 weeks, but only baseline and final values will be used for general final outcome assessment. The scale itself asses severity of hair pulling. (NCT01875445)
Timeframe: Once every two weeks for the 10 weeks of the study

Interventionunits on a scale (Mean)
Placebo8.4
Inositol8.4

[back to top]

Number of Participants With Unfavorable Outcome, Defined as Severe Retinopathy of Prematurity (ROP) or Death Prior to Reaching Acute/Final ROP Status

Death is defined as from any cause before Acute/Final ROP status is determined. ROP was identified by routine ophthalmologic examinations beginning at the latter of 31 weeks PMA or 4-6 weeks chronologic age. The favorable ROP endpoint requires that no ROP, or only mild ROP has occurred in both eyes and the eyes have matured beyond the risk of developing Type 1 ROP (severity meeting criteria for surgical intervention). The unfavorable ROP endpoint requires that one or both eyes reach Type 1 ROP. When ROP did not resolve by the time of discharge, participants were followed as outpatients until reaching an ROP endpoint, up to 55 weeks PMA. Since incomplete follow up is more likely among participants with mild or no ROP than for those with aggressive ROP, an independent adjudication process assigned an ROP endpoint of 'most likely never had Type 1 ROP', or 'most likely developed Type 1 ROP' based on clinical and ROP data review to reduce possible missing data bias. (NCT01954082)
Timeframe: by 55 weeks PMA

InterventionParticipants (Count of Participants)
Myo-Inositol 5% Injection91
5% Glucose(Dextrose)66

[back to top]

Number of Participants With All Cause Death Before Retinopathy of Prematurity (ROP) Endpoint

Defined as death from any cause following randomization through primary study follow-up (up to 55 weeks postmenstrual age (PMA)) (NCT01954082)
Timeframe: by 55 weeks PMA age

InterventionParticipants (Count of Participants)
Myo-Inositol 5% Injection50
5% Glucose(Dextrose)33

[back to top]

Number of Participants With Any Retinopathy of Prematurity (ROP)

ROP was identified by routine ophthalmologic examinations beginning at the latter of 31 weeks PMA or 4-6 weeks chronologic age. Any ROP is defined as ROP of any severity that is observed on at least 2 independent examinations in either eye through the time that Acute/Final ROP status is reached (up to 55 weeks postmenstrual age (PMA)). (NCT01954082)
Timeframe: by 55 weeks PMA

InterventionParticipants (Count of Participants)
Myo-Inositol 5% Injection171
5% Glucose(Dextrose)183

[back to top]

Number of Participants With Bronchopulmonary Dysplasia (BPD)

BPD is defined as supplemental oxygen required to maintain an oxygenation saturation of >90% at 36 weeks postmenstrual age (PMA) (NICHD physiologic definition). (NCT01954082)
Timeframe: 36 weeks PMA

InterventionParticipants (Count of Participants)
Myo-Inositol 5% Injection159
5% Glucose(Dextrose)165

[back to top]

Number of Participants With Bronchopulmonary Dysplasia (BPD) or Death From BPD

BPD is defined as supplemental oxygen required to maintain an oxygenation saturation of >90% at 36 weeks PMA (NICHD physiologic definition). Death from BPD prior to 37 weeks postmenstrual age (PMA) is defined when the cause of death is certified by the Center PI as BPD being the primary cause, or a significant co-contributing cause of death. (NCT01954082)
Timeframe: prior to 37 weeks PMA

InterventionParticipants (Count of Participants)
Myo-Inositol 5% Injection203
5% Glucose(Dextrose)195

[back to top]

Number of Participants With Severe Intraventricular Hemorrhage (IVH)

Severe IVH is defined as IVH Grades 3 or 4 on either side of the brain. The evaluation for IVH occurs early (within 28 days from birth) via a cranial sonogram and is classified as described by Papile. (NCT01954082)
Timeframe: by 28 days PMA

InterventionParticipants (Count of Participants)
Myo-Inositol 5% Injection51
5% Glucose(Dextrose)50

[back to top]

Number of Participants With Type 2 or More Severe Retinopathy of Prematurity (ROP)

Defined as one or both eyes reaching Type 2 ROP (ETROP 2003) or the more severe Type 1 ROP (as defined previously) through the time that Acute/Final ROP status is reached (up to 55 weeks postmenstrual age (PMA)). Type 2 ROP is defined as (ETROP 2003): Stage 3 ROP without Plus Disease (i.e. Zone II) or Stage 1 or 2 ROP without Plus Disease (i.e. Zone I). (NCT01954082)
Timeframe: by 55 weeks PMA

InterventionParticipants (Count of Participants)
Myo-Inositol 5% Injection125
5% Glucose(Dextrose)142

[back to top]

Fetal Enrichment of Mannose

The infusion of D-[U-13C]mannose and [U-13C]myoinositol into the maternal circulation is used to establish the degree of transplacental flux of these 2 carbohydrates and to determine if there is evidence of fetal and/or placental production of either of these substrates. (NCT02397291)
Timeframe: Measured at time of cesarean delivery

InterventionG/DL (Mean)
Placebo/Control Group58.54
Study Group (IUGR)76.50

[back to top]

Fetal Enrichment of Myoinositol

The infusion of D-[U-13C]mannose and [U-13C]myoinositol into the maternal circulation is used to establish the degree of transplacental flux of these 2 carbohydrates and to determine if there is evidence of fetal and/or placental production of either of these substrates. (NCT02397291)
Timeframe: Measured at time of cesarean delivery

InterventionG/DL (Mean)
Placebo/Control Group66.8
Study Group (IUGR)59.4

[back to top]

Maternal Enrichment of Mannose

The infusion of D-[U-13C]mannose and [U-13C]myoinositol into the maternal circulation is used to establish the degree of transplacental flux of these 2 carbohydrates and to determine if there is evidence of fetal and/or placental production of either of these substrates. (NCT02397291)
Timeframe: Measured at time of cesarean delivery

InterventionG/DL (Mean)
Placebo/Control Group63.8429
Study Group (IUGR)78.5

[back to top]

Maternal Enrichment of Myoinositol

The infusion of D-[U-13C]mannose and [U-13C]myoinositol into the maternal circulation is used to establish the degree of transplacental flux of these 2 carbohydrates and to determine if there is evidence of fetal and/or placental production of either of these substrates. (NCT02397291)
Timeframe: Measured at time of cesarean delivery

InterventionG/DL (Mean)
Placebo/Control Group58.543
Study Group (IUGR)76.5

[back to top]